Cognitive effects

From PsychonautWiki
Jump to navigation Jump to search

Cognitive effects are defined as any subjective effect which directly alters one's cognition or introduces new content to an aspect of it. This page lists and describes the various cognitive effects which can occur under the influence of certain psychoactive compounds. It also further organizes these effects into subcategories based on their features and behavior.

Cognitive enhancements

Cognitive enhancements are defined as any subjective effect which increases or raises the intensity of a facet of a person's cognition in a manner that could be generally considered functional.

This page lists and describes the various cognitive amplifications which can occur under the influence of certain psychoactive compounds.

Analysis enhancement

Main article: Analysis enhancement

Analysis enhancement is defined as a perceived improvement of a person's overall ability to logically process information[1][2][3] or creatively analyze concepts, ideas, and scenarios. This effect can lead to a deep state of contemplation which often results in an abundance of new and insightful ideas. It can give the person a perceived ability to better analyze concepts and problems in a manner which allows them to reach new conclusions, perspectives, and solutions which would have been otherwise difficult to conceive of.

Although this effect will often result in deep states of introspection, in other cases it can produce states which are not introspective but instead result in a deep analysis of the exterior world, both taken as a whole and as the things which comprise it. This can result in a perceived abundance of insightful ideas and conclusions with powerful themes pertaining to what is often described as "the bigger picture". These ideas generally involve (but are not limited to) insight into philosophy, science, spirituality, society, culture, universal progress, humanity, loved ones, the finite nature of our lives, history, the present moment, and future possibilities.

Cognitive performance is undeniably linked to personality,[4] and it has been repeatedly shown that psychedelics alter a user's personality for the long term. Experienced psychedelics users score significantly better than controls on several psychometric measures.[5]

Analysis enhancement is often accompanied by other coinciding effects such as stimulation, personal bias suppression, conceptual thinking, and thought connectivity. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds, such as amphetamine, methylphenidate, nicotine, and caffeine.[1][3] However, it can also occur in a more powerful although less consistent form under the influence of psychedelics such as certain LSD, psilocybin, and mescaline.[5]

Bodily control enhancement

Bodily control enhancement can be described as feeling as if there has been a distinct increase in a person's ability to control their physical body with precision, balance, coordination, and dexterity. This results in the feeling that they can accurately control a much greater variety of muscles across their body with the tiniest of subtle mental triggers.

The experience of this effect is often subjectively interpreted by people as a profound and primal feeling of being put back in touch with the animal body.

Bodily control enhancement is most commonly induced under the influence of moderate dosages of stimulating psychedelics, such as LSD, 2C-B, and DOC. However, it may also occur to a lesser extent under the influence of other compounds such as traditional stimulants and light dosages of stimulating dissociatives.

Color enhancement

Main article: Color enhancement

Color enhancement is defined as an intensification of the brightness and vividness of colors in the external environment. During this experience, reds may seem “redder”, greens may seem “greener", and all colors will likely appear much more distinct, complex, and visually intense than they comparatively would be during everyday sober living.[6][7][8][9][10][11][12] At higher levels, this effect can sometimes result in seeing colors which are perceived as surreal or seemingly impossible.[8][9]

Color enhancement is often accompanied by other coinciding effects such as visual acuity enhancement and pattern recognition enhancement.[6][7] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA, ketamine[13], or 3-MeO-PCP.

Image examples

 Caption
Enhancement of colours - woods.jpgThe Woods by Chelsea Morgan
Tree.jpgJapanese Garden by Anonymous
Enhancementofcolour.jpgShowing differences by Chelsea Morgan
Chur City in Switzerland.jpgChur, Switzerland by Naps284
Paradise island by Xanny.jpgParadise island by Subsentience
Chameleon.jpgChameleon by Anonymous.
Enhancement of colour rose.jpgRose by Chelsea Morgan

Creativity enhancement

Creativity enhancement is defined as an increase in one's capability to imagine new ideas, create art, or think about existing concepts in a novel manner.[14] This effect is particularly useful to artists of any sort because it can help a person overcome creative blocks on existing projects and induce inspiration for entirely new projects. Creativity enhancement can make imaginative activities more enjoyable and effortless in the moment and the inspiration from it can benefit the individual even after the effect has worn off.

A well-known example of psychedelic creativity enhancement comes from the Nobel Prize winning chemist Dr. Kary Mullis, who invented a method for copying DNA segments known as the PCR and is quoted as saying: "Would I have invented PCR if I hadn't taken LSD? I seriously doubt it. I could sit on a DNA molecule and watch the polymers go by. I learned that partly on psychedelic drugs".[15] In addition, although dubious, it has been claimed Francis Crick experimented with LSD during the time he helped elucidate the structure of DNA.[16] Many artists (such as The Beatles) have also attributed creativity enhancing properties to psychedelics like LSD.[citation needed]

Creativity enhancement is often accompanied by other coinciding effects such as thought connectivity, motivation enhancement, personal bias suppression, analysis enhancement, and thought acceleration in a manner which further amplifies a person's creativity. It is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.[17][18][19] However, it can also occur to a lesser extent under the influence of cannabinoids,[20][21] dissociatives,[22] and stimulants.

Empathy, affection and sociability enhancement

Empathy, affection, and sociability enhancement is defined as the experience of a mind state which is dominated by intense feelings of compassion, talkativeness, and happiness.[23][24] The experience of this effect creates a wide range of subjective changes to a person's perception of their feelings towards other people and themselves. These are described and documented in the list below:

  • Increased sociability and the feeling that communication comes easier and more naturally.
  • Increased urge to communicate or express one's affectionate feelings towards others, even if they happen to be strangers.
  • Increased feelings of empathy, love, and connection with others.
  • Increased motivation to resolve social conflicts and improve interpersonal relationships.
  • Decreased negative emotions and mental states such as stress, anxiety, and fear.
  • Decreased insecurity, defensiveness, and fear of emotional injury or rejection from others.
  • Decreased irritability, aggression, anger, and jealousy.

Empathy, affection, and sociability enhancement is often accompanied by other coinciding effects such as stimulation, personal bias suppression, motivation enhancement, and anxiety suppression. It is most commonly induced under the influence of moderate dosages of entactogenic compounds such as MDMA,[25] 4-FA, and 2C-B.[26] However, it can also subtly occur to a much lesser extent under the influence of GABAergic depressants, and certain stimulants.[27]

Increased music appreciation

Increased music appreciation is defined as a general sense of an increased enjoyment of music. When music is listened to during this state, not only does it subjectively sound better, but the perceived music and lyrical content may have a profound impact on the listener.[28][29][30][31][32][33]

This experience can give one a sense of hyper-awareness of every sound, lyric, melody, and complex layer of noise within a song in addition to an enhanced ability to individually comprehend their significance and interplay. The perceived emotional intent of the musician and the meaning of the music may also be felt in a greater level clarity than that which is attainable during everyday sober living.[30] This effect can result in the belief, legitimate or delusional, that one has connected with the “true meaning” or “spirit” behind an artist’s song. During particularly enjoyable songs, this effect can result in feelings of overwhelming harmony[32] and a general sense of appreciation that can leave the person with a deep sense of connection towards the artist they are listening to.

Increased music appreciation is commonly mistaken as a purely auditory effect but is more likely the result of several coinciding components such as novelty enhancement, personal meaning intensification, emotion intensification, and auditory acuity enhancement. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics,[28][31][34] dissociatives,[35] and cannabinoids.[30] However, it can also occur to a lesser extent under the influence of stimulants[30][34] and GABAergic depressants.

Increased sense of humor

Increased sense of humor is defined as a general enhancement of the likelihood and degree to which a person finds stimuli to be humorous and amusing. During this state, a person's sensitivity to finding things funny is noticeably amplified, often to the point that they will begin uncontrollably laughing at trivial things without any intelligible reason or apparent cause.[36][37][38][39]

In group settings, the experience of witnessing another person who is laughing intensely for no apparent reason can itself become a contagious trigger which induces semi-uncontrollable laughter within the people around them. In extreme cases, this can often form a lengthy feedback loop in which people begin to laugh hysterically at the absurdity of not being able to stop laughing and not knowing what started the laughter to begin with.

Increased sense of humor is often accompanied by other coinciding effects such as emotion intensification and novelty enhancement. It is most commonly induced under the influence of moderate dosages of certain hallucinogenic compounds, such as psychedelics, mescaline,[40] and cannabinoids.[36][41] However, it can also occur to a much lesser extent under the influence of stimulants,[42] GABAergic depressants, and dissociatives.[36][41]

Memory enhancement

Main article: Memory enhancement

Memory enhancement is defined as an improvement in a person's ability to recall or retain memories.[43][44][45][46] The experience of this effect can make it easier for a person to access and remember past memories at a greater level of detail when compared to that of everyday sober living. It can also help one retain new information that may then be more easily recalled once the person is no longer under the influence of the psychoactive substance.

Memory enhancement is often accompanied by other coinciding effects such as analysis enhancement and thought acceleration. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds, such as methylphenidate,[47] caffeine,[45] Noopept,[48] nicotine,[49] and modafinil.[50]

Types

Different substances can enhance different kinds of memory with some considerable overlap. Generally, there are three types:

  • Long-term memory: A vast store of knowledge and a record of prior events.[51]
  • Short-term memory: Faculties of the human mind that can hold a limited amount of information in a very accessible state temporarily.[51][52][53]
  • Working memory: Information used to plan and carry out behavior. Not completely distinct from short-term memory, it's generally viewed as the combination of multiple components working together. Measures of working memory have been found to correlate with intellectual aptitudes (and especially fluid intelligence) better than measures of short-term memory and, in fact, possibly better than measures of any other particular psychological process. Both storage and processing have to be engaged concurrently to assess working memory capacity, which relates it to cognitive aptitude.[51][52][53][54][55]

Motivation enhancement

Motivation enhancement is defined as an increased desire to perform tasks and accomplish goals in a productive manner.[56][57][58] This includes tasks and goals that would normally be considered too monotonous or overwhelming to fully commit oneself to.

A number of factors (which often, but not always, co-occur) reflect or contribute to task motivation: namely, wanting to complete a task, enjoying it or being interested in it.[58] Motivation may also be supported by closely related factors, such as positive mood, alertness, energy, and the absence of anxiety. Although motivation is a state, there are trait-like differences in the motivational states that people typically bring to tasks, just as there are differences in cognitive ability.[57]

Motivation enhancement is often accompanied by other coinciding effects such as stimulation and thought acceleration in a manner which further increases one's productivity. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds, such as amphetamine,[57][59] methylphenidate,[57] nicotine,[60] and modafinil.[61] However, it may also occur to a much lesser extent under the influence of certain opioids,[62][63] and GABAergic depressants.[62]

Novelty enhancement

Main article: Novelty enhancement

Novelty enhancement is defined as a feeling of increased fascination[64], awe,[64][65][66] and appreciation[66][67] attributed to specific parts or the entirety of one's external environment. This can result in an often overwhelming impression that everyday concepts such as nature, existence, common events, and even household objects are now considerably more profound, interesting, and significant.[68][33]

The experience of this effect commonly forces those who undergo it to acknowledge, consider, and appreciate the things around them in a level of detail and intensity which remains largely unparalleled throughout every day sobriety. It is often generally described using phrases such as "a sense of wonder"[64][66] or "seeing the world as new".[67]

Novelty enhancement is often accompanied by other coinciding effects such as personal bias suppression, emotion intensification and spirituality intensification in a manner which further intensifies the experience. It is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of cannabinoids, dissociatives, and entactogens.

Thought connectivity

Main article: Thought connectivity

Thought connectivity is defined as an alteration of a person's thought stream which is characterized by a distinct increase in unconstrained wandering thoughts which connect into each other through a fluid association of ideas.[69][70][71][72] During this state, thoughts may be subjectively experienced as a continuous stream of vaguely related ideas which tenuously connect into each other by incorporating a concept that was contained within the previous thought. When experienced, it is often likened to a complex game of word association.

During this state, it is often difficult for the person to consciously guide the direction of their thoughts in a manner that leads into a state of increased distractibility.[69] This will usually also result in one's train of thought contemplating an extremely broad variety of subjects, which can range from important, trivial, insightful, and nonsensical topics.

Thought connectivity is often accompanied by other coinciding effects such as thought acceleration and creativity enhancement. It is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of dissociatives, stimulants, and cannabinoids.

Thought organization

Main article: Thought organization

Thought organization (also known as fluid intelligence)[73] is defined as a state of mind in which one's ability to analyze and categorize conceptual information using a systematic and logical thought process is considerably increased.[74][75][76] It seemingly occurs through reducing thoughts which are unrelated or irrelevant to the topic at hand, therefore improving one's capacity for a structured and cohesive thought stream.[74][77] This effect also seems to allow the person to hold a greater amount of relevant information (as evidenced by language comprehension increases)[76] in their train of thought which can be useful for extended mental calculations, articulating ideas, and analyzing logical arguments.

Thought organization is often accompanied by other coinciding effects such as analysis enhancement and thought connectivity. It is most commonly induced under the influence of mild dosages of stimulant and nootropic compounds, such as amphetamine, methylphenidate, and Noopept. However, this effect can occur to a lesser extent under the influence of certain cannabis strains and spontaneously during psychedelic states. It is also worth noting that the same compounds which induce this mind state at light to moderate dosages can often result in the opposite effect of thought disorganization at heavier dosages.[75][77][78]


Cognitive depressions

Cognitive depressions are defined as any subjective effect which decreases or lowers the intensity of a facet of a person's cognition in a manner that could be generally considered dysfunctional. For a broad overview, consider reading the depression and depression reduction effects.

This page lists and describes the various cognitive amplifications which can occur under the influence of certain psychoactive compounds.

Amnesia

Main article: Amnesia

Amnesia is defined as a global impairment in the ability to acquire new memories regardless of sensory modality, and a loss of some memories, especially recent ones, from the period before amnesia began.[79] During states of amnesia a person will usually retain functional perceptual abilities and short-term memory which can still be used to recall events that recently occurred; this effect is distinct from the memory impairment produced by sedation.[80] As such, a person experiencing amnesia may not obviously appear to be doing so, as they can often carry on normal conversations and perform complex tasks.

This state of mind is commonly referred to as a "blackout", an experience that can be divided into 2 formal categories: "fragmentary" blackouts and "en bloc" blackouts.[81] Fragmentary blackouts, sometimes known as "brownouts", are characterized by having the ability to recall specific events from an intoxicated period but remaining unaware that certain memories are missing until reminded of the existence of those gaps in memory. Studies suggest that fragmentary blackouts are far more common than "en bloc" blackouts.[82] In comparison, En bloc blackouts are characterized by a complete inability to later recall any memories from an intoxicated period, even when prompted. It is usually difficult to determine the point at which this type of blackout has ended as sleep typically occurs before this happens.[83]

Amnesia is often accompanied by other coinciding effects such as disinhibition, sedation, and memory suppression. It is most commonly induced under the influence of heavy dosages of GABAergic depressants, such as alcohol,[84] benzodiazepines,[85] GHB,[86] and zolpidem[87]. However, it can also occur to a much lesser extent under the influence of extremely heavy dosages of hallucinogenic compounds such as psychedelics, dissociatives, Salvia divinorum, and deliriants.

Analysis depression

Main article: Analysis depression

Analysis depression is defined as a distinct decrease in a person's overall ability to process information[88][89][90] and logically or creatively analyze concepts, ideas, and scenarios.[91] The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.

Analysis suppression is often accompanied by other coinciding effects such as sedation, thought deceleration, and emotion suppression. It is most commonly induced under the influence of heavy dosages of antipsychotic compounds,[88][89][91] and is associated with long term use of such drugs[92] like quetiapine, haloperidol, and risperidone. However, it can also occur in a less consistent form under the influence of heavy dosages of dissociatives, cannabinoids,[90] and GABAergic depressants[93].

Cognitive fatigue

Main article: Cognitive fatigue

Cognitive fatigue (also called exhaustion, tiredness, lethargy, languidness, languor, lassitude, and listlessness) is medically recognized as a state usually associated with a weakening or depletion of one's mental resources.[94][95] The intensity and duration of this effect typically depends on the substance consumed and its dosage. It can also be further exacerbated by various factors such as a lack of sleep[96] or food[97]. These feelings of exhaustion involve a wide variety of symptoms which generally include some or all of the following effects:

Cognitive fatigue is most commonly induced under the influence of moderate dosages of antipsychotic compounds,[98][99] such as quetiapine, haloperidol, and risperidone. However, it can also occur during the withdrawal symptoms of many depressants,[100] and during the offset of many stimulants[101].

Confusion

Main article: Confusion

Confusion is defined as an impairment of abstract thinking demonstrated by an inability to think with one’s customary clarity and coherence.[102] Within the context of substance use, it is commonly experienced as a persistent inability to grasp or comprehend concepts and situations which would otherwise be perfectly understandable during sobriety. The intensity of this effect seems to to be further increased with unfamiliarity[103] in either setting or substance ingested.

Confusion is often accompanied by other coinciding effects such as delirium, delusions, and short term memory suppression in a manner which further increases the person's lack of comprehension. It is most commonly induced under the influence of heavy dosages of hallucinogenic compounds, such as psychedelics,[104] dissociatives,[105] synthetic cannabinoids,[106] and deliriants.[107] However, it can also occur to a lesser extent under the influence of heavy dosages of benzodiazepines[108] and antipsychotics[107].

Delirium

Main article: Delirium

Delirium (also known as acute confusion)[109] is medically recognized as a physiological disturbance of awareness that is accompanied by a change in baseline cognition which cannot be better explained by a preexisting or evolving neurocognitive disorder.[110] The disturbance in awareness is manifested by a reduced ability to direct, focus, sustain, and shift attention and the accompanying cognitive change in at least one other area may include memory and learning (particularly recent memory), disorientation (particularly to time and place), alteration in language, or perceptual distortions or a perceptual-motor disturbance. The perceptual disturbances accompanying delirium include misinterpretations, illusions, or hallucinations; these disturbances are typically visual but may occur in other modalities as well, and range from simple and uniform to highly complex. An individual with delirium may also exhibit emotional disturbances, such as anxiety, fear, depression, irritability, anger, euphoria, and apathy with rapid and unpredictable shifts from one emotional state to another.[111]

This disturbance develops over a short period of time, usually hours to a few days, and tends to fluctuate during the course of the day, often with worsening in the evening and night when external orienting stimuli decrease. It has been proposed that a core criterion for delirium is a disturbance in the sleep-wake cycle. Normal attention/arousal, delirium, and coma lie on a continuum, with coma defined as the lack of any response to verbal stimuli.[111]

Delirium may present itself in three distinct forms. These are referred to in the scientific literature as hyperactive, hypoactive, or mixed forms.[112] In its hyperactive form, it is manifested as severe confusion and disorientation, with a sudden onset and a fluctuating intensity. In its hypoactive (i.e. underactive) form, it is manifested by an equally sudden withdrawal from interaction with the outside world accompanied by symptoms such as drowsiness and general inactivity.[113] Delirium may also occur in a mixed type in which one can fluctuate between both hyper and hypoactive periods.

Delirium is most commonly induced under the influence of heavy dosages of deliriant compounds, such as DPH,[114] datura,[115] and benzydamine. However, it can also occur as a result of an extremely wide range of health problems such as urinary tract infections,[116] influenza,[117] and alzheimer’s.[118]

Creativity depression

Main article: Creativity depression

Creativity depression is defined as a decrease in both a person's motivation and capabilities when performing tasks that involve producing artistic output or novel problem-solving.[119] This effect may be particularly frustrating to deal with for artists of any sort as it will induce a temporary creative block.

Although creative subjects paradoxically more often have a history of depression than the average, their creative work is not done during their depressions, but in rebound periods of increased energy between depressions.[119][120]

Creativity suppression is often accompanied by other coinciding effects such as depression,[121] anxiety, and emotion suppression in a manner which further decreases the person's creative abilities.[119] It is most commonly induced under the influence of moderate dosages of antipsychotics.[119][122][123] However, it can also occur due to SSRI's[124] and during the withdrawal symptoms of any dopaminergic compound.[123]

Language depression

Main article: Language depression

Language depression (also known as aphasia) is medically recognized as the decreased ability to use and understand speech.[125] This creates the feeling of finding it difficult or even impossible to vocalize one's own thoughts and to process the speech of others. However, the ability to speak and to process the speech of others doesn't necessarily become suppressed simultaneously; a person may find themselves unable to formulate a coherent sentence while still being able to perfectly understand the speech of others.

Generally, this effect can be divided into four broad categories:[125]

  1. Expressive (also called Broca's aphasia): difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. For example, a person with Broca's aphasia may say, "Walk dog," meaning, "I will take the dog for a walk," or "book book two table," for "There are two books on the table."
  2. Receptive (Wernicke's aphasia): difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. These people may speak in long, complete sentences that have no meaning, adding unnecessary words and even creating made-up words. For example, "You know that smoodle pinkered and that I want to get him round and take care of him like you want before." As a result, it is often difficult to follow what the person is trying to say and the speakers are often unaware of their spoken mistakes.
  3. Global: People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write. This results from severe and extensive damage to the language areas of the brain. They may be unable to say even a few words or may repeat the same words or phrases over and over again.
  4. Anomic (or amnesiac): the least severe form of aphasia; people have difficulty in using the correct names for particular objects, people, places, or events.

Language suppression is often accompanied by other coinciding effects such as analysis depression and thought disorganization. It is most commonly induced under the influence of heavy dosages of antipsychotic compounds, such as quetiapine,[126] haloperidol,[127] and risperidone.[128] However, it can also occur in a less consistent form under the influence of extremely heavy dosages of hallucinogenic compounds such as psychedelics,[129] dissociatives,[129][130] and deliriants.[131] This is far more likely to occur when the person is inexperienced with that particular hallucinogen.

Motivation depression

Main article: Motivation depression

Motivation depression (also known as avolition or amotivation)[132] is defined as a decreased desire to initiate or persist in goal-directed behavior.[133][134] Motivation depression prevents an individual the ability to sustain the rewarding value of an action into an uncertain future; this includes tasks deemed challenging or unpleasant, such as working, studying, cleaning, and doing general chores. At its higher levels, motivation depression can cause one to lose their desire to engage in any activities, even the ones that would usually be considered entertaining or rewarding to the user. This effect can lead onto severe states of boredom and even mild depression when experienced at a high level of intensity for prolonged periods of time.

Motivation suppression is often accompanied by other coinciding effects such as sedation and thought deceleration. It is most commonly induced under the influence of an acute dosage of an antipsychotic compound, such as quetiapine, haloperidol, and risperidone.[135][136] However, it is worth noting that chronic treatment with any dose of antipsychotic medication does not cause this effect.[132] It can also occur under the influence of heavy dosages of cannabinoids[137] and benzodiazepines, as a result of long-term SSRI usage,[138] during the offset of stimulants, and during the withdrawal symptoms of almost any compound.

Thought disorganization

Thought disorganization is defined as a state in which one's ability to analyze and categorize conceptual information using a systematic and logical thought process is considerably decreased. It seemingly occurs through an increase in thoughts which are unrelated or irrelevant to the topic at hand, thus decreasing one's capacity for a structured and cohesive thought stream. This effect also seems to allow the user to hold a significantly lower amount of relevant information in their train of thought which can be useful for extended mental calculations, articulating ideas, and analyzing logical arguments.

Thought disorganization is often accompanied by other coinciding effects such as analysis depression and thought acceleration. It is most commonly induced under the influence of heavy dosages of hallucinogenic and depressant compounds, such as dissociatives,[139][140][141][142] psychedelics,[139][143] cannabinoids,[139][144][145] and GABAergics.[146][147] However, it is worth noting that the same stimulant or nootropics compounds which induce thought organization at lower dosages, can also often result in the opposite effect of thought disorganization at their higher dosages.[139][147][148][149]

Cognitive intensifications

Cognitive intensifications are defined as any subjective effect which increases or raises the intensity of a facet of a person's cognition in a manner that is generally considered either functional or dysfunctional.

This page lists and describes the various cognitive intensifications which can occur under the influence of certain psychoactive compounds.

Anxiety

Main article: Anxiety

Anxiety is medically recognized as the experience of negative feelings of apprehension, worry, and general unease.[150][151] These feelings can range from subtle and ignorable to intense and overwhelming enough to trigger panic attacks or feelings of impending doom. Anxiety is often accompanied by nervous behaviour such as stimulation, restlessness, difficulty concentrating, irritability, and muscular tension.[152] Psychoactive substance-induced anxiety can be caused as an inescapable effect of the drug itself, by a lack of experience with the substance or its intensity, as an intensification of a pre-existing state of mind, or by the experience of negative hallucinations. The focus of anticipated danger can be internally or externally derived.

Anxiety is often accompanied by other coinciding effects such as depression and irritability. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as cannabinoids,[153] psychedelics,[154] dissociatives, and deliriants.[155] However, it can also occur during the withdrawal symptoms of GABAergic depressants[156] and during stimulant comedowns.[157]

Dream potentiation

Main article: Dream potentiation

Dream potentiation is defined as an effect which increases the subjective intensity, vividness, and frequency of sleeping dream states.[158][159] This effect also results in dreams having a more complex and incohesive plot with a higher level of detail and definition.[159] Additionally, the effect causes a greatly increased likelihood of them becoming lucid dreams.

Dream potentiation is most commonly induced under the influence of moderate dosages of oneirogenic compounds, a class of hallucinogen that is used to specifically potentiate dreams when taken before sleep. However, it can also occur as a residual side effect from falling asleep under the influence of an extremely wide variety of substances. At other times, it can occur as a relatively persistent effect that has arisen as a symptom of hallucinogen persisting perception disorder (HPPD).

Ego inflation

Main article: Ego inflation

Ego inflation is defined as an effect that magnifies and intensifies one's own ego and self-regard in a manner which results in feeling an increased sense of confidence, superiority, and general arrogance.[160] During this state, it can often feel that one is considerably more intelligent, important, and capable in comparison to those around them. This occurs in a manner which is similar to the psychiatric condition known as narcissistic personality disorder.[161]

At lower levels, this experience can result in an enhanced ability to handle social situations due to a heightened sense of confidence.[162] However, at higher levels, it can result in a reduced ability to handle social situations due to magnifying egoistic behavioural traits that may come across as distinctly obnoxious, narcissistic, and selfish to other people.

It is worth noting that regular and repeated long-term exposure to this effect can leave certain individuals with persistent behavioural traits of ego inflation, even when sober, within their day to day life.

Ego inflation is often accompanied by other coinciding effects such as disinhibition, irritability, and paranoia in a manner which can lead to destructive behaviors and violent tendencies.[162] It is most commonly induced under the influence of moderate dosages of stimulant compounds, particularly dopaminergic stimulants such as amphetamines, and cocaine.[160][162][163][164] However, it may also occur under the influence of other compounds such as GABAergic depressants[160] and certain dissociatives.

Emotion intensification

Emotion intensification (also known as affect intensification)[165] is defined as an increase in a person's current emotional state beyond normal levels of intensity.[28][166][69]

Unlike many other subjective effects such as euphoria or anxiety, this effect does not actively induce specific emotions regardless of a person's current state of mind and mental stability. Instead, it works by passively amplifying and enhancing the genuine emotions that a person is already feeling prior to ingesting the drug or prior to the onset of this effect. This causes emotion intensification to be equally capable of manifesting in both a positive and negative direction.[165][28][69][167][33] This effect highlights the importance of set and setting when using psychedelics in a therapeutic context, especially if the goal is to produce a catharsis.[165][166][33]

For example, an individual who is currently feeling somewhat anxious or emotionally unstable may become overwhelmed with intensified negative emotions, paranoia, and confusion. In contrast, an individual who is generally feeling positive and emotionally stable is more likely to find themselves overwhelmed with states of emotional euphoria, happiness, and feelings of general contentment. The intensity of emotional states felt under emotion intensification can shape the tone of a trip and predispose the user to other effects, such as mania or unity in positive states and thought loops or feelings of impending doom in negative states.[69] Intense negative or difficult emotions may still arise in therapeutic contexts, however (with adequate support) people nevertheless view the experience positively due to the perceived value of integrating the emotional states' additional insight.[165][33]

Emotion intensification is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.[165][28][166][69][33] However, it can also occur under the influence of cannabinoids, GABAergic depressants,[168][169] and stimulants.[167][27]

Focus intensification

Main article: Focus intensification

Focus intensification is defined as the experience of an increased ability to selectively concentrate on an aspect of the environment while ignoring other things. It can be best characterized by feelings of intense concentration which can allow one to continuously focus on and perform tasks which would otherwise be considered too monotonous, boring, or dull to not get distracted from.[170][171]

The degree of focus induced by this effect can be much stronger than what a person is capable of sober. It can allow for hours of effortless, single-minded, and continuous focus on a particular activity to the exclusion of all other considerations such as eating and attending to bodily functions. However, although focus intensification can improve a person’s ability to engage in tasks and use time effectively, it is worth noting that it can also cause a person to focus intensely and spend excess time on unimportant activities.

Focus intensification is often accompanied by other coinciding effects such as motivation enhancement, thought acceleration, and stimulation. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds such as amphetamine,[172] methylphenidate,[173] modafinil,[174] and caffeine.[175] However, it is worth noting that the same compounds which induce this mind state at moderate dosages will also often result in the opposite effect of focus suppression at heavier dosages.[176]

Immersion intensification

{{Main|Immersion intensification||

Immersion intensification is defined as an effect which results in a pronounced increase in one's tendency to become fully captivated and engrossed by external stimuli such as music, film, TV shows, video games, and various other forms of media.[177][178][179][180] This greatly increases one's suspension of disbelief, increases one’s empathy with the characters, suppresses one's memory of the "outside world", and allows one to become engaged on a level that is largely unattainable during everyday sober living.

At its highest point of intensity, immersion intensification can reach a level in which the person begins to truly believe that the media they are consuming is a real-life event that is actually happening in front of them or is being relayed through a screen. This is likely a result of the effect synergizing with other accompanying components such as internal or external hallucinations, delusions, memory suppression, and suggestibility intensification. Immersion intensification often exaggerates the emotional response a person has towards media they are engaged with. Whether or not this experience is enjoyable can differ drastically depending on various factors such as the emotional tone and familiarity of what is being perceived.

Immersion intensification is most commonly induced under the influence of moderate dosages of dissociative compounds, such as ketamine, PCP, and DXM. However, it can also occur to a lesser extent under the influence of psychedelics[180] and cannabinoids.

Irritability

Main article: Irritability

Irritability is medically recognized as the pervasive and sustained emotional state of being easily annoyed and provoked to anger.[181] It may be expressed outwardly in the cases of violence towards others, or directed inwards towards oneself in the form of self-harm.[182]

This effect, especially when strong, can sometimes cause violent or aggressive outbursts in a small subset of people who may be predisposed to it. The chances of somebody responding in such a way differs wildly between people and depends on how susceptible an individual is to irritability and how well they cope with it. It is also worth noting that this typically only affects those who were already susceptible to aggressive behaviours. However, regardless of the person, this effect results in a lower ability to tolerate frustrations, negative stimuli, and other people. A person undergoing this effect may be prone to lashing out at others, fits of anger, or other behaviours that would be uncharacteristic for them sober.

Irritability is often accompanied by other coinciding effects such as anxiety, paranoia, and ego inflation. It is most commonly induced during the after effects of heavy dosages of stimulant compounds, such as cocaine, methamphetamine,[183] and methylphenidate.[184] However, it can be a withdrawal symptom of almost any substance, and can to a lesser extent present itself during alcohol intoxication.[185]

Personal meaning intensification

Personal meaning intensification (also known as aberrant salience) is defined as the experience of a considerably increased sense of personal significance becoming attributed to innocuous situations, and coincidences.[186][187][188][189][190] Trivial observations not usually noticed may seem connected, and a subjective state of "seeing solutions" might evolve to one of seeing problems, ultimately arriving at a full-fledged paranoid psychosis.[68] For example, one may feel that the lyrics of a song or events in a film directly relate to their life in a meaningful and distinct manner that is not usually felt during everyday sobriety. This feeling can continue to occur even when it is rationally understood that the external stimuli does not genuinely relate to the person experiencing it in such a direct manner.

At its highest level, this effect will often synergize with delusions in a manner which can result in one genuinely believing that innocuous events are directly related to them.[186] For example, one may begin to believe that the plot of a film is about their life or that a song was written for them. This phenomenon is well established within psychiatry and is commonly known as a "delusion of reference."[191][192]

Suggestibility intensification

Suggestibility intensification is defined as an increased tendency to accept and act on the ideas or attitudes of others.[193] A common example of suggestibility enhancement in action would be a trip sitter deliberately making a person believe a false statement without question simply by telling it to them as true, even if the statement would usually be easily recognizable as impossible or absurd. If this is successfully accomplished, it can potentially result in the experience of relevant accompanying hallucinations and delusions which further solidify the belief which has been suggested to them.

Suggestibility intensification most commonly occurs under the influence of heavy dosages of hallucinogenic compounds, such as psychedelics, dissociatives, deliriants, and cannabinoids. This holds particularly true for users who are inexperienced or currently undergoing delusions and memory suppression. It's worth noting that this effect has been studied extensively by the scientific literature and has a relatively large body of data confirming its presence across multiple hallucinogens. These include LSD,[194] mescaline,[193] psilocybin,[193] cannabis,[195] ketamine,[196] and nitrous oxide.[197] However, anecdotal reports suggest that it may also occur to a lesser extent under the influence of GABAergic depressants such as alcohol and benzodiazepines.

Thought acceleration

Main article: Thought acceleration

Thought acceleration (also known as racing thoughts)[198] is defined as the experience of thought processes being sped up significantly in comparison to that of everyday sobriety.[199][200] When experiencing this effect, it will often feel as if one rapid-fire thought after the other is being generated in incredibly quick succession. Thoughts while undergoing this effect are not necessarily qualitatively different, but greater in their volume and speed. However, they are commonly associated with a change in mood that can be either positive or negative.[198][201]

Thought acceleration is often accompanied by other coinciding effects such as stimulation, anxiety, and analysis enhancement in a manner which not only increases the speed of thought, but also significantly enhances the sharpness of a person's mental clarity. It is most commonly induced under the influence of moderate dosages of stimulant and nootropic compounds, such as amphetamine, methylphenidate, modafinil, and MDMA. However, it can also occur under the influence of certain stimulating psychedelics such as LSD, 2C-E, DOC, AMT.

Wakefulness

Main article: Wakefulness

Wakefulness is defined as an increased ability to stay conscious without feeling sleepy combined with a decreased need to sleep.[202] It is contrasted with stimulation in that it does not directly increase one's energy levels above a normal baseline but instead produces feelings of a wakeful, well-rested, and alert state.[203][204] If one is sleepy before using this substance, the impulse to sleep will fade, keeping one’s eyes open will become easier, and the cognitive fog of exhaustion will be reduced.[205] However, sufficiently accumulated sleep deficiency can overpower or negate this effect in extreme cases.[203]

Wakefulness is most commonly induced under the influence of moderate dosages of a wide variety of compounds such as stimulants, nootropics, and psychedelics. However, it is worth noting that the few compounds which selectively induce this effect without a number of other accompanying effects are referred to as eugeroics or wakefulness-promoting agents. These include modafinil[203][204][206][207] and armodafinil.[203]


Cognitive suppressions

Cognitive suppressions are defined as any subjective effect which decreases or lowers the intensity of a facet of a person's cognition in a manner that is generally considered either functional or dysfunctional.

This page lists and describes the various cognitive suppressions which can occur under the influence of certain psychoactive compounds.

Addiction suppression

Main article: Addiction suppression

Addiction suppression is defined as the experience of a total or partial suppression of a psychological addiction to a specific substance and the cravings associated with it. This can occur as an effect which lasts long after the compound which induced it wears off or it can last only while the compound is still active.

Addiction suppression is a rare effect that is most commonly associated with psychedelics,[31] psilocin,[208] LSD,[209] ibogaine[210] and N-acetylcysteine (NAC).[211]

Anxiety suppression

Main article: Anxiety suppression

Anxiety suppression (also known as anxiolysis or minimal sedation)[212] is medically recognized as a partial to complete suppression of a person’s ability to feel anxiety, general unease, and negative feelings of both psychological and physiological tension.[213] The experience of this effect may decrease anxiety-related behaviours such as restlessness, muscular tension,[214] rumination, and panic attacks. Complete anxiety suppression can produce feelings of extreme calmness and relaxation; however, it can also lead to undesirable outcomes when accompanied by other effects such as disinhibition or sedation.

It is most commonly induced under the influence of moderate dosages of anxiolytic compounds which primarily include GABAergic depressants,[215][216] such as benzodiazepines,[217] alcohol,[218] GHB,[219] and gabapentinoids[220]. However, it can also occur to a lesser extent under the influence of a large variety of other pharmacological classes which include but are not limited to cannabinoids,[221] dissociatives,[222] SSRIs, and opioids.

Disinhibition

Main article: Disinhibition

Disinhibition is medically recognized as an orientation towards immediate gratification, leading to impulsive behavior driven by current thoughts, feelings, and external stimuli, without regard for past learning or consideration of future consequences.[223][224][225] This is usually manifested through recklessness, poor risk assessment, and a disregard for social conventions.

At its lower levels of intensity, disinhibition can allow one to overcome emotional apprehension and suppressed social skills in a manner that is moderated and controllable for the average person. This can often prove useful for those who suffer from social anxiety or a general lack of self-confidence.

However, at higher levels of intensity, the disinhibited individual may be completely unable to maintain any semblance of self-restraint, at the expense of politeness, sensitivity, social appropriateness, or local laws and regulations. This lack of constraint can be negative, neutral, or positive depending on the individual and their current environment. The negative consequences of disinhibited behaviour range from relatively benign consequences (such as embarrassing oneself) to destructive and damaging ones (such as driving under the influence or committing criminal acts).

Disinhibition is often accompanied by other coinciding effects such as amnesia and anxiety suppression in a manner which can further decrease the person's observance of and regard for social norms. It is most commonly induced under the influence of moderate dosages of GABAergic depressants, such as alcohol,[226] benzodiazepines,[227] phenibut, and GHB. However, it may also occur under the influence of certain stimulants,[228] entactogens,[229] and dissociatives[230].

Dream suppression

Main article: Dream suppression

Dream suppression is defined as a decrease in the vividness, intensity, frequency, and recollection of a person's dreams. At its lower levels, this can be a partial suppression which results in the person having dreams of a lesser intensity and a lower rate of frequency. However, at its higher levels, this can be a complete suppression which results in the person not experiencing any dreams at all.

Dream suppression is most commonly induced under the influence of moderate dosages of cannabinoids[231] and most types of antidepressants[232][233][234]. This is due to the way in which they increase REM latency, decrease REM sleep, reduce total sleep time and efficiency, and increase wakefulness.[231][232][233][235] REM sleep is where the majority of dreams occur.[236]

Emotion suppression

Main article: Emotion suppression

Emotion suppression (also known as flat affect, apathy, or emotional blunting) is medically recognized as a flattening or decrease in the intensity of one's current emotional state below normal levels.[237][238][239] This dulls or suppresses the genuine emotions that a person was already feeling prior to ingesting the drug. For example, an individual who is currently feeling somewhat anxious or emotionally unstable may begin to feel very apathetic, neutral, uncaring, and emotionally blank. This also impacts the degree to which the person will express their emotional state through body language, tone of voice, and facial expressions.

It is worth noting that although a reduction in the intensity of one's emotions may be beneficial at times (e.g., the blunting of an anger response in a volatile patient), it may be detrimental at other times (e.g., emotional indifference at the funeral of a close family member).[240]

Emotion suppression is often accompanied by other coinciding effects such as motivation suppression, thought deceleration, and analysis suppression. It is most commonly induced under the influence of moderate dosages of antipsychotic compounds, such as quetiapine, haloperidol, and risperidone.[237][122] However, it can also occur in less consistent form under the influence of heavy dosages of dissociatives,[241][242] SSRI's,[240][124] and GABAergic depressants[243].

Focus suppression

Main article: Focus suppression

Focus suppression (also known as distractability[244]) is medically recognized as a decreased ability to selectively concentrate on an aspect of the environment while ignoring other things.[245][246] It can be best characterized by feelings of intense distractability which can prevent one from focusing on and performing basic tasks that would usually be relatively easy to not get distracted from.[247] This effect will often synergize with other coinciding effects such as motivation suppression, thought deceleration, and sedation.[21]

Focus suppression is often accompanied by other coinciding effects such as sedation, motivation suppression, and creativity suppression. It is most commonly induced under the influence of moderate or heavy dosages of antipsychotics,[248] benzodiazepines, cannabinoids,[21] and hallucinogens. However, it is worth noting that stimulant compounds which primarily induce focus enhancement at light to moderate dosages will also often lead into focus suppression at their heavier dosages.[176]

Memory suppression

Main article: Memory suppression

Memory suppression (also known as ego suppression, ego dissolution, ego loss or ego death) is defined as an inhibition of a person's ability to maintain a functional short and long-term memory.[249][188][70] This occurs in a manner that is directly proportional to the dosage consumed, and often begins with the degradation of one's short-term memory.

Memory suppression is a process which may be broken down into the 4 basic levels described below:

  1. Partial short-term memory suppression - At the lowest level, this effect is a partial and potentially inconsistent failure of a person's short-term memory. It can cause effects such as a general difficulty staying focused, an increase in distractibility, and a general tendency to forget what one is thinking or saying.
  2. Complete short-term memory suppression - At this level, this effect is the complete failure of a person's short-term memory. It can be described as the experience of being completely incapable of remembering any specific details regarding the present situation and the events leading up to it for more than a few seconds. This state of mind can often result in thought loops, confusion, disorientation, and a loss of control, especially for the inexperienced. At this level, it can also become impossible to follow both conversations and the plot of most forms of media.
  3. Partial long-term memory suppression - At this level, this effect is the partial, often intermittent failure of a person's long-term memory in addition to the complete failure of their short-term memory. It can be described as the experience of an increased difficulty recalling basic concepts and autobiographical information from one's long-term memory. Compounded with the complete suppression of short term memory, it creates an altered state where even basic tasks become challenging or impossible as one cannot mentally access past memories of how to complete them.

    For example, one may take a longer time to recall the identity of close friends or temporarily forget how to perform basic tasks. This state may create the sensation of experiencing something for the first time. At this stage, a reduction of certain learned personality traits, awareness of cultural norms, and linguistic recall may accompany the suppression of long-term memory.

  4. Complete long-term memory suppression - At the highest level, this effect is the complete and persistent failure of both a person's long and short-term memory. It can be described as the experience of becoming completely incapable of remembering even the most basic fundamental concepts stored within the person's long-term memory. This includes everything from their name, hometown, past memories, the awareness of being on drugs, what drugs even are, what human beings are, what life is, that time exists, what anything is, or that anything exists.

    Memory suppression of this level blocks all mental associations, attached meaning, acquired preferences, and value judgements one may have towards the external world. Sufficiently intense memory loss is also associated with the loss of a sense of self, in which one is no longer aware of their own existence. In this state, the user is unable to recall all learned conceptual knowledge about themselves and the external world, and no longer experiences the sensation of being a separate observer in an external world. This experience is commonly referred to as "ego death".

Memory suppression is often accompanied by other coinciding effects such as thought loops, personal bias suppression, amnesia, and delusions. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and deliriants.[250]

It is worth noting that although memory suppression is vaguely similar in its effects to amnesia, it differs in that it directly suppresses one's usage of their long or short term memory without inhibiting the person's ability to recall what happened during this experience afterward. In contrast, amnesia does not directly affect the usage of one's short or long-term memory during its experience but instead renders a person incapable of recalling events after it has worn off. A person experiencing memory suppression cannot access their existing memory, while a person with drug-induced amnesia cannot properly store new memories. As such, a person experiencing amnesia may not obviously appear to be doing so, as they can often carry on normal conversations and perform complex tasks. This is not the case with memory suppression.

Personal bias suppression

Personal bias suppression (also called cultural filter suppression) is defined as a decrease in the personal or cultural biases, preferences, and associations which a person knowingly or unknowingly filters and interprets their perception of the world through.[251]

Analyzing one's beliefs, preferences, or associations while experiencing personal bias suppression can lead to new perspectives that one could not reach while sober. The suppression of this innate tendency often induces the realization that certain aspects of a person's personality, world view and culture are not reflective of objective truths about reality, but are in fact subjective or even delusional opinions.[251] This realization often leads to or accompanies deep states of insight and critical introspection which can create significant alterations in a person's perspective that last anywhere from days, weeks, months, or even years after the experience itself.

Personal bias suppression is often accompanied by other coinciding effects such as conceptual thinking, analysis enhancement, and especially memory suppression. It is most commonly induced under the influence of heavy dosages of hallucinogens such as dissociatives and psychedelics. However, it can also occur to a much lesser extent under the influence of very heavy dosages entactogens and cannabinoids.

Sleepiness

Main article: Sleepiness

Sleepiness (also known as drowsiness) is medically recognized as a state of near-sleep, or a strong desire for sleep without feeling a decrease in one's physical energy levels.[252][253][254] This state is independent of a circadian rhythm;[252] so, unlike sedation, this effect does not necessarily decrease physical energy levels but instead decreases wakefulness. It results in a propensity for tired, clouded, and sleep-prone behaviour. This can lead into a decreased motivation to perform tasks, as the increase in one's desire to sleep begins to outweigh other considerations. Prolonged exposure to this effect without appropriate rest can lead to cognitive fatigue and a range of other cognitive suppressions.

Sleepiness is most commonly induced under the influence of moderate dosages of a wide variety of compounds such as cannabinoids,[255] GABAergic depressants,[256][257] opioids,[258] antipsychotics,[259][135] some antihistamines,[260] and certain psychedelics. However, it is worth noting that the few compounds which selectively induce this effect without a number of other accompanying effects are referred to as hypnotics.

Suggestibility suppression

Suggestibility suppression is defined as a decreased tendency to accept and act on the suggestions of others. A common example of suggestibility suppression in action would be a person being unwilling to believe or trust another person's suggestions without a greater amount of prior discussion than would usually be considered necessary during every day sobriety.

Although this effect can occur as a distinct mindstate, it may also arise due to interactions between a number of other effects. For example, a person who is currently experiencing mild paranoia combined with analysis enhancement may find themselves less trusting and more inclined to think through the suggestions of others before acting upon them, alternatively, a person who is experiencing ego inflation may find that they value their own opinion over others and are therefore equally less likely to follow the suggestions of others.

Alcohol has been shown to decrease suggestibility in a dose-dependent manner,[261][262] while its withdrawals increases suggestibility.[263] A large proportion of individuals who come in contact with law enforcement personnel are under the influence of alcohol, including perpetrators, victims, and witnesses of crimes. This has to be taken into account when investigative interviews are planned and conducted, and when the reliability of the information derived from such interviews is evaluated.[261][262][263]

Suggestibility suppression is often accompanied by other coinciding effects such as irritability[261] and ego inflation. It is most commonly induced under the influence of GABAergic depressants.[261][262][263]

Thought deceleration

Main article: Thought deceleration

Thought deceleration (also known as bradyphrenia)[264] is defined as the process of thought being slowed down significantly in comparison to that of normal sobriety. When experiencing this effect, it will feel as if the time it takes to think a thought and the amount of time which occurs between each thought has been slowed down to the point of greatly impairing cognitive processes. It can manifest itself in delayed recognition, slower reaction times, and fine motor skills deficits.

Thought deceleration is often accompanied by other coinciding effects such as analysis suppression and sedation in a manner which not only decreases the person's speed of thought, but also significantly decreases the sharpness of a person's mental clarity. It is most commonly induced under the influence of heavy dosages of depressant compounds, such as GABAergics,[265][266][267] antipsychotics,[268] and opioids.[269][270][271] However, it can also occur to a lesser extent under the influence of heavy dosages of hallucinogens such as psychedelics,[32] dissociatives,[272] deliriants,[267][273] and cannabinoids.[274][275][276][277]

Novel cognitive states

A novel cognitive state is defined as any cognitive effect which does not merely amplify or suppress familiar states of mind, but rather induces an experience that is qualitatively different from that of ordinary consciousness.

Although many transpersonal and psychological effects also technically fit into this definition, they are excluded from this category of effects as they have their own defining qualities which standard novel states do not.

This page lists and describes the various novel states which can occur under the influence of certain psychoactive compounds.

Cognitive dysphoria

Main article: Cognitive dysphoria

Cognitive dysphoria (semantically the opposite of euphoria) is medically recognized as a cognitive and emotional state in which a person experiences intense feelings of dissatisfaction, and in some cases indifference to the world around them.[278][279] These feelings can vary in their intensity depending on the dosage consumed and the user's susceptibility to mental instability. Although dysphoria is an effect, the term is also used colloquially to define a state of general melancholic unhappiness (such as that of mild depression)[280][281] often combined with an overwhelming sense of discomfort and malaise.[282]

Cognitive dysphoria is often accompanied by other coinciding effects such as anxiety and depression.[278][279][283] It is most commonly induced under the influence of moderate dosages of deliriant compounds, such as DPH and datura. However, it can also occur during a stimulant's offset and during the withdrawal symptoms of almost any substance.

Cognitive euphoria

Main article: Cognitive euphoria

Cognitive euphoria (semantically the opposite of cognitive dysphoria) is medically recognized as a cognitive and emotional state in which a person experiences intense feelings of well-being, elation, happiness, excitement, and joy.[284] Although euphoria is an effect (i.e. a substance is euphorigenic),[285][286] the term is also used colloquially to define a state of transcendent happiness combined with an intense sense of contentment.[287] However, recent psychological research suggests euphoria can largely contribute to but should not be equated with happiness.[288]

Cognitive euphoria is often accompanied by other coinciding effects such as physical euphoria and tactile intensification. It is most commonly induced under the influence of moderate dosages of opioids, entactogens, stimulants, and GABAergic depressants. However, it can also occur to a lesser extent under the influence of hallucinogenic compounds such as psychedelics, dissociatives, and cannabinoids.

Compulsive redosing

Main article: Compulsive redosing

Compulsive redosing is defined as the experience of a powerful and difficult to resist urge to continuously redose a psychoactive substance in an effort to increase or maintain the subjective effects which it induces.[289][290][291][292]

This effect is considerably more likely to manifest itself when the user has a large supply of the given substance within their possession. It can be partially avoided by pre-weighing dosages, not keeping the remaining material within sight, exerting self-control, and giving the compound to a trusted individual to keep until they deem it safe to return.

Compulsive redosing is often accompanied by other coinciding effects such as cognitive euphoria, physical euphoria, or anxiety suppression alongside of other effects which inhibit the clarity of one's decision-making processes such as disinhibition, motivation enhancement, and ego inflation. It is most commonly induced under the influence of moderate dosages of a wide variety of compounds, such as opioids, stimulants,[290][292][293] GABAergics,[290] and entactogens.[291] However, it can also occur to a lesser extent under the influence of dissociatives and cannabinoids.[291]

Conceptual thinking

Main article: Conceptual thinking

Conceptual thinking is defined as an alteration to the nature and content of one's internal thought stream. This alteration predisposes a user to think thoughts which are no longer primarily comprised of words and linear sentence structures. Instead, thoughts become equally comprised of what is perceived to be incredibly detailed renditions of the innately understandable and internally stored concepts for which no words exist. Thoughts cease to be spoken by an internal narrator and are instead “felt” and intuitively understood.

For example, if a person was to think of an idea such as a "chair" during this state, one would not hear the word as part of an internal thought stream, but would feel the internally stored, pre-linguistic and innately understandable data which comprises the specific concept labelled within one's memory as a "chair". These conceptual thoughts are felt in a comprehensive level of detail that feels as if it is unparalleled within the primarily linguistic thought structure of everyday life. This is sometimes interpreted by those who undergo it as some "higher level of understanding".

During this experience, conceptual thinking can cause one to feel not just the entirety of a concept's attributed data, but also how a given concept relates to and depends upon other known concepts. This can result in the perception that the person can better comprehend the complex interplay between the idea that is being contemplated and how it relates to other ideas.

Conceptual thinking is often accompanied by other coinciding effects such as personal bias suppression and analysis enhancement. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics and dissociatives. However, it can also occur to a lesser extent under the influence of entactogens, cannabinoids, and meditation.

Multiple thought streams

Multiple thought streams is defined as a state of mind in which a person has more than one internal narrative or stream of consciousness simultaneously occurring within their head. This can result in any number of independent thought streams occurring at the same time, each of which are often controllable in a similar manner to that of one's everyday thought stream.

These multiple coinciding thought streams can be experienced simultaneously in a manner which is evenly distributed and does not prioritize the awareness of any particular thought stream over an other. However, they can also be experienced in a manner which feels as if it brings awareness of a particular thought stream to the foreground while the others continue processing information in the background. This form of multiple thought streams typically swaps between specific trains of thought at seemingly random intervals.

The experience of this effect can sometimes allow one to analyze many different ideas simultaneously and can be a source of great insight. However, it will usually overwhelm the person with an abundance of information that becomes difficult or impossible to fully process at a normal speed.

Multiple thought streams are often accompanied by other coinciding effects such as memory suppression and thought disorganization. They are most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Simultaneous emotions

Main article: Simultaneous emotions

Simultaneous emotions is defined as the experience of feeling multiple emotions simultaneously without an obvious external trigger. For example, during this state a user may suddenly feel intense conflicting emotions such as simultaneous happiness, sadness, love, hate, etc. This can result in states of mind in which the user can potentially feel any number of conflicting emotions in any possible combination.

Simultaneous emotions are often accompanied by other coinciding effects such as memory suppression and emotion intensification. They are most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Thought loops

Main article: Thought loops

A thought loop is defined as the experience of becoming trapped within a chain of thoughts, actions and emotions which repeats itself over and over again in a cyclic loop. These loops usually range from anywhere between 5 seconds and 2 minutes in length. However, some users have reported them to be up to a few hours in length. It can be extremely disorientating to undergo this effect and it often triggers states of progressive anxiety within people who may be unfamiliar with the experience. The most effective way to end a cycle of thought loops is to simply sit down and try to let go.

This state of mind is most likely to occur during states of memory suppression in which there is a partial or complete failure of the person's short-term memory. This may suggest that thought loops are the result of cognitive processes becoming unable to sustain themselves for appropriate lengths of time due to a lapse in short-term memory, resulting in the thought process attempting to restart from the beginning only to fall short once again in a perpetual cycle.

Thought loops are most commonly induced under the influence of heavy dosages of hallucinogenic compounds,[7] such as psychedelics and dissociatives. However, they can also occur to a lesser extent under the influence of extremely heavy dosages of stimulants and benzodiazepines.

Time distortion

Main article: Time distortion

Time distortion is defined as an effect that makes the passage of time feel difficult to keep track of and wildly distorted.[294] It is usually felt in two different forms, time dilation and time compression.[31] These two forms are described and documented below:

Time dilation

Time dilation is defined as the feeling that time has slowed down.[295] This commonly occurs during intense hallucinogenic experiences and seems to stem from the fact that during an intense trip, abnormally large amounts of experience are felt in very short periods of time.[296][297] This can create the illusion that more time has passed than actually has. For example, at the end of certain experiences, one may feel that they have subjectively undergone days, weeks, months, years, or even infinite periods of time.

Time dilation is often accompanied by other coinciding effects such as spirituality intensification,[298] thought loops, novelty enhancement, and internal hallucinations in a manner which may lead one into perceiving a disproportionately large number of events considering the amount of time that has actually passed in the real world. It is most commonly induced under the influence of heavy dosages of hallucinogenic compounds, such as psychedelics,[299][300] dissociatives, entactogens,[301][302] and cannabinoids.

Time compression

Time compression is defined as the experience of time speeding up and passing much quicker than it usually would while sober. For example, during this state a person may realize that an entire evening has passed them by in what feels like only a couple of hours.

This commonly occurs under the influence of certain stimulating compounds and seems to at least partially stem from the fact that during intense levels of stimulation, people typically become hyper-focused on activities and tasks in a manner which can allow time to pass them by without realizing it. However, the same experience can also occur on depressant compounds which induce amnesia. This occurs due to the way in which a person can literally forget everything that has happened while still experiencing the effects of the substance, thus giving the impression that they have suddenly jumped forward in time.

Time compression is often accompanied by other coinciding effects such as memory suppression, focus intensification, stimulation, and amnesia in a manner which may lead one into perceiving a disproportionately small number of events considering the amount of time that has actually passed in the real world. It is most commonly induced under the influence of heavy dosages of stimulating and/or amnesic compounds,[303] such as dissociatives,[304] entactogens, amphetamines, and benzodiazepines.

Time reversal

Time reversal is defined as the perception that the events, hallucinations, and experiences that occurred around one's self within the previous several minutes to several hours are spontaneously playing backwards in a manner which is somewhat similar to that of a rewinding VHS tape. During this reversal, the person's cognition and train of thought will typically continue to play forward in a coherent and linear manner while they watch the external environment around them and their body's physical actions play in reverse order. This can either occur in real time, with 5 minutes of time reversal taking approximately 5 minutes to fully rewind, or it can occur in a manner which is sped up, with 5 minutes of time reversal only taking less than a minute. It can reasonably be speculated that the experience of time reversal may potentially occur through a combination of internal hallucinations and errors in memory encoding.

Time reversal is often accompanied by other coinciding effects such as internal hallucinations, thought loops, and deja vu. It is most commonly induced under the influence of extremely heavy dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and deliriants.

Psychological effects

Psychological effects are defined as any cognitive effect that is either established within the psychological literature or arises as a result of the complex interplay between other more simplistic components such as cognitive enhancements, intensifications, and suppressions.

This page lists and describes the various psychological effects which can occur under the influence of certain psychoactive compounds.

Catharsis

Main article: Catharsis

Catharsis (from the Greek katharsis) is precisely defined as a cleansing, with no substantial consensus in regards to its exact meaning.[305] Generally, this effect is a form of emotional insight.[306][307][308][309][310] The process typically starts off being difficult to fully face and is sometimes accompanied by physically intense sensations which typically lead into pronounced emotion intensification, deep introspection, and an analysis of one's character and past events.[33] During this experience many people describe reliving traumatic events, witnessing painful memories, having enhanced mental imagery, reliving of past experiences, painful feelings in general, and a release of previously repressed emotions.[308][310][33] This process of integrating manifestations of conflicts and traumas into long-term stable memories is often described as feeling very natural.

This effect can be helpful in aiding an individual overcome conditions such as addiction,[308][311] post-traumatic stress disorder (PTSD), and other personal afflictions relating to suffered past traumas.[312] After this experience is over, most users report feelings of increased life satisfaction, rejuvenation, and spirituality intensification which may last days, weeks, or even years after the event is over.[310][313]

Catharsis is most commonly induced in therapeutic settings under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.[312][314][315][316][317][318] However, it can also occur to a lesser extent under the influence of entactogens, dissociatives,[312][316][317] and meditation.

Delusions

Main article: Delusions

A delusion is a false belief based on incorrect inference about external reality that is firmly held despite what almost everyone else believes and despite what constitutes incontrovertible and obvious proof or evidence to the contrary. The belief is not ordinarily accepted by other members of the person's culture or subculture (i.e., it is not an article of religious faith). When a false belief involves a value judgement, it is regarded as a delusion only when the judgement is so extreme as to defy credibility. Delusional conviction can sometimes be inferred from an overvalued idea (in which case the individual has an unreasonable belief or idea but does not hold it as firmly as is the case with a delusion).[319][320][321]

This article focuses primarily on the types of delusion that are commonly induced by hallucinogens or other psychoactive substances, as opposed to the various categories that are listed within the DSM as occurring within people who suffer from psychiatric disorders such as schizophrenia. Although there are common themes between these two causes of delusion, the underlying circumstances are distinct enough that they are seemingly very different in their themes, behaviour, and frequency of occurrence.

Within the context of psychoactive substance usage, delusions can usually be broken out of when overwhelming evidence is provided to the contrary or when the person has sobered up enough to logically analyse the situation. It is exceedingly rare for hallucinogen induced delusions to persist into sobriety.

It is also worth noting that delusions can often spread between individuals in group settings.[322] For example, if one person makes a verbal statement regarding a delusional belief they are currently holding while in the presence of other similarly intoxicated people, these other people may also begin to hold the same delusion. This can result in shared hallucinations and a general reinforcement of the level of conviction in which they are each holding the delusional belief.

Delusions are most commonly induced under the influence of heavy dosages of hallucinogenic compounds, such as psychedelics, deliriants, and dissociatives. However, they can also occur to a lesser extent under the influence of cannabinoids, stimulant psychosis, and sleep deprivation. They are most likely to occur during states of memory suppression and share common themes and elements with clinical schizophrenia.

Depersonalization

Main article: Depersonalization

Depersonalization or depersonalisation (sometimes abbreviated as DP) is medically recognized as the experience of feeling detached from, and as if one is an outside observer of, one's thoughts, body, or actions.[319][323][305][310] During this state, the affected person may feel like they are "on autopilot" and that the world is lacking in significance.[310][324] Individuals who experience depersonalization feel detached from aspects of the self, including feelings (e.g., "I know I have feelings but I don't feel them"),[308] thoughts (e.g., "My thoughts don't feel like my own")[312], and sensations (e.g., touch, hunger, thirst, libido).[305][325][316] This can be distressing to the user, who may become disoriented by the loss of a sense that their self is the origin of their thoughts and actions.

It is perfectly normal for people to slip into this state temporarily,[326] often without even realizing it. For example, many people often note that they enter a detached state of autopilot during stressful situations or when performing monotonous routine tasks such as driving.

It is worth noting that this state of mind is also commonly associated with and occurs alongside derealization. While depersonalization is the subjective experience of unreality in one's sense of self, derealization is the perception of unreality in the outside world.[323][305][324][325][316]

Depersonalization is often accompanied by other coinciding effects such as anxiety,[305][308] depression,[308] time distortion,[312] and derealization.[325][317] It is most commonly induced under the influence of moderate dosages of dissociative compounds, such as ketamine,[326] PCP,[327][328] and DXM. However, it can also occur under the influence of cannabis,[326][317][329] psychedelics,[326] and to a lesser extent during the withdrawal symptoms of depressants[330][331] and SSRI's[326].

Derealization

Main article: Derealization
An artistic replication of what it feels like to experience watching the world through a screen.

Derealization or derealisation (sometimes abbreviated as DR) is medically recognized as the experience of feeling detached from, and as if one is an outside observer of, one's surroundings.[319][323] This effect is characterized by the individual feeling as if they are in a fog, dream, bubble, or something watched through a screen,[332] like a film or video game.[325] These feelings instill the person with a sensation of alienation and distance from those around them.

Derealization can be distressing to the user, who may become disoriented by the loss of the innate sense that their external environment is genuinely real. The loss of the sense that the external world is real can make it feel inherently artificial and lifeless.[325]

This state of mind is commonly associated with and often coincides with depersonalization. While derealization is a perception of the unreality of the outside world, depersonalization is a subjective experience of unreality in one's sense of self.

Derealization is often accompanied by various perceptual distortions such as visual acuity suppression, visual acuity enhancement, and perspective distortions.[325] Other coinciding effects include auditory distortions and depersonalization.[332][325] This effect is most commonly induced under the influence of moderate dosages of dissociative compounds, such as ketamine, PCP, and DXM. However, it can also occur to a lesser extent during the withdrawal symptoms of stimulants and depressants.

Depression

Main article: Depression

Depression medically encompasses a variety of different mood disorders whose common features are a sad, empty, or irritable mood accompanied by bodily and cognitive changes that significantly affect an individual's ability to function.[333][334] These different mood disorders have different durations, timing, or presumed origin. Differentiating normal sadness/grief from a depressive episode requires a careful and meticulous examination. For example, the death of a loved one may cause great suffering, but it does not typically produce a medically defined depressive episode.[333]

Within the context of psychoactive substance usage, depressivity is often accompanied by other coinciding effects such as anxiety, irritability and dysphoria. It is most commonly induced through prolonged chronic stimulant or depressant use, during the withdrawal symptoms of almost any substance, or during the comedown/crash of a stimulant. It is associated specifically with higher alcohol consumption.[335] However, it is worth noting that substance-induced depressivity is often much shorter lasting than clinical depression, usually subsiding once the effects or withdrawal symptoms of a drug have ended.

If you suspect you are experiencing symptoms of depression, it is highly recommended to seek therapeutic medical attention and/or a support group. Additionally, you may want to read the depression reduction effect.

Depression as an effect has an unfortunate non-specific definition. There are several other relevant terms which should be taken into account when trying to understand this state of mind. These are listed and described.

Depression reduction

Main article: Depression reduction

Depression reduction is the experience of minimizing the symptoms associated with depression and low mood states. It is distinct from effects such as cognitive euphoria, as it does not simply elevate the user's mood but instead results in a sense of stable emotional well-being.

Depression reduction most commonly occurs with adequate nutritional intake.[336][337][338][339][340] Severe depression is effectively reduced with conventional antidepressants; although in mild to moderate depression, SSRI's and tricyclic antidepressants appear (on average) to be either only minimally helpful or completely ineffective.[341] However, depression reduction can also occur under the influence of hormone replacement therapies[342][343] and modafinil.[344]

Euthymia

Euthymia (semantically the opposite of dysthymia) is a long-lasting and self-sustaining experience of stable emotional well-being.[345] This state is characterized by:

  • A lack disordered mood in patients with prior clinically diagnosed mood disorders; if sadness/anxiety/irritability are experienced they are short-lived and do not significantly impact everyday life.
  • Feeling cheerful, calm, active, and interested in things.
  • Possessing cognitive flexibility.
  • Sleep is refreshing or restorative.
  • A unifying outlook on life which guides actions and feelings to shape the future.
  • Being resistant to stress (resilience and anxiety or frustration tolerance).

This is unlikely to be an isolated effect component but rather the result of combining an appropriate environment with other coinciding effects such as rejuvenation, introspection, personal bias suppression, and spirituality intensification. It may also stem from the direct neurological changes that occur as a result of a substances’ pharmacological action.

Euthymia most commonly occurs at varying levels of efficacy under the influence of a range of different substances, primarily psychedelics in combination with psychotherapy,[346][347] or dissociatives.[348] However, it can also occur throughout the course of prescribed psychiatric medications and under the influence of certain entactogens.

Ego replacement

Main article: Ego replacement

Ego replacement is defined as the sudden perception that one's sense of self and personality has been replaced with that of another person's, a fictional character's, an animal's, or an inanimate object's perspective. This can manifest in a number of ways which include but are not limited to feeling is one has literally become another human, animal, or alien consciousness. During this state, the person will be unlikely to realize that their personality has been temporarily swapped with another's and will usually not remember their previous life.

Ego replacement is often accompanied by other coinciding effects such as delusions, psychosis, and memory suppression. It is most commonly induced under the influence of moderate dosages of heavy dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and deliriants.

Feelings of impending doom

Feelings of impending doom are defined as the sudden sensations of overwhelming fear and urgency based on the belief that a negative event is about to occur in the immediate future. Negative events typically include some kind of medical emergency, such as the vasovagal response presenting as fainting during a blood donation;[349] fearing the potential to cause harm to others, being harmed, or dying;[350] or that the world coming to an end. This effect can be the result of real evidence, but may also be based on an unfounded delusion or negative hallucinations. The intensity of these feelings can become overwhelming enough to trigger panic attacks.[351][352]

Feelings of impending doom are often accompanied by vague/paradoxical physical effects[349] and other coinciding effects such as anxiety, panic attacks,[353] and unspeakable horrors. They are most commonly induced under the influence of heavy dosages of hallucinogenic compounds, such as deliriants like myristicin,[354][355][356][357] psychedelics,[358][359][360][361][362] and dissociatives. However, they can also occur during medical issues, cardiac arrest, mental illness, or interpersonal problems.

Introspection

Main article: Introspection

Increased introspection is a metacognitive effect defined as the state of mind in which a person feels encouraged to reflect upon and examine their internal psychological processes, judgements, or perceptions.[363][364][365][366][367][368] Questions such as "Why am I feeling so?", "How can I describe it?", "How may I cease/sustain this undesirable/desirable experience?" are examples of introspection.[369] It is important to note that introspection is only an inner observation; verbalizing the contents, especially outloud, is considered an entirely different process.[370]

This state of mind is effective at facilitating therapeutic self-improvement and positive personal growth. Contrary to early psychological assumptions, introspection appears to be an ability that can be honed; humans do not have automatic or unbiased access to experience.[366][367] Increasing introspection often results in insightful resolutions to the present situation, future possibilities, insecurities, and goals coinciding with personal acceptance of insecurities, fears, hopes, struggles, and traumas.

Increased introspection is likely the result of a combination of an appropriate setting in conjunction with other coinciding effects such as analysis enhancement, mindfulness,[366] and personal bias suppression. It is most commonly induced during meditation[367] or under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics[371] and dissociatives.[365][372][373] However, it can also occur in a less consistent form under the influence of entactogens.

Mania

Main article: Mania

Mania can be described as a state of abnormally elevated energy levels and general arousal. The typical symptoms of mania are the following: heightened mood (either euphoric or irritable), thought acceleration, a flooding of ideas, extreme talkativeness, increased energy, a decreased need for sleep, and hyperactivity. This state of mind can vary wildly in its intensity, from mild mania (hypomania) to full-on manic psychosis[374]. The accompanying symptoms are most obvious during states of fully developed delirious mania in which the person exhibits increasingly severe manic tendencies that become more and more obscured by other signs and symptoms, such as delusions, psychosis, incoherence, catatonia and extreme disorderly behavior.

Within the context of clinical psychology, standardized tools such as Altman Self-Rating Mania Scale[375] and Young Mania Rating Scale[376] can be used to measure severity of manic episodes. It is worth noting that since mania and hypomania is often associated with creativity and artistic talent, it is not always the case that a clearly manic person needs or wants medical help; such persons often either retain sufficient self-control to function normally or are simply unaware that they are severely manic enough to be committed to a psychiatric ward or to commit themselves.

Although mania is often stereotyped as a “mirror image” of depression, the heightened mood can be either euphoric or irritable. As irritable mania worsens, the irritability often becomes more pronounced and may eventually result in violent behaviour.

Mania is often accompanied by other coinciding effects such as ego inflation and stimulation. It commonly occurs under the influence of heavy doses of stimulant (e.g. methamphetamine, cocaine, MDPV, a-PVP) or dissociative (e.g. PCP, dextromethorphan) compounds.

Mindfulness

Main article: Mindfulness

Mindfulness can be described as a psychological concept which is well established within the scientific literature and commonly discussed in association with meditation.[377][378]

It is often broken down into two separate subcomponents which comprise this effect: The first of these components involves the self-regulation of attention so that its focus is completely directed towards immediate experience, thereby quietening one's internal narrative and allowing for increased recognition of external and mental events within the present moment.[379][380] The second of these components involves adopting a particular orientation toward one’s experiences in the present moment that is characterized by a lack of judgement, curiosity, openness, and acceptance.[381]

Within meditation, this state of mind is deliberately practised and maintained via the conscious and manual redirection of one's awareness towards a singular point of focus for extended periods of time. However, within the context of psychoactive substance usage, this state is often spontaneously induced without any conscious effort or the need of any prior knowledge regarding meditative techniques.

Mindfulness is often accompanied by other coinciding effects such as anxiety suppression and focus intensification. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and cannabinoids. However, it can also occur on entactogens, certain nootropics such as l-theanine, and during simultaneous doses of benzodiazepines and stimulants.

Panic attacks

Main article: Panic attacks

A panic attack is a discrete episode of sudden onset of intense fear or apprehension.[319][382] During these attacks there are symptoms such as shortness of breath or smothering sensations; palpitations, pounding heart, or accelerated heart rate; chest pain or discomfort; choking; and fear of going crazy or losing control. Panic attacks may be unexpected, in which the onset of the attack is not associated with an obvious trigger and instead occurs "out of the blue," or expected, in which the panic attack is associated with an obvious trigger, either internal or external.

Panic attacks are usually triggered in moments of severe anxiety, such as that caused by a bad trip. They are so subjectively overwhelming both physically and mentally that the user may believe they are dying, or that some great calamity is imminent, and are commonly mistaken for heart attacks. The subjective sensations can overwhelm rational thought even when the user recognizes that they are having a panic attack, especially in those who have not experienced them before.

Panic attacks are often accompanied by uncomfortable physical symptoms that may further aggravate a person’s anxiety as they may be mistaken for a serious health problem. The strongest mental effect of panic attacks is a crushing sense of impending doom,[319] accompanied by despair, panic, and dread. These usually begin abruptly and may reach their peak within 10 to 20 minutes, but may also continue for hours in extreme cases before subsiding on their own. Although this experience is incredibly stressful it is important to note that it is not physically dangerous or harmful.

The various cognitive and physical symptoms of a panic attack are described and listed below:

  • Hyperventilation - Hyperventilation occurs when one breathes deeper and more rapidly than usual. When hyperventilating, one may feel as though they are struggling to get enough air. As this causes a decrease of carbon dioxide in the blood, it may result in light headedness, a rapid heartbeat, chest pain, or a tingling sensation in a person's limbs.
  • Abnormal heart rate and palpitations - Due to the release of stress hormones, one may experience heart symptoms including missed beats, palpitations, chest pain, and an accelerated heart rate.
  • Tactile suppression - This can be described as a loss of sensation as well as numbness and tingling sensations throughout the body. It may feel as if one's skin or body parts are numb to the touch, and this can occur in a small area or become all-encompassing throughout multiple body parts or the entire body. Numbness most frequently occurs within the hands, legs, arms, feet, and face. This effect is often accompanied by a pins and needle sensation and it generally increases alongside of hyperventilation.
  • Shortness of breath
  • Sweating
  • Trembling or shaking
  • Feelings of choking
  • Chest pain or discomfort
  • Bodily pressures
  • Nausea or abdominal distress
  • Feeling dizzy, unsteady, lightheaded, or faint
  • Derealization
  • Depersonalization
  • Fear of losing control or going insane
  • Feelings of impending doom
  • Chills or hot flashes
  • Delusions

Paranoia

Main article: Paranoia

Paranoia is the suspiciousness or the belief that one is being harassed, persecuted, or unfairly treated.[383] These feelings can range from subtle and ignorable to intense and overwhelming enough to trigger panic attacks and feelings of impending doom. Paranoia also frequently leads to excessively secretive and overcautious behavior which stems from the perceived ideation of one or more scenarios, some of which commonly include: fear of surveillance, imprisonment, conspiracies, plots against an individual, betrayal, and being caught. This effect can be the result of real evidence, but is often based on assumption and false pretense.

Paranoia is often accompanied by other coinciding effects such as anxiety and delusions. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as cannabinoids,[384] psychedelics, dissociatives, and deliriants. However, it can also occur during the withdrawal symptoms of GABAergic depressants and during stimulant comedowns.

Personality regression

Personality regression is a mental state in which one suddenly adopts an identical or similar personality, thought structure, mannerisms and behaviours to that of their past self from a younger age.[385] During this state, the person will often believe that they are literally a child again and begin outwardly exhibiting behaviours which are consistent to this belief. These behaviours can include talking in a childlike manner, engaging in childish activities, and temporarily requiring another person to act as a caregiver or guardian. There are also anecdotal reports of people speaking in languages which they have not used for many years under the influence of this effect.[386]

Personality regression is often accompanied by other coinciding effects such as anxiety, memory suppression, and ego dissolution. It is a relatively rare effect that is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, most notably Ayahuasca, LSD and Ibogaine in particular as well as certain dissociatives. However, it can also occur for people during times of stress,[385] as a response to childhood trauma, as a symptom of borderline personality disorder,[387] or as a regularly reoccuring facet of certain peoples lives that is not necessarily associated with any psychological problems.

Psychosis

Main article: Psychosis

Psychosis is defined as an abnormal condition of the mind and a general psychiatric term for a mental state in which one experiences a "loss of contact with reality."[388] The features of psychoticism are characterized by delusions, hallucinations, and formal thought disorders exhibiting a wide range of culturally incongruent, odd, eccentric, or unusual behaviors and cognitions, including both process (e.g., perception, dissociation) and content (e.g., beliefs).[389] Depending on its severity, this may also be accompanied by difficulty with social interaction and a general impairment in carrying out daily life activities.

Within the context of clinical psychology, psychosis is a very broad term that can mean anything from relatively mild delusions to the complex and catatonic expressions of schizophrenia and bipolar type 1 disorder. Generally speaking, however, psychosis involves noticeable deficits in cognitive functioning and diverse types of hallucinations or delusional beliefs, particularly those that are in regard to the relation between self and others such as delusions of grandiosity, paranoia, or conspiracy. The most common of these signs and symptoms of psychosis are listed as separate subcomponents below:

Psychosis is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as deliriants,[390][391] psychedelics,[392] dissociatives,[393] and cannabinoids[394][395]. However, it can also occur under the influence of stimulants,[396][397] particularly during the comedown or as a result of prolonged binges. It may also manifest from abrupt discontinuation of long term or heavy usage of certain drugs such as benzodiazepines[398] or alcohol[399]; this is known as delirium tremens (DTs). Aside from substance abuse it may also occur as a result of sleep deprivation, emotional trauma, urinary tract infections, and various other medical conditions.[citation needed]

Rejuvenation

Main article: Rejuvenation

Rejuvenation can be described as feelings of mild to extreme cognitive refreshment which are felt during the afterglow of certain compounds. The symptoms of rejuvenation often include a sustained sense of heightened mental clarity, increased emotional stability, increased calmness, mindfulness, increased motivation, personal bias suppression, increased focus and decreased depression. At its highest level, feelings of rejuvenation can become so intense that they manifest as the profound and overwhelming sensation of being "reborn" anew. This mindstate can potentially last anywhere from several hours to several months after the substance has worn off.

Rejuvination is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics and dissociatives. However, it can also occur to a lesser extent under the influence of entactogens, cannnabinoids, and meditation.

Suicidal ideation

Main article: Suicidal ideation

Suicidal ideation can be described as the experience of compulsive suicidal thoughts and a general desire to end one's own life. These thoughts patterns and desires range in intensity from fleeting thoughts to an intense fixation. This effect can also create a predisposition to other self-destructive behaviors such as self-harm or drug abuse and, if left unresolved, can eventually lead to attempts of suicide.

Suicidal ideation is often accompanied by other coinciding effects such as depression and motivation enhancement in a manner which maintains the person's negative view on life but also increases their will to take immediate action. It is most commonly induced under the influence of moderate dosages of various antidepressants of the selective serotonin reuptake inhibitor class. However, outside of psychoactive substance usage, it can also occur as a manifestation of a number of things including mental illness, traumatic life events, and interpersonal problems.

If you suspect that you are experiencing symptoms of suicidal ideation, it is highly recommended that you seek out therapy, medical attention, or a support group.

Transpersonal effects

Transpersonal effects are defined as any subjective effect which feels as if it alters a person's cognition in a manner which relates to or contains information regarding their place in the universe, the inner workings of reality or consciousness, and the context of their existence. The fullest manifestation of these effects fall under what are sometimes called "peak", "transcendent" or "transformative" experiences.

These effects are typically associated with high dose psychedelic or dissociative experiences. They can occur regardless of the person's spiritual or religious beliefs and often have a distinct and lasting impact on the user's perspective of the world around them. During the experience of a substance-induced transpersonal state, the information conveyed is often felt to be a real and objective truth. However, the person will often come to disagree with these supposed "epiphanies" once the effects of the substance have worn off.

It should be noted that these mind-states are the least reproducible of all effects within the subjective effect index. They are unique in that that simply taking more of a given substance does not necessarily increase the chances of having these states occur. Instead, they seem to rely more on contextual factors such as the person's set and setting.

This page lists and describes the various transpersonal states which can occur under the influence of certain psychoactive compounds.

Ego dissolution

Main article: Memory suppression

Memory suppression (also known as ego suppression, ego dissolution, ego loss or ego death) is defined as an inhibition of a person's ability to maintain a functional short and long-term memory.[249][188][70] This occurs in a manner that is directly proportional to the dosage consumed, and often begins with the degradation of one's short-term memory.

Memory suppression is a process which may be broken down into the 4 basic levels described below:

  1. Partial short-term memory suppression - At the lowest level, this effect is a partial and potentially inconsistent failure of a person's short-term memory. It can cause effects such as a general difficulty staying focused, an increase in distractibility, and a general tendency to forget what one is thinking or saying.
  2. Complete short-term memory suppression - At this level, this effect is the complete failure of a person's short-term memory. It can be described as the experience of being completely incapable of remembering any specific details regarding the present situation and the events leading up to it for more than a few seconds. This state of mind can often result in thought loops, confusion, disorientation, and a loss of control, especially for the inexperienced. At this level, it can also become impossible to follow both conversations and the plot of most forms of media.
  3. Partial long-term memory suppression - At this level, this effect is the partial, often intermittent failure of a person's long-term memory in addition to the complete failure of their short-term memory. It can be described as the experience of an increased difficulty recalling basic concepts and autobiographical information from one's long-term memory. Compounded with the complete suppression of short term memory, it creates an altered state where even basic tasks become challenging or impossible as one cannot mentally access past memories of how to complete them.

    For example, one may take a longer time to recall the identity of close friends or temporarily forget how to perform basic tasks. This state may create the sensation of experiencing something for the first time. At this stage, a reduction of certain learned personality traits, awareness of cultural norms, and linguistic recall may accompany the suppression of long-term memory.

  4. Complete long-term memory suppression - At the highest level, this effect is the complete and persistent failure of both a person's long and short-term memory. It can be described as the experience of becoming completely incapable of remembering even the most basic fundamental concepts stored within the person's long-term memory. This includes everything from their name, hometown, past memories, the awareness of being on drugs, what drugs even are, what human beings are, what life is, that time exists, what anything is, or that anything exists.

    Memory suppression of this level blocks all mental associations, attached meaning, acquired preferences, and value judgements one may have towards the external world. Sufficiently intense memory loss is also associated with the loss of a sense of self, in which one is no longer aware of their own existence. In this state, the user is unable to recall all learned conceptual knowledge about themselves and the external world, and no longer experiences the sensation of being a separate observer in an external world. This experience is commonly referred to as "ego death".

Memory suppression is often accompanied by other coinciding effects such as thought loops, personal bias suppression, amnesia, and delusions. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and deliriants.[250]

It is worth noting that although memory suppression is vaguely similar in its effects to amnesia, it differs in that it directly suppresses one's usage of their long or short term memory without inhibiting the person's ability to recall what happened during this experience afterward. In contrast, amnesia does not directly affect the usage of one's short or long-term memory during its experience but instead renders a person incapable of recalling events after it has worn off. A person experiencing memory suppression cannot access their existing memory, while a person with drug-induced amnesia cannot properly store new memories. As such, a person experiencing amnesia may not obviously appear to be doing so, as they can often carry on normal conversations and perform complex tasks. This is not the case with memory suppression.

Existential self-realization

Existential self-realization can be described as a sudden realization, revelation, or reaffirmation of a person's existence within this universe. This typically feels like a sudden and profound "waking up" or "rebirth" that results in an intense sense of motivation, an added sense of purpose to one’s life, a sudden comprehension of their own situation, an appreciation for life, and a sense of urgency to make the most out of it while it lasts. During this state, no new knowledge is learned but the previously known information regarding their existence is reintegrated in a sudden and profound manner that results in a deep sense of appreciation for the unlikely circumstances of their own existence. The residual impacts of this effect often carry over into sobriety, potentially resulting in lasting positive benefits for the person.

Existential self-realization is most commonly induced under the influence of moderate dosages of psychedelic and dissociative compounds such as ketamine, LSD, 4-AcO-DMT, and DCK. However, it can also occur to a lesser extent after near death experiences and under the influence of entactogens such as MDMA.

Identity alteration

Main article: Identity alteration

Identity alteration can be defined as the experience of one's sense of self becoming temporarily changed to feel as if it is comprised of different concepts than that which it previously did. For example, while a person may usually feel that they are exclusively their “ego” or a combination of their “ego” and physical body, during this state their sense of identity can change to include the external environment or an object they are interacting with. Alternatively, a person could feel as if their sense of self embodies nothing at all, which is an experience commonly referred to as depersonalisation.

The concept of identity itself can be defined as a fundamental and near universal component of human perception that provides the experience of feeling like a self, a separate system intrinsically differentiated from the external world. This feeling is commonly referred to as one's sense of identity, ego, or selfhood. In general conversation, it is referred to using pronouns such as "I", "me", "mine", and "myself" as a tool for contrasting one's self from other people and any other system which is not felt to be them.

However, it is worth noting that rather than being a static, unmoving, or objective concept that it is often assumed to be, a person's identity can actually be experienced in many ways. There is no component of the human brain, body, or consciousness which can be singled out as the location of a person's individual selfhood. The self is thus speculated to be a learned and constructed concept that arises through a combination of experience, the structure of language, and social interactions with other people. This notion is in stark contrast to the common Western cultural conception that human beings each contain a tangible identity that is a real and separate system from that which resides around it.

Within traditional religions, the intrinsic nature of human identity differs depending on the specific doctrine. For example, Abrahamic religions such as Christianity and Islam use an inherently dualist approach which claims that the self is a soul which resides within the body and is intrinsically separate from its external environment.[400] In contrast, Eastern religions such as Hinduism and Buddhism take an approach known as monism, or nondualism which generally speaking, assumes that the separate self is illusory and that there is no difference between one's identity or soul and the "external" universe which it resides in.

In regard to identity alteration, there are a total of 5 distinct levels of identity which a person can experience. These various altered states of identity have been arranged into a levelling system that orders its different states from least to the most number of concepts one's identity is currently attributed to. These levels are described and documented below:

1. Total absence of attributed identity (depersonalization)

Main article: Depersonalization

The lowest level of identity can be described as the sensation that there is a complete absence of having any sense of self at all. This is referred to in psychiatry as "depersonalization". It can be described as an anomaly of self-awareness that consists of a feeling of watching oneself act as one normally would, while also feeling is if they have no control over the situation. It can occur under the influence of hallucinogenic substances, particularly dissociatives,[401] and may persist for some time after sobriety.[332] During this state, the affected person may feel that they are "on autopilot" and that the world has become vague, dreamlike, less real, or lacking in significance. Individuals who experience depersonalization often feel divorced from their own personal physicality by no longer sensing their body sensations, feelings, emotions, and behaviors as belonging to a person or identity. It is also often claimed by people who have depersonalization that reality seems unreal, distant or hazy. Depersonalization can sometimes be distressing to the user, who may become disoriented by the loss of a sense that their self is the origin of their thoughts and actions. However, it does not have to be an inherently negative altered state of awareness, as it does not directly affect a person's emotions or thought patterns.

It is perfectly normal for many people to slip into this state temporarily, often without even realizing it. For example, many people often note that they enter a detached state of autopilot during stressful situations or when performing monotonous routine tasks such as driving.

In psychology, chronic depersonalization that persists during sobriety for prolonged periods of time is identified as "depersonalization disorder" and is classified by the DSM-IV as a dissociative disorder. While degrees of depersonalization are common and can happen temporarily to anyone who is subject to an anxiety or stress provoking situation, chronic depersonalization is more common within individuals who have experienced a severe trauma or prolonged stress and anxiety. The symptoms of both chronic derealization and depersonalization are common within the general population, with a lifetime prevalence of up to 26-74% and 31–66% at the time of a traumatic event.[402] It has also been demonstrated that derealization may be caused by a dysfunction within the brains visual processing center (occipital lobe) or the temporal lobe, which is used for processing the meaning of sensory input, language comprehension, and emotion association.[403]

Within the context of identity altering effects, depersonalization can be considered as being at the opposite end of the identity spectrum relative to states of unity and interconnectedness. This is because during depersonalisation, a person senses and attributes their identity to nothing, giving a sense of having no self. However, during a state of unity and interconnectedness, one senses and attributes their identity to everything, giving a sense that the entirety of existence is their self.

Depersonalization is often accompanied by other coinciding effects such as anxiety and a very similar psychological disorder known as derealization.[332] It is most commonly induced under the influence of moderate dosages of dissociative compounds, such as ketamine, PCP, and DXM. However, it can also occur to a lesser extent during the withdrawal symptoms of stimulants and depressants.

2. Self-contained separate identity

The second level of identity can be described as feeling as if one's identity is attributed to their brain and/or body. This is often said to feel as if one is a consciousness, the guiding force located within a body which is immersed in and interacting with a distinctly separate external environment. It is usually accompanied with a sense of free will or agency over all the thoughts and actions the person makes, which results in them feeling as if their decision-making processes are arising from an internal source which is not necessarily determined by cause and effect in the same manner as external systems.

A self-contained separate identity is by far the most common form of identity. Mainstream Western cultural notions consider this conception of the self to be the self-evident or logical way to perceive the world and the only form of identity which isn't intrinsically delusional. Despite being culturally normative, this belief has received considerable debate and criticism within modern neuroscience and philosophy.[404]

Although drastically altered in comparison to that of sobriety, it is worth noting that hallucinatory states such as ego replacement and 2nd person perspective hallucinations typically still fall under the classification of this level. In both cases, a person still feels as if they are a separate agent facing the external world, but have the perception of being a different identity than their sober self.

3. Identifying with specific "external" systems

The third level of identity alteration can be described as feeling as if one's identity is attributed to (in addition to the body and/or brain) specific external systems or concepts within the immediate environment, particularly those that would usually be considered as intrinsically separate from one's own being.

The experience itself is often described as a loss of perceived boundaries between a person’s identity and the specific physical systems or concepts within the perceivable external environment which are currently the subjects of their thoughts or focus. This creates a sensation of becoming inextricably "connected to", "one with", "the same as", or "unified" with whatever the perceived external system happens to be.

There are an endless number of ways in which this level manifests itself, but common examples of the experience often include:

  • Becoming unified with and identifying with a specific object one is interacting with.
  • Becoming unified with and identifying with another person or multiple people, particularly common if engaging in sexual or romantic activities.
  • Becoming unified with and identifying with the entirety of one's own physical body.
  • Becoming unified with and identifying with large crowds of people, particularly common at raves and music festivals.
  • Becoming unified with and identifying with the immediately perceivable external environment, but not the people within it.

This level of identity alteration most commonly occurs during intense states of focus, meditation, or under the influence of hallucinogens such as psychedelics.

4. Identifying with all perceivable "external" systems

The fourth level of identity alteration can be defined as feeling as if one's identity is attributed to the entirety of their immediately perceivable external environment.

The experience itself is often described as a loss of perceived boundaries between a person’s identity and the entirety of their sensory input or the currently perceivable external environment. It creates a sensation in the person that they have “become one with their surroundings.” This is felt to be the result of a person’s sense of self becoming attributed to not just primarily the internal narrative of the ego, but in equal measure to the body itself and everything around it which it is physically perceiving through the senses. This sensation creates the compelling perspective that the person is the external environment experiencing itself through a specific point within it, namely the physical sensory perceptions of the body their consciousness currently resides in.

It is at this point that a key component of the high-level identity alteration experience becomes an extremely noticeable factor. Once a person's sense of self has become attributed to the entirety of their surroundings, this new perspective completely changes how it feels to physically interact with what was previously felt to be an external environment. For example, when a person is not in this state and is interacting with a physical object, it typically feels as though they are a central agent acting on the separate world around them.

However, while undergoing a state of unity with the currently perceivable environment, interacting with an external object consistently feels as if the whole unified system is autonomously acting on itself with no central, separate agent operating the process of interaction. Instead, the process suddenly feels as if it has become completely decentralized and wholistic, as the environment begins to autonomously and harmoniously respond to itself in a predetermined manner to perform the interaction carried out by the individual.

This level of identity alteration most commonly occurs during intense states of focus, meditation, or under the influence of hallucinogens such as psychedelics.

5. Identifying with all known "external" systems

This symbol depicts the universe as a "self-excited circuit". It was originally created by the late theoretical physicist John Archibald Wheeler in his 1983 paper Law Without Law.

The fifth level of identity alteration can be defined as feeling as if one's identity is simultaneously attributed to the entirety of the immediately perceivable external environment and all known concepts that exist outside of it. These known concepts typically include all of humanity, nature, and the universe as it presently stands in its complete entirety. This feeling is commonly interpreted by people as becoming one with the universe.

When experienced, the effect creates the sudden perspective that the person is not a separate agent approaching an external reality, but is instead the entire universe as a whole experiencing itself, exploring itself, and performing actions upon itself through the specific point in space and time which this particular body and conscious perception happens to currently reside within. People who undergo this experience consistently interpret it as the removal of a deeply embedded illusion, with the revelation often described as some sort of supposedly profound “awakening” or “enlightenment.”

Although they are not necessarily literal truths about reality, at this point, many commonly reported conclusions of a religious and metaphysical nature often begin to manifest themselves as profound realizations. These are described below:

  • The sudden and total acceptance of death as a fundamental complement of life. Death is no longer felt to be the destruction of a person, but simply the end of this specific point of a greater whole, which has always existed and will continue to exist and live on through everything else in which it resides. Therefore, the death of a small part of the whole is seen as an inevitable, and not worthy of grief or any emotional attachment, but simply a fact of reality.
  • The subjective perspective that the person's preconceived notions of "god" or deities can be felt as identical to the nature of existence and the totality of its contents, including oneself. This typically entails the intuition that if the universe contains all possible power (omnipotence), all possible knowledge (omniscience), is self-creating, and self-sustaining then on either a semantic or literal level the universe and its contents could also be viewed as god.
  • The subjective perspective that the person, by nature of being the universe, is personally responsible for the design, planning, and implementation of every single specific detail and plot element of one's personal life, the history of humanity, and the entirety of the universe. This naturally includes personal responsibility for all humanity's sufferings and flaws but also includes its acts of love and achievements.

This state most commonly occurs during intense states of well-practiced meditation or under the influence of hallucinogens such as psychedelics.

Similar concepts

Similar accounts of the experience of unity with the universe and the apparent illusory nature of the self can be found across a surprisingly large variety of independent religious, philosophical, and psychological sources. A number of these have been collected and listed as a set of documented examples below:

  • Egolessness is a documented emotional state within psychology where one feels no ego (or self) and no distinct sense of self apart from the world around oneself. This is often described as feelings of oneness and being inextricably woven into the fabric of one’s surroundings or environment.
  • Monism is a philosophical position which argues that there is only one thing which all things are not separate from and it works together as a unified system of behavior.
  • Dialectical monism is a philosophical position which argues that the appearance of duality arises from the mind's need to impose divisions and boundaries upon an essentially unified whole. Thus, for the dialectical monist, reality is ultimately a single unified system but can usually only be experienced in terms of division.
  • Oceanic feeling is a state within psychology which is described as a sensation of an indissoluble bond of being connected with the external world in its integral form.
  • Nondualism is a philosophy found within many religions which states that there is no difference between the concept of the external environment and the self.
  • Alan Watts is a philosopher who spoke extensively about the illusory nature of the self. His lectures can be found for free on the Pirate Bay and in parts within many videos across YouTube. His book “The Book on the Taboo of Knowing Who You Are” is dedicated to a formal explanation of the philosophies and logic behind this perspective and can be found within the form of a free PDF.
  • Interconnectedness is a philosophical concept which defines itself as part of the terminology of a world view which sees a oneness in all things. This is based on the idea that all things are of a single underlying substance or reality and that there is no true separation deeper than appearances.
  • Samadhi is a Buddhist concept described as a state of mind in which the consciousness of the experiencing subject becomes one with the experienced object.
  • Overview effect is a cognitive shift in awareness reported by some astronauts and cosmonauts during spaceflight, often while viewing the Earth from orbit or from the lunar surface.

Perceived exposure to inner mechanics of consciousness

Perceived exposure to inner mechanics of consciousness can be described the experience of being exposed to an array of complex, autonomously-generated, cognitive sensations and conceptual thoughts which contain detailed sets of innately readable information.

The information within these sensations is felt to convey the organization, structure, architecture, framework and inner mechanics of the underlying programming behind all conscious and subconscious psychological processes. Those who undergo this effect commonly interpret the experience as suddenly having perceivable access to the inner workings of either the universe, reality, or consciousness itself.

The experience of this effect often feels capable of bestowing specific pieces of information onto trippers regarding the nature of human consciousness, and sometimes reality itself. The pieces of information felt to be revealed are highly varied, but some common sensations, revelations, and concepts are manifested between individuals. These generally include:

  • Insight into the processes behind the direction, behavior, and content of one's conscious thought stream.
  • Insight into the processes behind the organization, behavior, and content of one's short and long-term memory.
  • Insight into the selection and behavior of one's responses to external input and decision-making processes as based on their individual personality.
  • Insight into the origin and influences behind one’s character traits and beliefs.

These specific pieces of information are often felt and understood to be a profound unveiling of an undeniable truth at the time. Afterward, they are usually realized to be ineffable due to the limitations of human language and cognition, or simply nonsensical, and delusional due to the impairment caused by of other accompanying cognitive effects.

Perceived exposure to inner mechanics of consciousness is often accompanied by a vastly more complex and visual version of this effect which is referred to as Level 8B Geometry. It is most commonly induced under the influence of heavy dosages of psychedelic tryptamines such as psilocin, ayahuasca, DMT, and 4-AcO-DMT. cannabinoids.

Perception of eternalism

The image above represents how a person under the influence of this component would view themselves as an organism. This is often described as being a singular structure which stretches through the physical dimension of time alongside of all other identically behaving structures which the universe as a whole is entirely comprised of.

Perception of eternalism can be described as the experience of a major alteration of one's perspective of the fundamental mechanics behind the linear continuity of time moving from the past to the present to the future. During this state of mind, it feels as if all points across the timeline of existence are equally "real" and are occurring simultaneously alongside each other. Every point in time is felt to exist regardless of the person's current position within the overall timeline, much as all points in physical space persist regardless of the observer's location. However, it is important to understand that these conclusions and feelings should not be accepted at face value as inherently true.

While all moments are felt to be equally real, the directional flow of time is felt to be maintained, with the present always being the moment which is currently experienced. All moments in time are still felt to be linked together by causality, the past necessitating the present, which necessitates the future, and so forth.

A common conclusion that is reached during the experience of this state is that although one's life inevitably will end, it will apparently persist forever within its own timeframe and is therefore perpetual despite not being infinite in its length. Birth and death are therefore merely the start and end points of the range of time that a person exists in eternally, if not experiences eternally.

This sudden change in perspective starkly contrasts with the standard perception of time in which only the present is felt to exist, while the past no longer is and the future is yet to be.

Perception of eternalism is often accompanied by other coinciding transpersonal effects such as unity and interconnectedness and feelings of interdependent opposites. It is most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Perception of interdependent opposites

In Chinese philosophy, yin and yang, are concepts used to describe how opposite or contrary forces are actually complementary, interconnected, and interdependent in the natural world.

Perception of interdependent opposites can be described as the experience of a powerful subjective feeling that reality is based upon a binary system in which the existence of fundamentally important concepts or situations logically arise from and depend upon the co-existence of their opposite. This perception is not just understood at a cognitive level, but manifests as intuitive sensations which are felt rather than thought by the person.

This experience is usually interpreted as providing a deep insight into the fundamental nature of reality. For example, concepts such as existence and non-existence, life and death, up and down, self and other, light and dark, good and bad, big and small, pleasure and suffering, yes and no, internal and external, hot and cold, young and old, etc are felt to exist as harmonious forces which necessarily contrast their opposite force in a state of equilibrium.

Perception of interdependent opposites is often accompanied by other coinciding transpersonal effects such as ego dissolution, unity and interconnectedness, and perception of eternalism. It is most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Perception of predeterminism

Perception of predeterminism can be described as the sensation that all physical and mental processes are the result of prior causes, that every event and choice is an inevitable outcome that could not have happened differently, and that all of reality is a complex causal chain that can be traced back to the beginning of time. This is accompanied by the absence of the feeling that a person's decision-making processes and general cognitive faculties inherently possess "free will”. This sudden change in perspective causes the person to feel as if their personal choices, physical actions, and individual personality traits have always been completely predetermined by prior causes and are, therefore, outside of their conscious control.

During this state, a person begins to feel as if their decisions arise from a complex set of internally stored, pre-programmed, and completely autonomous, instant electrochemical responses to perceived sensory input. These sensations are often interpreted as somehow disproving the concept of free will, as the experience of this effect feels as if it is fundamentally incompatible with the notion of being self-determined. This state can also lead a person to the conclusion that their very identity and selfhood are the cumulative results of their biology and past experiences.

Once the effect begins to wear off, a person will often return to their everyday feelings of freedom and independence. Despite this, however, they will often retain realizations regarding what is often interpreted as a profound insight into the apparent illusory nature of free will.

Perception of predeterminism is often accompanied by other coinciding effects such as ego dissolution and physical autonomy. It is most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Perception of self-design

Perception of self-design can be described as the experience of feeling that one is personally responsible for the creation, design, manifestation of a concept, process, or event which is normally seen as the result of unrelated external causes. It can be broken down into two separate sub-components which include:

  • Feeling as if one designed, planned out, and created certain, or even all, aspects of one's life such as current or past events, loved ones, and key events.
  • Feeling as if one designed, planned out and created certain, or even all, aspects of the external world such as current or historical events, nature, life, the universe as a whole, and the physical laws which it abides by.

This effect typically occurs suddenly and spontaneously. However, it is most commonly felt during emotionally significant situations which are so enjoyable and fulfilling that they are exactly how the person would have designed it had they have somehow been given the conscious choice to do so in advance. This is especially true of situations that seem improbable or are completely unexpected.

Perception of self-design is often accompanied by other coinciding effects such as ego dissolution, delusions of grandiosity and high level unity and interconnectedness. It is most commonly induced under the influence of heavy dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline.

Spirituality intensification

Spirituality intensification is defined as the experience of a shift in a person’s personal beliefs regarding their existence and place within the universe, their relationship to others, and what they value as meaningful in life. It results in a person rethinking the significance they place on certain key concepts, holding some in higher regard than they did previously, and dismissing others as less important.[405] These concepts and notions are not limited to but generally include:

  • An increased sense of personal purpose.[406]
  • An increased interest in the pursuit of developing personal religious and spiritual ideologies.[407][408]
    • The formation of complex personal religious beliefs.
  • An increased sense of compassion towards nature and other people.[407][408][409]
  • An increased sense of unity and interconnectedness between oneself, nature, "god", and the universe as a whole.[405][407][409][410][411][412][413]
  • A decreased sense of value placed upon money and material objects.[409]
  • A decreased fear and greater acceptance of death and the finite nature of existence.[405][414][415]

Although difficult to fully specify due to the subjective aspect of spirituality intensification, these changes in to a person's belief system can often result in profound changes in a person's personality[409][411][416] which can sometimes be distinctively noticeable to the people around those who undergo it. This shift can occur suddenly but will usually increase gradually over time as a person repeatedly uses the psychoactive substance which is inducing it.

Spirituality intensification is unlikely to be an isolated effect component but rather the result of a combination of an appropriate setting[407] in conjunction with other coinciding effects such as analysis enhancement, autonomous voice communication, novelty enhancement, perception of interdependent opposites, perception of predeterminism, perception of self-design, personal bias suppression, and unity and interconnectedness. It is most commonly induced under the influence of moderate dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of dissociatives, such as ketamine, PCP, and DXM.

Unity and interconnectedness

This symbol depicts the universe as a "self-excited" circuit. It was originally created by the late theoretical physicist John Archibald Wheeler in his 1983 paper Law Without Law. The eye represents the self and the line directly opposite represents that which it is perceiving within the "external" environment. The two sections are connected into each other via arrows to demonstrate that it is a singular and unified system.

Unity and interconnectedness can be described as the experience of one's sense of self becoming temporarily changed to feel as if it is constituted by a wider array of concepts than that which it previously did. For example, while a person may usually feel that they are exclusively their “ego” or a combination of their “ego” and physical body, during this state their sense of identity can change to also include the external environment or an object they are interacting with. This results in intense and inextricable feelings of unity or interconnectedness between oneself and varying arrays of previously "external" systems.

It is worth noting that many people who undergo this experience consistently interpret it as the removal of a deeply embedded illusion, the destruction of which is often described as some sort of profound “awakening” or “enlightenment.” However, it is important to understand that these conclusions and feelings should not necessarily be accepted at face value as inherently true.

Unity and interconnectedness most commonly occurs under the influence of psychedelic and dissociative compounds such as LSD, DMT, ayahuasca, mescaline, and ketamine. However it can also occur during well-practiced meditation, deep states of contemplation, and intense focus.

There are a total of 5 distinct levels of identity which a person can experience during this state. These various altered states of unity have been arranged into a leveling system that orders its different states from least to the most number of concepts that one's identity is currently attributed to. These levels are described below:

1. Unity between specific "external" systems

At the lowest level, this effect can be described as a perceived sense of unity between two or more systems within the external environment which in everyday life are usually perceived as separate from each other. This is the least complex level of unity, as it is the only level of interconnectedness in which the subjective experience of unity does not involve a state of interconnectedness between the self and the external.

There are an endless number of ways in which this level can manifest, but common examples of the experience often include:

  • A sense of unity between specific living things such as animals or plants and their surrounding ecosystems.
  • A sense of unity between other human beings and the objects they are currently interacting with.
  • A sense of unity between any number of currently perceivable inanimate objects.
  • A sense of unity between humanity and nature.
  • A sense of unity between literally any combination of perceivable external systems and concepts.

2. Unity between the self and specific "external" systems

At this level, unity can be described as feeling as if one's identity is attributed to (in addition to the body and/or brain) specific external systems or concepts within the immediate environment, particularly those that would usually be considered as intrinsically separate from one's own being.

The experience itself is often described as a loss of perceived boundaries between a person’s identity and the specific physical systems or concepts within the perceivable external environment which are currently the subject of a person's attention. This creates a sensation of becoming inextricably "connected to", "one with", "the same as", or "unified" with whatever the perceived external system happens to be.

There are an endless number of ways in which this level can manifest itself, but common examples of the experience often include:

  • Becoming unified with and identifying with a specific object one is interacting with.
  • Becoming unified with and identifying with another person or multiple people, particularly common if engaging in sexual or romantic activities.
  • Becoming unified with and identifying with the entirety of one's own physical body.
  • Becoming unified with and identifying with large crowds of people, particularly common at raves and music festivals.
  • Becoming unified with and identifying with the external environment, but not the people within it.

3. Unity between the self and all perceivable "external" systems

At this level, unity can be described as feeling as if one's identity is attributed to the entirety of their immediately perceivable external environment due to a loss of perceived boundaries between the previously separate systems.

The effect creates a sensation in the person that they have become "one with their surroundings.” This is felt to be the result of a person’s sense of self becoming attributed to not just primarily the internal narrative of the ego, but in equal measure to the body itself and everything around it which it is physically perceiving through the senses. It creates the compelling perspective that one is the external environment experiencing itself through a specific point within it, namely the physical sensory perceptions of the body that one's consciousness is currently residing in.

It is at this point that a key component of the high-level unity experience becomes an extremely noticeable factor. Once a person's sense of self has become attributed to the entirety of their surroundings, this new perspective completely changes how it feels to physically interact with what was previously felt to be an external environment. For example, when one is not in this state and is interacting with a physical object, it typically feels as though one is a central agent acting on the separate world around them. However, while undergoing a state of unity with the currently perceivable environment, interacting with an external object consistently feels as if the whole unified system is autonomously acting on itself with no central, separate agent operating the process of interaction. Instead, the process suddenly feels as if it has become completely decentralized and holistic, as the environment begins to autonomously and harmoniously respond to itself in a predetermined manner to perform the interaction carried out by the individual.

4. Unity between the self and all known "external" systems

At the highest level, this effect can be described as feeling as if one's identity is simultaneously attributed to the entirety of the immediately perceivable external environment and all known concepts that exist outside of it. These known concepts typically include all of humanity, nature, and the universe as it presently stands in its complete entirety. This feeling is commonly interpreted by people as "becoming one with the universe".

When experienced, the effect creates the sudden perspective that one is not a separate agent approaching an external reality, but is instead the entire universe as a whole experiencing itself, exploring itself, and performing actions upon itself through the specific point in space and time which this particular body and conscious perception happens to currently reside within. People who undergo this experience consistently interpret it as the removal of a deeply embedded illusion, with the revelation often described as some sort of profound “awakening” or “enlightenment.”

Although they are not necessarily literal truths about reality, at this point, many commonly reported conclusions of a religious and metaphysical nature often begin to manifest themselves as profound realizations. These are described and listed below:

  • The sudden and total acceptance of death as a fundamental complement of life. Death is no longer felt to be the destruction of oneself, but simply the end of this specific point of a greater whole, which has always existed and will continue to exist and live on through everything else in which it resides. Therefore, the death of a small part of the whole is seen as an inevitable, and not worthy of grief or any emotional attachment, but simply a fact of reality.
  • The subjective perspective that one's preconceived notions of "god" or deities can be felt as identical to the nature of existence and the totality of its contents, including oneself. This typically entails the intuition that if the universe contains all possible power (omnipotence), all possible knowledge (omniscience), is self-creating, and self-sustaining then on either a semantic or literal level the universe and its contents could also be viewed as a god.
  • The subjective perspective that one, by nature of being the universe, is personally responsible for the design, planning, and implementation of every single specific detail and plot element of one's personal life, the history of humanity, and the entirety of the universe. This naturally includes personal responsibility for all humanity's sufferings and flaws but also includes its acts of love and achievements.

See also

References

  1. 1.0 1.1 Fillmore, Mark T.; Kelly, Thomas H.; Martin, Catherine A. (2005). "Effects of d-amphetamine in human models of information processing and inhibitory control". Drug and Alcohol Dependence. 77 (2): 151–159. doi:10.1016/j.drugalcdep.2004.07.013. ISSN 0376-8716. 
  2. Bättig, K.; Buzzi, R. (1986). "Effect of Coffee on the Speed of Subject-Paced Information Processing". Neuropsychobiology. 16 (2-3): 126–130. doi:10.1159/000118312. ISSN 0302-282X. 
  3. 3.0 3.1 Warburton, David; Bersellini, Elisabetta; Sweeney, Eve (2001). "An evaluation of a caffeinated taurine drink on mood, memory and information processing in healthy volunteers without caffeine abstinence". Psychopharmacology. 158 (3): 322–328. doi:10.1007/s002130100884. ISSN 0033-3158. 
  4. Humphreys, Michael S.; Revelle, William (1984). "Personality, motivation, and performance: A theory of the relationship between individual differences and information processing". Psychological Review. 91 (2): 153–184. doi:10.1037/0033-295X.91.2.153. ISSN 1939-1471. 
  5. 5.0 5.1 Bouso, José Carlos; Palhano-Fontes, Fernanda; Rodríguez-Fornells, Antoni; Ribeiro, Sidarta; Sanches, Rafael; Crippa, José Alexandre S.; Hallak, Jaime E.C.; de Araujo, Draulio B.; Riba, Jordi (2015). "Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans". European Neuropsychopharmacology. 25 (4): 483–492. doi:10.1016/j.euroneuro.2015.01.008. ISSN 0924-977X. 
  6. 6.0 6.1 Papoutsis, Ioannis; Nikolaou, Panagiota; Stefanidou, Maria; Spiliopoulou, Chara; Athanaselis, Sotiris (2014). "25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers". Forensic Toxicology. 33 (1): 1–11. doi:10.1007/s11419-014-0242-9. ISSN 1860-8965. 
  7. 7.0 7.1 7.2 Bersani, Francesco Saverio; Corazza, Ornella; Albano, Gabriella; Valeriani, Giuseppe; Santacroce, Rita; Bolzan Mariotti Posocco, Flaminia; Cinosi, Eduardo; Simonato, Pierluigi; Martinotti, Giovanni; Bersani, Giuseppe; Schifano, Fabrizio (2014). "25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug". BioMed Research International. 2014: 1–6. doi:10.1155/2014/734749. ISSN 2314-6133. 
  8. 8.0 8.1 Hartman, Alan M.; Hollister, Leo E. (1963). "Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception". Psychopharmacologia. 4 (6): 441–451. doi:10.1007/BF00403349. ISSN 0033-3158. 
  9. 9.0 9.1 Kleinman, J. E.; Gillin, J. C.; Wyatt, R. J. (1977). "A Comparison of the Phenomenology of Hallucinogens and Schizophrenia From Some Autobiographical Accounts*". Schizophrenia Bulletin. 3 (4): 560–586. doi:10.1093/schbul/3.4.560. ISSN 0586-7614. 
  10. Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS (REVIEW). PHARMACIA, 64(1), 41-42. http://bsphs.org/wp-content/uploads/2017/04/Angelova.pdf
  11. Abraham, Henry David (1983). "Visual Phenomenology of the LSD Flashback". Archives of General Psychiatry. 40 (8): 884. doi:10.1001/archpsyc.1983.01790070074009. ISSN 0003-990X. 
  12. Baggott, M.J.; Coyle, J.R.; Erowid, E.; Erowid, F.; Robertson, L.C. (2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. ISSN 0376-8716. 
  13. Dillon, P (2003). "Patterns of use and harms associated with non-medical ketamine use". Drug and Alcohol Dependence. 69 (1): 23–28. doi:10.1016/S0376-8716(02)00243-0. ISSN 0376-8716. 
  14. Iszáj, Fruzsina; Griffiths, Mark D.; Demetrovics, Zsolt (2016). "Creativity and Psychoactive Substance Use: A Systematic Review". International Journal of Mental Health and Addiction. 15 (5): 1135–1149. doi:10.1007/s11469-016-9709-8. ISSN 1557-1874. 
  15. Hongbao, M. (2005). "Development Application Polymerase Chain Reaction (PCR)" (PDF). The Journal of American Science. 1 (3): 1–15. 
  16. Brooks, M. (2012). Free radicals: the secret anarchy of science (1st U.S. hardcover ed ed.). Overlook Press. ISBN 9781590208540. 
  17. Sessa, B. (2008). "Is it time to revisit the role of psychedelic drugs in enhancing human creativity?". Journal of Psychopharmacology. 22 (8): 821–827. doi:10.1177/0269881108091597. ISSN 0269-8811. 
  18. Krippiwr, Stanley (2008). "Research in creativity and psychedelic drugs". International Journal of Clinical and Experimental Hypnosis. 25 (4): 274–290. doi:10.1080/00207147708415985. ISSN 0020-7144. 
  19. Krippner, Stanley (1985). "Psychedelic Drugs and Creativity". Journal of Psychoactive Drugs. 17 (4): 235–246. doi:10.1080/02791072.1985.10524328. ISSN 0279-1072. 
  20. Green, Bob; Kavanagh, David; Young, Ross (2003). "Being stoned: a review of self-reported cannabis effects". Drug and Alcohol Review. 22 (4): 453–460. doi:10.1080/09595230310001613976. ISSN 0959-5236. 
  21. 21.0 21.1 21.2 Kowal, Mikael A.; Hazekamp, Arno; Colzato, Lorenza S.; van Steenbergen, Henk; van der Wee, Nic J. A.; Durieux, Jeffrey; Manai, Meriem; Hommel, Bernhard (2014). "Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users". Psychopharmacology. 232 (6): 1123–1134. doi:10.1007/s00213-014-3749-1. ISSN 0033-3158. 
  22. Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J. A., Curran, H. V. (June 2008). "Journey through the K-hole: Phenomenological aspects of ketamine use". Drug and Alcohol Dependence. 95 (3): 219–229. doi:10.1016/j.drugalcdep.2008.01.024. ISSN 0376-8716. 
  23. Nichols, David E. (1986). "Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens". Journal of Psychoactive Drugs. 18 (4): 305–313. doi:10.1080/02791072.1986.10472362. ISSN 0279-1072. 
  24. Bedi, Gillinder; Hyman, David; de Wit, Harriet (2010). "Is Ecstasy an "Empathogen"? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others". Biological Psychiatry. 68 (12): 1134–1140. doi:10.1016/j.biopsych.2010.08.003. ISSN 0006-3223. 
  25. Scahill, Lawrence; Anderson, George M. (2010). "Is Ecstasy an Empathogen?". Biological Psychiatry. 68 (12): 1082–1083. doi:10.1016/j.biopsych.2010.10.020. ISSN 0006-3223. 
  26. González, Débora; Torrens, Marta; Farré, Magí (2015). "Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions". BioMed Research International. 2015: 1–9. doi:10.1155/2015/643878. ISSN 2314-6133. 
  27. 27.0 27.1 Wardle, Margaret C.; Garner, Matthew J.; Munafò, Marcus R.; de Wit, Harriet (2012). "Amphetamine as a social drug: effects of d-amphetamine on social processing and behavior". Psychopharmacology. 223 (2): 199–210. doi:10.1007/s00213-012-2708-y. ISSN 0033-3158. 
  28. 28.0 28.1 28.2 28.3 28.4 Kaelen, M.; Barrett, F. S.; Roseman, L.; Lorenz, R.; Family, N.; Bolstridge, M.; Curran, H. V.; Feilding, A.; Nutt, D. J.; Carhart-Harris, R. L. (2015). "LSD enhances the emotional response to music". Psychopharmacology. 232 (19): 3607–3614. doi:10.1007/s00213-015-4014-y. ISSN 0033-3158. 
  29. Kaelen, Mendel; Roseman, Leor; Kahan, Joshua; Santos-Ribeiro, Andre; Orban, Csaba; Lorenz, Romy; Barrett, Frederick S.; Bolstridge, Mark; Williams, Tim; Williams, Luke; Wall, Matthew B.; Feilding, Amanda; Muthukumaraswamy, Suresh; Nutt, David J.; Carhart-Harris, Robin (2016). "LSD modulates music-induced imagery via changes in parahippocampal connectivity". European Neuropsychopharmacology. 26 (7): 1099–1109. doi:10.1016/j.euroneuro.2016.03.018. ISSN 0924-977X. 
  30. 30.0 30.1 30.2 30.3 Fachner, J. (2002). "The space between the notes-Research on cannabis and music perception". Looking Back, Looking Ahead-Popular Music Studies (20): 308–319. 
  31. 31.0 31.1 31.2 31.3 Nichols, D. E. (2016). "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478. ISSN 1521-0081. 
  32. 32.0 32.1 32.2 Kaelen, Mendel; Giribaldi, Bruna; Raine, Jordan; Evans, Lisa; Timmerman, Christopher; Rodriguez, Natalie; Roseman, Leor; Feilding, Amanda; Nutt, David; Carhart-Harris, Robin (2018). "The hidden therapist: evidence for a central role of music in psychedelic therapy". Psychopharmacology. 235 (2): 505–519. doi:10.1007/s00213-017-4820-5. ISSN 0033-3158. 
  33. 33.0 33.1 33.2 33.3 33.4 33.5 33.6 33.7 Belser, Alexander B.; Agin-Liebes, Gabrielle; Swift, T. Cody; Terrana, Sara; Devenot, Neşe; Friedman, Harris L.; Guss, Jeffrey; Bossis, Anthony; Ross, Stephen (2017). "Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis". Journal of Humanistic Psychology. 57 (4): 354–388. doi:10.1177/0022167817706884. ISSN 0022-1678. 
  34. 34.0 34.1 McGlothlin, William (1967). "Long Lasting Effects of LSD on Normals". Archives of General Psychiatry. 17 (5): 521. doi:10.1001/archpsyc.1967.01730290009002. ISSN 0003-990X. 
  35. Lim, D. K. (January 2003). "Ketamine associated psychedelic effects and dependence". Singapore Medical Journal. 44 (1): 31–34. ISSN 0037-5675. 
  36. 36.0 36.1 36.2 Siegel, Ronald K.; Hirschman, Ada E. (1985). "Hashish and Laughter: Historical Notes and Translations of Early French Investigations". Journal of Psychoactive Drugs. 17 (2): 87–91. doi:10.1080/02791072.1985.10472327. ISSN 0279-1072. 
  37. Bøhling, Frederik (2017). "Psychedelic pleasures: An affective understanding of the joys of tripping". International Journal of Drug Policy. 49: 133–143. doi:10.1016/j.drugpo.2017.07.017. ISSN 0955-3959. 
  38. Xu, Xiaomeng; Ma, Shifan; Feng, Zhiwei; Hu, Guanxing; Wang, Lirong; Xie, Xiang-Qun (2016). "Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification—Salvinorin A as a case study". Journal of Molecular Graphics and Modelling. 70: 284–295. doi:10.1016/j.jmgm.2016.08.001. ISSN 1093-3263. 
  39. Kremer, Christian; Paulke, Alexander; Wunder, Cora; Toennes, Stefan W. (2012). "Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds". Forensic Science International. 214 (1-3): e6–e8. doi:10.1016/j.forsciint.2011.06.025. ISSN 0379-0738. 
  40. Shulgin, A., Shulgin, A. (1995). PIHKAL: a chemical love story. Transform press. 
  41. 41.0 41.1 Morgan, Celia JA; Noronha, Louise A; Muetzelfeldt, Mark; Feilding, Amanda; Curran, H Valerie (2013). "Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users". Journal of Psychopharmacology. 27 (6): 497–506. doi:10.1177/0269881113477744. ISSN 0269-8811. 
  42. Mobbs, Dean; Greicius, Michael D; Abdel-Azim, Eiman; Menon, Vinod; Reiss, Allan L (2003). "Humor Modulates the Mesolimbic Reward Centers". Neuron. 40 (5): 1041–1048. doi:10.1016/S0896-6273(03)00751-7. ISSN 0896-6273. 
  43. Mondadori, Cesare; Möbius, Hans-Jörg; Borkowski, Jürgen (1996). "The GABAB receptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory". Behavioural Brain Research. 77 (1-2): 223–225. doi:10.1016/0166-4328(95)00222-7. ISSN 0166-4328. 
  44. Ilieva, Irena P.; Hook, Cayce J.; Farah, Martha J. (2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. ISSN 0898-929X. 
  45. 45.0 45.1 Borota, Daniel; Murray, Elizabeth; Keceli, Gizem; Chang, Allen; Watabe, Joseph M; Ly, Maria; Toscano, John P; Yassa, Michael A (2014). "Post-study caffeine administration enhances memory consolidation in humans". Nature Neuroscience. 17 (2): 201–203. doi:10.1038/nn.3623. ISSN 1097-6256. 
  46. Morgan, Annette; Stevens, John (2010). "Does Bacopa monnieri Improve Memory Performance in Older Persons? Results of a Randomized, Placebo-Controlled, Double-Blind Trial". The Journal of Alternative and Complementary Medicine. 16 (7): 753–759. doi:10.1089/acm.2009.0342. ISSN 1075-5535. 
  47. Mehta, Mitul A.; Owen, Adrian M.; Sahakian, Barbara J.; Mavaddat, Nahal; Pickard, John D.; Robbins, Trevor W. (2000). "Methylphenidate Enhances Working Memory by Modulating Discrete Frontal and Parietal Lobe Regions in the Human Brain". The Journal of Neuroscience. 20 (6): RC65–RC65. doi:10.1523/JNEUROSCI.20-06-j0004.2000. ISSN 0270-6474. 
  48. Ostrovskaia, R. U., Gudasheva, T. A., Voronina, T. A., Seredenin, S. B. (October 2002). "[The original novel nootropic and neuroprotective agent noopept]". Eksperimental’naia I Klinicheskaia Farmakologiia. 65 (5): 66–72. ISSN 0869-2092. 
  49. Heishman, Stephen J.; Kleykamp, Bethea A.; Singleton, Edward G. (2010). "Meta-analysis of the acute effects of nicotine and smoking on human performance". Psychopharmacology. 210 (4): 453–469. doi:10.1007/s00213-010-1848-1. ISSN 0033-3158. 
  50. Müller, Ulrich; Steffenhagen, Nikolai; Regenthal, Ralf; Bublak, Peter (2004). "Effects of modafinil on working memory processes in humans". Psychopharmacology. 177 (1-2): 161–169. doi:10.1007/s00213-004-1926-3. ISSN 0033-3158. 
  51. 51.0 51.1 51.2 Cowan, Nelson (2008). "Chapter 20 What are the differences between long-term, short-term, and working memory?". 169: 323–338. doi:10.1016/S0079-6123(07)00020-9. ISSN 0079-6123. 
  52. 52.0 52.1 Engle, Randall W.; Tuholski, Stephen W.; Laughlin, James E.; Conway, Andrew R. A. (1999). "Working memory, short-term memory, and general fluid intelligence: A latent-variable approach". Journal of Experimental Psychology: General. 128 (3): 309–331. doi:10.1037/0096-3445.128.3.309. ISSN 1939-2222. 
  53. 53.0 53.1 Daneman, Meredyth; Merikle, Philip M. (1996). "Working memory and language comprehension: A meta-analysis". Psychonomic Bulletin & Review. 3 (4): 422–433. doi:10.3758/BF03214546. ISSN 1069-9384. 
  54. Daneman, Meredyth; Carpenter, Patricia A. (1980). "Individual differences in working memory and reading". Journal of Verbal Learning and Verbal Behavior. 19 (4): 450–466. doi:10.1016/S0022-5371(80)90312-6. ISSN 0022-5371. 
  55. Kyllonen, Patrick C.; Christal, Raymond E. (1990). "Reasoning ability is (little more than) working-memory capacity?!". Intelligence. 14 (4): 389–433. doi:10.1016/S0160-2896(05)80012-1. ISSN 0160-2896. 
  56. Kjærsgaard, Torben (2015). "Enhancing Motivation by Use of Prescription Stimulants: The Ethics of Motivation Enhancement". AJOB Neuroscience. 6 (1): 4–10. doi:10.1080/21507740.2014.990543. ISSN 2150-7740. 
  57. 57.0 57.1 57.2 57.3 Ilieva, Irena P.; Farah, Martha J. (2013). "Enhancement stimulants: perceived motivational and cognitive advantages". Frontiers in Neuroscience. 7. doi:10.3389/fnins.2013.00198. ISSN 1662-453X. 
  58. 58.0 58.1 Nyholm, Sven (2015). "Motivation-Enhancements and Domain-Specific Values". AJOB Neuroscience. 6 (1): 37–39. doi:10.1080/21507740.2014.995313. ISSN 2150-7740. 
  59. Terbeck, Sylvia (2013). "Why Students Bother Taking Adderall: Measurement Validity of Self-Reports". AJOB Neuroscience. 4 (1): 21–22. doi:10.1080/21507740.2012.762064. ISSN 2150-7740. 
  60. Sagara, H.; Kitamura, Y.; Esumi, S.; Sendo, T.; Araki, H.; Gotima, Y. (2008). "Motivational effects of nicotine as measured by the runway method using priming stimulation of intracranial self-stimulation behavior". Acta Med Okayama. 62 (4): 227–233. doi:10.18926/amo/30940. ISSN 0386-300X. 
  61. Young, Jared W.; Geyer, Mark A. (2010). "Action of Modafinil—Increased Motivation Via the Dopamine Transporter Inhibition and D1 Receptors?". Biological Psychiatry. 67 (8): 784–787. doi:10.1016/j.biopsych.2009.12.015. ISSN 0006-3223. 
  62. 62.0 62.1 Ting-A-Kee, R.; van der Kooy, D. (2012). "The Neurobiology of Opiate Motivation". Cold Spring Harbor Perspectives in Medicine. 2 (10): a012096–a012096. doi:10.1101/cshperspect.a012096. ISSN 2157-1422. 
  63. Riters, Lauren V. (2010). "Evidence for opioid involvement in the motivation to sing". Journal of Chemical Neuroanatomy. 39 (2): 141–150. doi:10.1016/j.jchemneu.2009.03.008. ISSN 0891-0618. 
  64. 64.0 64.1 64.2 Hunt, Harry T. (1976). "A Test of the Psychedelic Model of Altered States of Consciousness". Archives of General Psychiatry. 33 (7): 867. doi:10.1001/archpsyc.1976.01770070097012. ISSN 0003-990X. 
  65. Bonner, Edward T.; Friedman, Harris L. (2011). "A conceptual clarification of the experience of awe: An interpretative phenomenological analysis". The Humanistic Psychologist. 39 (3): 222–235. doi:10.1080/08873267.2011.593372. ISSN 1547-3333. 
  66. 66.0 66.1 66.2 Griffiths, Roland R; Johnson, Matthew W; Richards, William A; Richards, Brian D; Jesse, Robert; MacLean, Katherine A; Barrett, Frederick S; Cosimano, Mary P; Klinedinst, Maggie A (2017). "Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors". Journal of Psychopharmacology. 32 (1): 49–69. doi:10.1177/0269881117731279. ISSN 0269-8811. 
  67. 67.0 67.1 Das, Saibal; Barnwal, Preeti; Ramasamy, Anand; Sen, Sumalya; Mondal, Somnath (2016). "Lysergic acid diethylamide: a drug of 'use'?". Therapeutic Advances in Psychopharmacology. 6 (3): 214–228. doi:10.1177/2045125316640440. ISSN 2045-1253. 
  68. 68.0 68.1 Bowers, Malcolm B. (1966). ""Psychedelic" Experiences in Acute Psychoses". Archives of General Psychiatry. 15 (3): 240. doi:10.1001/archpsyc.1966.01730150016003. ISSN 0003-990X. 
  69. 69.0 69.1 69.2 69.3 69.4 69.5 Swanson, Link R. (2018). "Unifying Theories of Psychedelic Drug Effects". Frontiers in Pharmacology. 9. doi:10.3389/fphar.2018.00172. ISSN 1663-9812. 
  70. 70.0 70.1 70.2 Carhart-Harris, Robin L.; Leech, Robert; Hellyer, Peter J.; Shanahan, Murray; Feilding, Amanda; Tagliazucchi, Enzo; Chialvo, Dante R.; Nutt, David (2014). "The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs". Frontiers in Human Neuroscience. 8. doi:10.3389/fnhum.2014.00020. ISSN 1662-5161. 
  71. Tagliazucchi, Enzo; Carhart-Harris, Robin; Leech, Robert; Nutt, David; Chialvo, Dante R. (2014). "Enhanced repertoire of brain dynamical states during the psychedelic experience". Human Brain Mapping. 35 (11): 5442–5456. doi:10.1002/hbm.22562. ISSN 1065-9471. 
  72. Hu, Dewen; Palhano-Fontes, Fernanda; Andrade, Katia C.; Tofoli, Luis F.; Santos, Antonio C.; Crippa, Jose Alexandre S.; Hallak, Jaime E. C.; Ribeiro, Sidarta; de Araujo, Draulio B. (2015). "The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network". PLOS ONE. 10 (2): e0118143. doi:10.1371/journal.pone.0118143. ISSN 1932-6203. 
  73. Diamond, Adele (2013). "Executive Functions". Annual Review of Psychology. 64 (1): 135–168. doi:10.1146/annurev-psych-113011-143750. ISSN 0066-4308. 
  74. 74.0 74.1 Biederman, Joseph; Seidman, Larry J.; Petty, Carter R.; Fried, Ronna; Doyle, Alysa E.; Cohen, Daniel R.; Kenealy, Deborah C.; Faraone, Stephen V. (2008). "Effects of Stimulant Medication on Neuropsychological Functioning in Young Adults With Attention-Deficit/Hyperactivity Disorder". The Journal of Clinical Psychiatry. 69 (7): 1150–1156. doi:10.4088/JCP.v69n0715. ISSN 0160-6689. 
  75. 75.0 75.1 Gupta, B.S. (1977). "Dextroamphetamine and measures of intelligence". Intelligence. 1 (3): 274–280. doi:10.1016/0160-2896(77)90010-1. ISSN 0160-2896. 
  76. 76.0 76.1 Hellwig-Brida, Susanne; Daseking, Monika; Keller, Ferdinand; Petermann, Franz; Goldbeck, Lutz (2011). "Effects of Methylphenidate on Intelligence and Attention Components in Boys with Attention-Deficit/Hyperactivity Disorder". Journal of Child and Adolescent Psychopharmacology. 21 (3): 245–253. doi:10.1089/cap.2010.0041. ISSN 1044-5463. 
  77. 77.0 77.1 Arnsten, Amy F.T.; Li, Bao-Ming (2005). "Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions". Biological Psychiatry. 57 (11): 1377–1384. doi:10.1016/j.biopsych.2004.08.019. ISSN 0006-3223. 
  78. Lundqvist, T (2005). "Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions". Pharmacology Biochemistry and Behavior. 81 (2): 319–330. doi:10.1016/j.pbb.2005.02.017. ISSN 0091-3057. 
  79. Squire, L. R.; Zola, S. M. (1997). "Amnesia, memory and brain systems". Philosophical Transactions of the Royal Society B: Biological Sciences. 352 (1362): 1663–1673. doi:10.1098/rstb.1997.0148. ISSN 0962-8436. 
  80. Veselis, R. A., Reinsel, R. A., Feshchenko, V. A. (1 October 2001). "Drug-induced Amnesia Is a Separate Phenomenon from Sedation". Anesthesiology. 95 (4): 896–907. doi:10.1097/00000542-200110000-00018. ISSN 0003-3022. 
  81. Hartzler, Bryan; Fromme, Kim (2003). "Fragmentary and en bloc blackouts: similarity and distinction among episodes of alcohol-induced memory loss". Journal of Studies on Alcohol. 64 (4): 547–550. doi:10.15288/jsa.2003.64.547. ISSN 0096-882X. 
  82. White, A. M., Signer, M. L., Kraus, C. L., Swartzwelder, H. S. (1 January 2004). "Experiential Aspects of Alcohol‐Induced Blackouts Among College Students". The American Journal of Drug and Alcohol Abuse. 30 (1): 205–224. doi:10.1081/ADA-120029874. 
  83. Goodwin, Donald W.; Crane, J. Bruce; Guze, Samuel B. (1969). "Alcoholic "Blackouts": A Review and Clinical Study of 100 Alcoholics". American Journal of Psychiatry. 126 (2): 191–198. doi:10.1176/ajp.126.2.191. ISSN 0002-953X. 
  84. Lee, Hamin; Roh, Sungwon; Kim, Dai Jin (2009). "Alcohol-Induced Blackout". International Journal of Environmental Research and Public Health. 6 (11): 2783–2792. doi:10.3390/ijerph6112783. ISSN 1660-4601. 
  85. Mejo, S. L. (October 1992). "Anterograde Amnesia Linked to Benzodiazepines:". The Nurse Practitioner. 17 (10): 44–50. doi:10.1097/00006205-199210000-00013. ISSN 0361-1817. 
  86. Barker, Judith C.; Harris, Shana L.; Dyer, Jo E. (2007). "Experiences of Gamma Hydroxybutyrate (GHB) Ingestion: A Focus Group Study". Journal of Psychoactive Drugs. 39 (2): 115–129. doi:10.1080/02791072.2007.10399870. ISSN 0279-1072. 
  87. Canaday, B. R. (August 1996). "Amnesia possibly associated with zolpidem administration". Pharmacotherapy. 16 (4): 687–689. ISSN 0277-0008. 
  88. 88.0 88.1 Knowles, Emma E.M.; David, Anthony S.; Reichenberg, Abraham (2010). "Processing Speed Deficits in Schizophrenia: Reexamining the Evidence". American Journal of Psychiatry. 167 (7): 828–835. doi:10.1176/appi.ajp.2010.09070937. ISSN 0002-953X. 
  89. 89.0 89.1 Takeuchi, H.; Suzuki, T.; Remington, G.; Bies, R. R.; Abe, T.; Graff-Guerrero, A.; Watanabe, K.; Mimura, M.; Uchida, H. (2013). "Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study". Schizophrenia Bulletin. 39 (5): 993–998. doi:10.1093/schbul/sbt090. ISSN 0586-7614. 
  90. 90.0 90.1 Fried, P; Watkinson, B; Gray, R (2005). "Neurocognitive consequences of marihuana—a comparison with pre-drug performance". Neurotoxicology and Teratology. 27 (2): 231–239. doi:10.1016/j.ntt.2004.11.003. ISSN 0892-0362. 
  91. 91.0 91.1 Kawai, Nobutoshi; Yamakawa, Yuriko; Baba, Atsuomi; Nemoto, Kiyotaka; Tachikawa, Hirokazu; Hori, Takafumi; Asada, Takashi; Iidaka, Tetsuya (2006). "High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 (6): 1009–1014. doi:10.1016/j.pnpbp.2006.03.013. ISSN 0278-5846. 
  92. Husa, Anja P.; Moilanen, Jani; Murray, Graham K.; Marttila, Riikka; Haapea, Marianne; Rannikko, Irina; Barnett, Jennifer H.; Jones, Peter B.; Isohanni, Matti; Remes, Anne M.; Koponen, Hannu; Miettunen, Jouko; Jääskeläinen, Erika (2017). "Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort". Psychiatry Research. 247: 130–138. doi:10.1016/j.psychres.2016.10.085. ISSN 0165-1781. 
  93. Paraherakis, Antonios; Charney, Dara A.; Gill, Kathryn (2009). "NEUROPSYCHOLOGICAL FUNCTIONING IN SUBSTANCE-DEPENDENT PATIENTS". Substance Use & Misuse. 36 (3): 257–271. doi:10.1081/JA-100102625. ISSN 1082-6084. 
  94. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 821. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  95. Mizuno, Kei; Tanaka, Masaaki; Yamaguti, Kouzi; Kajimoto, Osami; Kuratsune, Hirohiko; Watanabe, Yasuyoshi (2011). "Mental fatigue caused by prolonged cognitive load associated with sympathetic hyperactivity". Behavioral and Brain Functions. 7 (1): 17. doi:10.1186/1744-9081-7-17. ISSN 1744-9081. 
  96. Alhola, P., & Polo-Kantola, P. (2007). Sleep deprivation: Impact on cognitive performance. Neuropsychiatric disease and treatment. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656292/
  97. Kim, Jin Young; Kang, Seung Wan (2017). "Relationships between Dietary Intake and Cognitive Function in Healthy Korean Children and Adolescents". Journal of Lifestyle Medicine. 7 (1): 10–17. doi:10.15280/jlm.2017.7.1.10. ISSN 2234-8549. 
  98. Seo, Rubo J.; MacPherson, Holly; Young, Allan H. (2010). "Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder". Pharmaceuticals. 3 (12): 3522–3542. doi:10.3390/ph3123522. ISSN 1424-8247. 
  99. Wittkampf, Laura Christina; Arends, Johannes; Timmerman, Leo; Lancel, Marike (2012). "A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia". Therapeutic Advances in Psychopharmacology. 2 (3): 115–125. doi:10.1177/2045125312441815. ISSN 2045-1253. 
  100. Chaudhuri, Abhijit; Behan, Peter O (2000). "Fatigue and basal ganglia". Journal of the Neurological Sciences. 179 (1-2): 34–42. doi:10.1016/S0022-510X(00)00411-1. ISSN 0022-510X. 
  101. Lago, Jesus A.; Kosten, Thomas R. (1994). "Stimulant withdrawal". Addiction. 89 (11): 1477–1481. doi:10.1111/j.1360-0443.1994.tb03746.x. ISSN 0965-2140. 
  102. Burns, A (2004). "Delirium". Journal of Neurology, Neurosurgery & Psychiatry. 75 (3): 362–367. doi:10.1136/jnnp.2003.023366. ISSN 0022-3050. 
  103. Sheehan, Peter W.; Lewis, Sue-Ellen (2016). "Subjects' Reports of Confusion in Consciousness and the Arousal of Imagery". Perceptual and Motor Skills. 38 (3): 731–734. doi:10.2466/pms.1974.38.3.731. ISSN 0031-5125. 
  104. Lu, Lin; Krebs, Teri S.; Johansen, Pål-Ørjan (2013). "Psychedelics and Mental Health: A Population Study". PLoS ONE. 8 (8): e63972. doi:10.1371/journal.pone.0063972. ISSN 1932-6203. 
  105. Mozayani, A. (January 2003). "Phencyclidine - Effects on Human Performance and Behavior". Forensic Science Review. 15 (1): 61–74. ISSN 1042-7201. 
  106. Chase, Peter B.; Hawkins, Jeff; Mosier, Jarrod; Jimenez, Ernest; Boesen, Keith; Logan, Barry K.; Walter, Frank G. (2015). "Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs". Clinical Toxicology. 54 (1): 14–19. doi:10.3109/15563650.2015.1101769. ISSN 1556-3650. 
  107. 107.0 107.1 Kalisch Ellett, Lisa M.; Pratt, Nicole L.; Ramsay, Emmae N.; Barratt, John D.; Roughead, Elizabeth E. (2014). "Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia". Journal of the American Geriatrics Society. 62 (10): 1916–1922. doi:10.1111/jgs.13054. ISSN 0002-8614. 
  108. Nicholson, Katherine L.; Balster, Robert L. (2001). "GHB: a new and novel drug of abuse". Drug and Alcohol Dependence. 63 (1): 1–22. doi:10.1016/S0376-8716(00)00191-5. ISSN 0376-8716. 
  109. Sendelbach, Sue; Guthrie, Patty Finch; Schoenfelder, Deborah Perry (2009). "Acute Confusion/Delirium". Journal of Gerontological Nursing. 35 (11): 11–18. doi:10.3928/00989134-20090930-01. ISSN 0098-9134. 
  110. "Delirium". International statistical classification of diseases and related health problems (11th ed.). 2022. Retrieved 20 May 2022. 
  111. 111.0 111.1 "Neurocognitive Disorders". Diagnostic and statistical manual of mental disorders (5th ed.): 596–602. 2013. doi:10.1176/appi.books.9780890425596.dsm17. 
  112. Fong, Tamara G.; Tulebaev, Samir R.; Inouye, Sharon K. (2009). "Delirium in elderly adults: diagnosis, prevention and treatment". Nature Reviews Neurology. 5 (4): 210–220. doi:10.1038/nrneurol.2009.24. ISSN 1759-4758. 
  113. Hosker, Christian; Ward, David (2017). "Hypoactive delirium". BMJ: j2047. doi:10.1136/bmj.j2047. ISSN 0959-8138. 
  114. Serio, Ryan N (2004). "Acute Delirium Associated with Combined Diphenhydramine and Linezolid Use". Annals of Pharmacotherapy. 38 (1): 62–65. doi:10.1345/aph.1D018. ISSN 1060-0280. 
  115. Hanna, J. P., Schmidley, J. W., Braselton, W. E. (April 1992). "Datura Delirium:". Clinical Neuropharmacology. 15 (2): 109–113. doi:10.1097/00002826-199204000-00004. ISSN 0362-5664. 
  116. Balogun, Seki A.; Philbrick, John T. (2014). "Delirium, a Symptom of UTI in the Elderly: Fact or Fable? A Systematic Review*". Canadian Geriatrics Journal. 17 (1). doi:10.5770/cgj.17.90. ISSN 1925-8348. 
  117. Manjunatha, Narayana; Math, SureshBada; Kulkarni, GirishBaburao; Chaturvedi, SantoshKumar (2011). "The neuropsychiatric aspects of influenza/swine flu: A selective review". Industrial Psychiatry Journal. 20 (2): 83. doi:10.4103/0972-6748.102479. ISSN 0972-6748. 
  118. Lerner, A. J., Hedera, P., Koss, E., Stuckey, J., Friedland, R. P. (March 1997). "Delirium in Alzheimer Disease:". Alzheimer Disease & Associated Disorders. 11 (1): 16–20. doi:10.1097/00002093-199703000-00004. ISSN 0893-0341. 
  119. 119.0 119.1 119.2 119.3 Flaherty, Alice W. (2005). "Frontotemporal and dopaminergic control of idea generation and creative drive". The Journal of Comparative Neurology. 493 (1): 147–153. doi:10.1002/cne.20768. ISSN 0021-9967. 
  120. Jamison, K. R. (1989). Mood disorders and patterns of creativity in British writers and artists. Psychiatry, 52(2), 125-134. https://www.ncbi.nlm.nih.gov/pubmed/2734415/
  121. von Hecker, Ulrich; Meiser, Thorsten (2005). "Defocused Attention in Depressed Mood: Evidence From Source Monitoring". Emotion. 5 (4): 456–463. doi:10.1037/1528-3542.5.4.456. ISSN 1931-1516. 
  122. 122.0 122.1 Moncrieff, J.; Cohen, D.; Mason, J. P. (2009). "The subjective experience of taking antipsychotic medication: a content analysis of Internet data". Acta Psychiatrica Scandinavica. 120 (2): 102–111. doi:10.1111/j.1600-0447.2009.01356.x. ISSN 0001-690X. 
  123. 123.0 123.1 Szmulewicz, Alejandro; Samamé, Cecilia; Caravotta, Pablo; Martino, Diego J.; Igoa, Ana; Hidalgo-Mazzei, Diego; Colom, Francesc; Strejilevich, Sergio A. (2016). "Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications". International Journal of Bipolar Disorders. 4 (1). doi:10.1186/s40345-016-0047-3. ISSN 2194-7511. 
  124. 124.0 124.1 Bolling, Madelon Y.; Kohlenberg, Robert J. (2004). "Reasons for Quitting Serotonin Reuptake Inhibitor Therapy: Paradoxical Psychological Side Effects and Patient Satisfaction". Psychotherapy and Psychosomatics. 73 (6): 380–385. doi:10.1159/000080392. ISSN 0033-3190. 
  125. 125.0 125.1 What Is Aphasia? — Types, Causes and Treatment, National Institute on Deafness and Other Communication Disorders (NIDCD) 
  126. Chien, Ching-Fang; Huang, Poyin; Hsieh, Sun-Wung (2017). "Reversible global aphasia as a side effect of quetiapine: a case report and literature review". Neuropsychiatric Disease and Treatment. Volume 13: 2257–2260. doi:10.2147/NDT.S141273. ISSN 1178-2021. 
  127. Iqbal, M. M., Aneja, A., Rahman, A., Megna, J., Freemont, W., Shiplo, M., Nihilani, N., Lee, K. (August 2005). "The Potential Risks of Commonly Prescribed Antipsychotics". Psychiatry (Edgmont). 2 (8): 36–44. ISSN 1550-5952. 
  128. Sinha, Preeti; Vandana, V.P.; Lewis, Nikita Vincent; Jayaram, M.; Enderby, Pamela (2015). "Evaluating the effect of risperidone on speech: A cross-sectional study". Asian Journal of Psychiatry. 15: 51–55. doi:10.1016/j.ajp.2015.05.005. ISSN 1876-2018. 
  129. 129.0 129.1 Dell'Erba, Sara; Brown, David J.; Proulx, Michael J. (2018). "Synesthetic hallucinations induced by psychedelic drugs in a congenitally blind man". Consciousness and Cognition. 60: 127–132. doi:10.1016/j.concog.2018.02.008. ISSN 1053-8100. 
  130. Kjellgren, Anette; Jonsson, Kristoffer (2013). "Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a "Legal High" from the Internet". Journal of Psychoactive Drugs. 45 (3): 276–286. doi:10.1080/02791072.2013.803647. ISSN 0279-1072. 
  131. Nguyen, Huy TV; Juurlink, David N (2004). "Recurrent Ibuprofen-Induced Aseptic Meningitis". Annals of Pharmacotherapy. 38 (3): 408–410. doi:10.1345/aph.1D329. ISSN 1060-0280. 
  132. 132.0 132.1 Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Foussias, George; Fletcher, Paul J; Agid, Ofer; Remington, Gary (2015). "Antipsychotics and Amotivation". Neuropsychopharmacology. 40 (6): 1539–1548. doi:10.1038/npp.2015.3. ISSN 0893-133X. 
  133. Lee, Jung; Jung, Suwon; Park, Il; Kim, Jae-Jin (2015). "Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System". Current Neuropharmacology. 13 (6): 750–759. doi:10.2174/1570159X13666150612230333. ISSN 1570-159X. 
  134. Barch, D. M.; Dowd, E. C. (2010). "Goal Representations and Motivational Drive in Schizophrenia: The Role of Prefrontal-Striatal Interactions". Schizophrenia Bulletin. 36 (5): 919–934. doi:10.1093/schbul/sbq068. ISSN 0586-7614. 
  135. 135.0 135.1 Artaloytia, Juan Francisco; Arango, Celso; Lahti, Adrienne; Sanz, Javier; Pascual, Ana; Cubero, Pedro; Prieto, David; Palomo, Tomás (2006). "Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers". American Journal of Psychiatry. 163 (3): 488–493. doi:10.1176/appi.ajp.163.3.488. ISSN 0002-953X. 
  136. Saeedi, H; Remington, G; Christensen, B (2006). "Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood". Schizophrenia Research. 85 (1-3): 222–231. doi:10.1016/j.schres.2006.03.033. ISSN 0920-9964. 
  137. Lawn, Will; Freeman, Tom P; Pope, Rebecca A; Joye, Alyssa; Harvey, Lisa; Hindocha, Chandni; Mokrysz, Claire; Moss, Abigail; Wall, Matthew B; Bloomfield, Michael AP; Das, Ravi K; Morgan, Celia JA; Nutt, David J; Curran, H Valerie (2016). "Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses". Psychopharmacology. 233 (19-20): 3537–3552. doi:10.1007/s00213-016-4383-x. ISSN 0033-3158. 
  138. Starcevic, Vladan (2014). "The reappraisal of benzodiazepines in the treatment of anxiety and related disorders". Expert Review of Neurotherapeutics. 14 (11): 1275–1286. doi:10.1586/14737175.2014.963057. ISSN 1473-7175. 
  139. 139.0 139.1 139.2 139.3 Murray, Robin M.; Morrison, Paul D.; Di Forti, Marta; Paparelli, Alessandra (2011). "Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light". Frontiers in Behavioral Neuroscience. 5. doi:10.3389/fnbeh.2011.00001. ISSN 1662-5153. 
  140. Flohr, H., Glade, U., Motzko, D. (1998). "The neural correlate of consciousness and the mechanisms of general anaesthesia". Toxicology Letters. 100: 23–29. 
  141. Flohr, H.; Glade, U.; Motzko, D. (1998). "The role of the NMDA synapse in general anesthesia". Toxicology Letters. 100-101: 23–29. doi:10.1016/S0378-4274(98)00161-1. ISSN 0378-4274. 
  142. Lahti, A (2001). "Effects of Ketamine in Normal and Schizophrenic Volunteers". Neuropsychopharmacology. 25 (4): 455–467. doi:10.1016/S0893-133X(01)00243-3. ISSN 0893-133X. 
  143. Winkelman, Michael J. (2017). "The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology". Frontiers in Neuroscience. 11. doi:10.3389/fnins.2017.00539. ISSN 1662-453X. 
  144. D’Souza, Deepak Cyril; Sewell, Richard Andrew; Ranganathan, Mohini (2009). "Cannabis and psychosis/schizophrenia: human studies". European Archives of Psychiatry and Clinical Neuroscience. 259 (7): 413–431. doi:10.1007/s00406-009-0024-2. ISSN 0940-1334. 
  145. Radhakrishnan, Rajiv; Wilkinson, Samuel T.; D’Souza, Deepak Cyril (2014). "Gone to Pot â€" A Review of the Association between Cannabis and Psychosis". Frontiers in Psychiatry. 5. doi:10.3389/fpsyt.2014.00054. ISSN 1664-0640. 
  146. Bennett, W. R. Murray; Wilson, Lawrence G.; Roy-Byrne, Peter P. (2007). "Gamma-Hydroxybutyric Acid (GHB) Withdrawal: A Case Report". Journal of Psychoactive Drugs. 39 (3): 293–296. doi:10.1080/02791072.2007.10400616. ISSN 0279-1072. 
  147. 147.0 147.1 Tsuang, Ming T. (1982). "Subtypes of Drug Abuse With Psychosis". Archives of General Psychiatry. 39 (2): 141. doi:10.1001/archpsyc.1982.04290020013003. ISSN 0003-990X. 
  148. Angrist, Burton; Thompson, Hyacinth; Shopsin, Baron; Gershon, Samuel (1975). "Clinical studies with dopamine-receptor stimulants". Psychopharmacologia. 44 (3): 273–280. doi:10.1007/BF00428906. ISSN 0033-3158. 
  149. Krystal, John H.; Perry, Edward B.; Gueorguieva, Ralitza; Belger, Aysenil; Madonick, Steven H.; Abi-Dargham, Anissa; Cooper, Thomas B.; MacDougall, Lisa; Abi-Saab, Walid; D’Souza, D. Cyril (2005). "Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine". Archives of General Psychiatry. 62 (9): 985. doi:10.1001/archpsyc.62.9.985. ISSN 0003-990X. 
  150. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 189–190. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  151. "Anxiety or fear-related disorders". International statistical classification of diseases and related health problems (11th ed.). 2022. Retrieved 20 May 2022. 
  152. "Anxiety Disorders". Diagnostic and statistical manual of mental disorders (5th ed.): 818. 2013. doi:10.1176/appi.books.9780890425596.dsm05. 
  153. Crippa, José Alexandre; Zuardi, Antonio Waldo; Martín-Santos, Rocio; Bhattacharyya, Sagnik; Atakan, Zerrin; McGuire, Philip; Fusar-Poli, Paolo (2009). "Cannabis and anxiety: a critical review of the evidence". Human Psychopharmacology: Clinical and Experimental. 24 (7): 515–523. doi:10.1002/hup.1048. ISSN 0885-6222. 
  154. Wolbach, A. B.; Miner, E. J.; Isbell, Harris (1962). "Comparison of psilocin with psilocybin, mescaline and LSD-25". Psychopharmacologia. 3 (3): 219–223. doi:10.1007/BF00412109. ISSN 0033-3158. 
  155. Datura effects (Erowid) | https://erowid.org/plants/datura/datura_effects.shtml
  156. "Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment". American Journal of Psychiatry. 141 (7): 848–852. 1984. doi:10.1176/ajp.141.7.848. ISSN 0002-953X. 
  157. Williamson, S (1997). "Adverse effects of stimulant drugs in a community sample of drug users". Drug and Alcohol Dependence. 44 (2-3): 87–94. doi:10.1016/S0376-8716(96)01324-5. ISSN 0376-8716. 
  158. Pavel, S.; Goldstein, R.; Petrescu, Magdalena (1980). "Vasotocin, melatonin and narcolepsy: Possible involvement of the pineal gland in its patho-physiological mechanism". Peptides. 1 (4): 281–284. doi:10.1016/0196-9781(80)90003-0. ISSN 0196-9781. 
  159. 159.0 159.1 Pace-Schott, Edward F.; Gersh, Tamara; Silvestri, Rosalia; Stickgold, Robert; Salzman, Carl; Hobson, J. Allan (2001). "SSRI Treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects". Journal of Sleep Research. 10 (2): 129–142. doi:10.1046/j.1365-2869.2001.00249.x. ISSN 0962-1105. 
  160. 160.0 160.1 160.2 Nour, Matthew M.; Evans, Lisa; Nutt, David; Carhart-Harris, Robin L. (2016). "Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)". Frontiers in Human Neuroscience. 10. doi:10.3389/fnhum.2016.00269. ISSN 1662-5161. 
  161. "Personality Disorders". Diagnostic and statistical manual of mental disorders (5th ed.): 669–672. 2013. doi:10.1176/appi.books.9780890425596.dsm18. 
  162. 162.0 162.1 162.2 Spotts, James V.; Shontz, Franklin C. (2009). "Drug-Induced Ego States. I. Cocaine: Phenomenology and Implications". International Journal of the Addictions. 19 (2): 119–151. doi:10.3109/10826088409057173. ISSN 0020-773X. 
  163. Woodham, Robert L. (1988). "A Self-Psychological Consideration in Cocaine Addiction". Alcoholism Treatment Quarterly. 4 (3): 41–46. doi:10.1300/J020V04N03_04. ISSN 0734-7324. 
  164. Kuypers, K.P.C.; Steenbergen, L.; Theunissen, E.L.; Toennes, S.W.; Ramaekers, J.G. (2015). "Emotion recognition during cocaine intoxication". European Neuropsychopharmacology. 25 (11): 1914–1921. doi:10.1016/j.euroneuro.2015.08.012. ISSN 0924-977X. 
  165. 165.0 165.1 165.2 165.3 165.4 Gasser, Peter; Kirchner, Katharina; Passie, Torsten (2014). "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects". Journal of Psychopharmacology. 29 (1): 57–68. doi:10.1177/0269881114555249. ISSN 0269-8811. 
  166. 166.0 166.1 166.2 Hartogsohn, Ido (2018). "The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity". Frontiers in Neuroscience. 12. doi:10.3389/fnins.2018.00129. ISSN 1662-453X. 
  167. 167.0 167.1 Miller, Melissa A.; Bershad, Anya K.; de Wit, Harriet (2015). "Drug effects on responses to emotional facial expressions". Behavioural Pharmacology. 26 (6): 571–579. doi:10.1097/FBP.0000000000000164. ISSN 0955-8810. 
  168. Kamboj, Sunjeev K.; Joye, Alyssa; Bisby, James A.; Das, Ravi K.; Platt, Bradley; Curran, H. Valerie (2012). "Processing of facial affect in social drinkers: a dose–response study of alcohol using dynamic emotion expressions". Psychopharmacology. 227 (1): 31–39. doi:10.1007/s00213-012-2940-5. ISSN 0033-3158. 
  169. Philippot, Pierre; Kornreich, Charles; Blairy, Sylvie; Baert, Iseult; Dulk, Anne Den; Bon, Olivier Le; Streel, Emmanuel; Hess, Ursula; Pelc, Isy; Verbanck, Paul (1999). "Alcoholics'Deficits in the Decoding of Emotional Facial Expression". Alcoholism: Clinical and Experimental Research. 23 (6): 1031–1038. doi:10.1111/j.1530-0277.1999.tb04221.x. ISSN 0145-6008. 
  170. Ford, Jason A.; Schroeder, Ryan D. (2008). "Academic Strain and Non-Medical Use of Prescription Stimulants among College Students". Deviant Behavior. 30 (1): 26–53. doi:10.1080/01639620802049900. ISSN 0163-9625. 
  171. Riccio, Cynthia A.; Waldrop, Jennifer J.M.; Reynolds, Cecil R.; Lowe, Patricia (2001). "Effects of Stimulants on the Continuous Performance Test (CPT)". The Journal of Neuropsychiatry and Clinical Neurosciences. 13 (3): 326–335. doi:10.1176/jnp.13.3.326. ISSN 0895-0172. 
  172. Seiden, L S; Sabol, K E; Ricaurte, G A (1993). "Amphetamine: Effects on Catecholamine Systems and Behavior". Annual Review of Pharmacology and Toxicology. 33 (1): 639–676. doi:10.1146/annurev.pa.33.040193.003231. ISSN 0362-1642. 
  173. Sprague, R.; Sleator, E. (1977). "Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior". Science. 198 (4323): 1274–1276. doi:10.1126/science.337493. ISSN 0036-8075. 
  174. Randall, Delia C.; Viswanath, Aparna; Bharania, Punam; Elsabagh, Sarah M.; Hartley, David E.; Shneerson, John M.; File, Sandra E. (2005). "Does Modafinil Enhance Cognitive Performance in Young Volunteers Who Are Not Sleep-Deprived?". Journal of Clinical Psychopharmacology. 25 (2): 175–179. doi:10.1097/01.jcp.0000155816.21467.25. ISSN 0271-0749. 
  175. Bernstein, Gail A.; Carroll, Marilyn E.; Crosby, Ross D.; Perwien, Amy R.; Go, Frances S.; Benowitz, Neal L. (1994). "Caffeine Effects on Learning, Performance, and Anxiety in Normal School-Age Children". Journal of the American Academy of Child & Adolescent Psychiatry. 33 (3): 407–415. doi:10.1097/00004583-199403000-00016. ISSN 0890-8567. 
  176. 176.0 176.1 Salo, Ruth; Nordahl, Thomas E.; Natsuaki, Yutaka; Leamon, Martin H.; Galloway, Gantt P.; Waters, Christy; Moore, Charles D.; Buonocore, Michael H. (2007). "Attentional Control and Brain Metabolite Levels in Methamphetamine Abusers". Biological Psychiatry. 61 (11): 1272–1280. doi:10.1016/j.biopsych.2006.07.031. ISSN 0006-3223. 
  177. Waller, Niels; Putnam, Frank W.; Carlson, Eve B. (1996). "Types of dissociation and dissociative types: A taxometric analysis of dissociative experiences". Psychological Methods. 1 (3): 300–321. doi:10.1037/1082-989X.1.3.300. ISSN 1082-989X. 
  178. Giesbrecht, Timo; Merckelbach, Harald; Geraerts, Elke (2007). "The Dissociative Experiences Taxon Is Related to Fantasy Proneness". The Journal of Nervous and Mental Disease. 195 (9): 769–772. doi:10.1097/NMD.0b013e318142ce55. ISSN 0022-3018. 
  179. Levin, Ross; Spei, Ekaterina (2016). "Relationship of Purported Measures of Pathological and Nonpathological Dissociation to Self-Reported Psychological Distress and Fantasy Immersion". Assessment. 11 (2): 160–168. doi:10.1177/1073191103256377. ISSN 1073-1911. 
  180. 180.0 180.1 Lynn, Christopher Dana (2005). "Adaptive and Maladaptive Dissociation: An Epidemiological and Anthropological Comparison and Proposition for an Expanded Dissociation Model". Anthropology of Consciousness. 16 (2): 16–49. doi:10.1525/ac.2005.16.2.16. ISSN 1053-4202. 
  181. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 824–5. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  182. Snaith, R. P.; Constantopoulos, A. A.; Jardine, M. Y.; McGuffin, P. (1978). "A clinical scale for the self-assessment of irritability". The British Journal of Psychiatry. 132 (2): 164–171. doi:10.1192/bjp.132.2.164. ISSN 0007-1250. 
  183. Sommers, Ira; Baskin, Deborah; Baskin-Sommers, Arielle (2006). "Methamphetamine use among young adults: Health and social consequences". Addictive Behaviors. 31 (8): 1469–1476. doi:10.1016/j.addbeh.2005.10.004. ISSN 0306-4603. 
  184. Ahmann, P. A., Waltonen, S. J., Olson, K. A., Theye, F. W., Van Erem, A. J., LaPlant, R. J. (June 1993). "Placebo-controlled evaluation of Ritalin side effects". Pediatrics. 91 (6): 1101–1106. ISSN 0031-4005. 
  185. Norström, Thor; Pape, Hilde (2010). "Alcohol, suppressed anger and violence". Addiction. 105 (9): 1580–1586. doi:10.1111/j.1360-0443.2010.02997.x. ISSN 0965-2140. 
  186. 186.0 186.1 Corlett, Philip R.; Honey, Garry D.; Aitken, Michael R. F.; Dickinson, Anthony; Shanks, David R.; Absalom, Anthony R.; Lee, Michael; Pomarol-Clotet, Edith; Murray, Graham K.; McKenna, Peter J.; Robbins, Trevor W.; Bullmore, Edward T.; Fletcher, Paul C. (2006). "Frontal Responses During Learning Predict Vulnerability to the Psychotogenic Effects of Ketamine". Archives of General Psychiatry. 63 (6): 611. doi:10.1001/archpsyc.63.6.611. ISSN 0003-990X. 
  187. Preller, Katrin H.; Herdener, Marcus; Pokorny, Thomas; Planzer, Amanda; Kraehenmann, Rainer; Stämpfli, Philipp; Liechti, Matthias E.; Seifritz, Erich; Vollenweider, Franz X. (2017). "The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation". Current Biology. 27 (3): 451–457. doi:10.1016/j.cub.2016.12.030. ISSN 0960-9822. 
  188. 188.0 188.1 188.2 Carhart-Harris, Robin L.; Muthukumaraswamy, Suresh; Roseman, Leor; Kaelen, Mendel; Droog, Wouter; Murphy, Kevin; Tagliazucchi, Enzo; Schenberg, Eduardo E.; Nest, Timothy; Orban, Csaba; Leech, Robert; Williams, Luke T.; Williams, Tim M.; Bolstridge, Mark; Sessa, Ben; McGonigle, John; Sereno, Martin I.; Nichols, David; Hellyer, Peter J.; Hobden, Peter; Evans, John; Singh, Krish D.; Wise, Richard G.; Curran, H. Valerie; Feilding, Amanda; Nutt, David J. (2016). "Neural correlates of the LSD experience revealed by multimodal neuroimaging". Proceedings of the National Academy of Sciences. 113 (17): 4853–4858. doi:10.1073/pnas.1518377113. ISSN 0027-8424. 
  189. Kapur, Shitij (2003). "Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia". American Journal of Psychiatry. 160 (1): 13–23. doi:10.1176/appi.ajp.160.1.13. ISSN 0002-953X. 
  190. Murray, Robin M.; Morrison, Paul D.; Henquet, Cécile; Forti, Marta Di (2007). "Cannabis, the mind and society: the hash realities". Nature Reviews Neuroscience. 8 (11): 885–895. doi:10.1038/nrn2253. ISSN 1471-003X. 
  191. Chaudhury, Suprakash; Kiran, Chandra (2009). "Understanding delusions". Industrial Psychiatry Journal. 18 (1): 3. doi:10.4103/0972-6748.57851. ISSN 0972-6748. 
  192. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 819. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  193. 193.0 193.1 193.2 Sjoberg, B. M.; Hollister, L. E. (1965). "The effects of psychotomimetic drugs on primary suggestibility". Psychopharmacologia. 8 (4): 251–262. doi:10.1007/BF00407857. ISSN 0033-3158. 
  194. Carhart-Harris, R. L.; Kaelen, M.; Whalley, M. G.; Bolstridge, M.; Feilding, A.; Nutt, D. J. (2014). "LSD enhances suggestibility in healthy volunteers". Psychopharmacology. 232 (4): 785–794. doi:10.1007/s00213-014-3714-z. ISSN 0033-3158. 
  195. Kelly, Sean F.; Fisher, Seymour; Kelly, Reid J. (1978). "Effects of cannabis intoxication on primary suggestibility". Psychopharmacology. 56 (2): 217–219. doi:10.1007/BF00431853. ISSN 0033-3158. 
  196. Cheong, Soon Ho; Lee, Kun Moo; Lim, Se Hun; Cho, Kwang Rae; Kim, Myoung Hun; Ko, Myoung Jin; Shim, Joo Cheol; Oh, Min Kyung; Kim, Yong Han; Lee, Sang Eun (2011). "The Effect of Suggestion on Unpleasant Dreams Induced by Ketamine Administration". Anesthesia & Analgesia. 112 (5): 1082–1085. doi:10.1213/ANE.0b013e31820eeb0e. ISSN 0003-2999. 
  197. Whalley, M. G.; Brooks, G. B. (2008). "Enhancement of suggestibility and imaginative ability with nitrous oxide". Psychopharmacology. 203 (4): 745–752. doi:10.1007/s00213-008-1424-0. ISSN 0033-3158. 
  198. 198.0 198.1 Piguet, Camille; Dayer, Alexandre; Kosel, Markus; Desseilles, Martin; Vuilleumier, Patrik; Bertschy, Gilles (2010). "Phenomenology of racing and crowded thoughts in mood disorders: A theoretical reappraisal". Journal of Affective Disorders. 121 (3): 189–198. doi:10.1016/j.jad.2009.05.006. ISSN 0165-0327. 
  199. Pronin, Emily; Jacobs, Elana; Wegner, Daniel M. (2008). "Psychological effects of thought acceleration". Emotion. 8 (5): 597–612. doi:10.1037/a0013268. ISSN 1931-1516. 
  200. Yang, Kaite; Friedman-Wheeler, Dara G.; Pronin, Emily (2014). "Thought Acceleration Boosts Positive Mood Among Individuals with Minimal to Moderate Depressive Symptoms". Cognitive Therapy and Research. 38 (3): 261–269. doi:10.1007/s10608-014-9597-9. ISSN 0147-5916. 
  201. Pronin, Emily; Jacobs, Elana (2008). "Thought Speed, Mood, and the Experience of Mental Motion". Perspectives on Psychological Science. 3 (6): 461–485. doi:10.1111/j.1745-6924.2008.00091.x. ISSN 1745-6916. 
  202. Porkka-Heiskanen, T. (1997). "Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness". Science. 276 (5316): 1265–1268. doi:10.1126/science.276.5316.1265. ISSN 0036-8075. 
  203. 203.0 203.1 203.2 203.3 Repantis, Dimitris; Schlattmann, Peter; Laisney, Oona; Heuser, Isabella (2010). "Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review". Pharmacological Research. 62 (3): 187–206. doi:10.1016/j.phrs.2010.04.002. ISSN 1043-6618. 
  204. 204.0 204.1 Engber, T.M; Dennis, S.A; Jones, B.E; Miller, M.S; Contreras, P.C (1998). "Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine". Neuroscience. 87 (4): 905–911. doi:10.1016/S0306-4522(98)00015-3. ISSN 0306-4522. 
  205. Caldwell, John A.; Caldwell, J. Lyn; Smyth, Nicholas K.; Hall, Kecia K. (2000). "A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study". Psychopharmacology. 150 (3): 272–282. doi:10.1007/s002130000450. ISSN 0033-3158. 
  206. Myrick, Hugh; Malcolm, Robert; Taylor, Brent; LaROWE, STEVEN (2004). "Modafinil: Preclinical, Clinical, and Post-Marketing Surveillance—A Review of Abuse Liability Issues". Annals of Clinical Psychiatry. 16 (2): 101–109. doi:10.1080/10401230490453743. ISSN 1040-1237. 
  207. Scammell, Thomas E.; Estabrooke, Ivy V.; McCarthy, Marie T.; Chemelli, Richard M.; Yanagisawa, Masashi; Miller, Matthew S.; Saper, Clifford B. (2000). "Hypothalamic Arousal Regions Are Activated during Modafinil-Induced Wakefulness". The Journal of Neuroscience. 20 (22): 8620–8628. doi:10.1523/JNEUROSCI.20-22-08620.2000. ISSN 0270-6474. 
  208. Johnson, Matthew W; Garcia-Romeu, Albert; Cosimano, Mary P; Griffiths, Roland R (2014). "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction". Journal of Psychopharmacology. 28 (11): 983–992. doi:10.1177/0269881114548296. ISSN 0269-8811. 
  209. Krebs, Teri S; Johansen, Pål-Ørjan (2012). "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials". Journal of Psychopharmacology. 26 (7): 994–1002. doi:10.1177/0269881112439253. ISSN 0269-8811. 
  210. Brown, Thomas (2013). "Ibogaine in the Treatment of Substance Dependence". Current Drug Abuse Reviews. 6 (1): 3–16. doi:10.2174/15672050113109990001. ISSN 1874-4737. 
  211. Moran, M. M. (2005). "Cystine/Glutamate Exchange Regulates Metabotropic Glutamate Receptor Presynaptic Inhibition of Excitatory Transmission and Vulnerability to Cocaine Seeking". Journal of Neuroscience. 25 (27): 6389–6393. doi:10.1523/JNEUROSCI.1007-05.2005. ISSN 0270-6474. 
  212. anxiolysis, National Cancer Institute 
  213. Gordon, Joshua A. (2002). "Anxiolytic drug targets: beyond the usual suspects". Journal of Clinical Investigation. 110 (7): 915–917. doi:10.1172/JCI0216846. ISSN 0021-9738. 
  214. Tyrer, P. (27 February 1988). "Prescribing psychotropic drugs in general practice". BMJ. 296 (6622): 588–589. doi:10.1136/bmj.296.6622.588. 
  215. Lydiard, R. B. (2003). "The role of GABA in anxiety disorders". The Journal of Clinical Psychiatry. 64 Suppl 3: 21–27. ISSN 0160-6689. 
  216. Gauthier, Isabelle; Nuss, Philippe (2015). "Anxiety disorders and GABA neurotransmission: a disturbance of modulation". Neuropsychiatric Disease and Treatment: 165. doi:10.2147/NDT.S58841. ISSN 1178-2021. 
  217. Wood, Alastair J.J.; Shader, Richard I.; Greenblatt, David J. (1993). "Use of Benzodiazepines in Anxiety Disorders". New England Journal of Medicine. 328 (19): 1398–1405. doi:10.1056/NEJM199305133281907. ISSN 0028-4793. 
  218. Smith, J. P., Randall, C. L. (2012). "Anxiety and alcohol use disorders: comorbidity and treatment considerations". Alcohol Research: Current Reviews. 34 (4): 414–431. ISSN 2168-3492. 
  219. Schmidt-Mutter, Catherine; Pain, Laure; Sandner, Guy; Gobaille, Serge; Maitre, Michel (1998). "The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil". European Journal of Pharmacology. 342 (1): 21–27. doi:10.1016/S0014-2999(97)01503-3. ISSN 0014-2999. 
  220. Pollack, Mark H.; Matthews, John; Scott, Erin L. (1998). "Gabapentin as a Potential Treatment for Anxiety Disorders". American Journal of Psychiatry. 155 (7): 992–993. doi:10.1176/ajp.155.7.992. ISSN 0002-953X. 
  221. Blessing, Esther M.; Steenkamp, Maria M.; Manzanares, Jorge; Marmar, Charles R. (2015). "Cannabidiol as a Potential Treatment for Anxiety Disorders". Neurotherapeutics. 12 (4): 825–836. doi:10.1007/s13311-015-0387-1. ISSN 1933-7213. 
  222. Irwin, Scott A.; Iglewicz, Alana (2010). "Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care". Journal of Palliative Medicine. 13 (7): 903–908. doi:10.1089/jpm.2010.9808. ISSN 1096-6218. 
  223. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 820. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  224. Zamboni, G.; Huey, E. D.; Krueger, F.; Nichelli, P. F.; Grafman, J. (2008). "Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates". Neurology. 71 (10): 736–742. doi:10.1212/01.wnl.0000324920.96835.95. ISSN 0028-3878. 
  225. Källmén, Håkan; Gustafson, Roland (1998). "Alcohol and Disinhibition". European Addiction Research. 4 (4): 150–162. doi:10.1159/000018948. ISSN 1022-6877. 
  226. Bettinger, Jill C.; Topper, Stephen M.; Aguilar, Sara C.; Topper, Viktoria Y.; Elbel, Erin; Pierce-Shimomura, Jonathan T. (2014). "Alcohol Disinhibition of Behaviors in C. elegans". PLoS ONE. 9 (3): e92965. doi:10.1371/journal.pone.0092965. ISSN 1932-6203. 
  227. Paton, Carol (2018). "Benzodiazepines and disinhibition: a review". Psychiatric Bulletin. 26 (12): 460–462. doi:10.1192/pb.26.12.460. ISSN 0955-6036. 
  228. Fillmore, M (2003). "Effects of d-amphetamine on behavioral control in stimulant abusers: the role of prepotent response tendencies". Drug and Alcohol Dependence. 71 (2): 143–152. doi:10.1016/S0376-8716(03)00089-9. ISSN 0376-8716. 
  229. Ando, Romeo D.; Benko, Anita; Ferrington, Linda; Kirilly, Eszter; Kelly, Paul A.T.; Bagdy, Gyorgy (2006). "Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test". Neuropharmacology. 50 (7): 884–896. doi:10.1016/j.neuropharm.2005.12.010. ISSN 0028-3908. 
  230. Lissek, Silke; Güntürkün, Onur (2003). "Dissociation of Extinction and Behavioral Disinhibition: The Role of NMDA Receptors in the Pigeon Associative Forebrain during Extinction". The Journal of Neuroscience. 23 (22): 8119–8124. doi:10.1523/JNEUROSCI.23-22-08119.2003. ISSN 0270-6474. 
  231. 231.0 231.1 Schierenbeck, Thomas; Riemann, Dieter; Berger, Mathias; Hornyak, Magdolna (2008). "Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana". Sleep Medicine Reviews. 12 (5): 381–389. doi:10.1016/j.smrv.2007.12.004. ISSN 1087-0792. 
  232. 232.0 232.1 Sharpley, Ann L.; Cowen, Philip J. (1995). "Effect of pharmacologic treatments on the sleep of depressed patients". Biological Psychiatry. 37 (2): 85–98. doi:10.1016/0006-3223(94)00135-P. ISSN 0006-3223. 
  233. 233.0 233.1 Trivedi, M (1999). "Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression". Neuropsychopharmacology. 20 (5): 447–459. doi:10.1016/S0893-133X(98)00131-6. ISSN 0893-133X. 
  234. Vogel, G.W.; Buffenstein, A.; Minter, K.; Hennessey, Ann (1990). "Drug effects on REM sleep and on endogenous depression". Neuroscience & Biobehavioral Reviews. 14 (1): 49–63. doi:10.1016/S0149-7634(05)80159-9. ISSN 0149-7634. 
  235. Feinberg, I., Jones, R., Walker, J. M., Cavness, C., March, J. (April 1975). "Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man". Clinical Pharmacology & Therapeutics. 17 (4): 458–466. doi:10.1002/cpt1975174458. ISSN 0009-9236. Retrieved 4 June 2022. 
  236. Hobson, J. A., Stickgold, R., Pace-Schott, E. F. (February 1998). "The neuropsychology of REM sleep dreaming:". NeuroReport. 9 (3): R1–R14. doi:10.1097/00001756-199802160-00033. ISSN 0959-4965. Retrieved 4 June 2022. 
  237. 237.0 237.1 Ueda, Satoshi; Sakayori, Takeshi; Omori, Ataru; Fukuta, Hajime; Kobayashi, Takashi; Ishizaka, Kousuke; Saijo, Tomoyuki; Okubo, Yoshiro (2016). "Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis". Neuropsychiatric Disease and Treatment: 265. doi:10.2147/NDT.S99577. ISSN 1178-2021. 
  238. "Neurocognitive Disorders". Diagnostic and statistical manual of mental disorders (5th ed.): 609. 2013. doi:10.1176/appi.books.9780890425596.dsm17. 
  239. Gur, R. E; Kohler, C. G; Ragland, J D.; Siegel, S. J; Lesko, K.; Bilker, W. B; Gur, R. C (2006). "Flat Affect in Schizophrenia: Relation to Emotion Processing and Neurocognitive Measures". Schizophrenia Bulletin. 32 (2): 279–287. doi:10.1093/schbul/sbj041. ISSN 0586-7614. 
  240. 240.0 240.1 Sansone, R. A., Sansone, L. A. (October 2010). "SSRI-Induced Indifference". Psychiatry (Edgmont (Pa.: Township)). 7 (10): 14–18. ISSN 1555-5194. 
  241. Vollenweider, F. X. (31 December 2001). "Brain mechanisms of hallucinogens and entactogens". Dialogues in Clinical Neuroscience. 3 (4): 265–279. doi:10.31887/DCNS.2001.3.4/fxvollenweider. ISSN 1958-5969. 
  242. Micallef, J; Tardieu, S; Gentile, S; Fakra, E; Jouve, E; Sambuc, R; Blin, O (2003). "Évaluation psychocomportementale de l'administration de faible dose de kétamine chez le sujet sain". Neurophysiologie Clinique/Clinical Neurophysiology. 33 (3): 138–147. doi:10.1016/S0987-7053(03)00028-5. ISSN 0987-7053. 
  243. Oscar-Berman, M., Bowirrat, A. (September 2005). "Genetic influences in emotional dysfunction and alcoholism-related brain damage". Neuropsychiatric Disease and Treatment. 1 (3): 211–229. ISSN 1176-6328. 
  244. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 820. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  245. Lleras, Alejandro; Buetti, Simona; Mordkoff, J. Toby (2013). "When Do the Effects of Distractors Provide a Measure of Distractibility?". 59: 261–315. doi:10.1016/B978-0-12-407187-2.00007-1. ISSN 0079-7421. 
  246. Ahveninen, Jyrki; Jaaskelainen, Iiro P.; Pekkonen, Eero; Hallberg, Anja; Hietanen, Marja; Naatanen, Risto; Schroger, Erich; Sillanaukee, Pekka (2000). "Increased Distractibility by Task-Irrelevant Sound Changes in Abstinent Alcoholics". Alcoholism: Clinical and Experimental Research. 24 (12): 1850–1854. doi:10.1111/j.1530-0277.2000.tb01989.x. ISSN 0145-6008. 
  247. McCarthy, Danielle E.; Gloria, Rebecca; Curtin, John J. (2009). "Attention bias in nicotine withdrawal and under stress". Psychology of Addictive Behaviors. 23 (1): 77–90. doi:10.1037/a0014288. ISSN 1939-1501. 
  248. Vigen, Cheryl L.P.; Mack, Wendy J.; Keefe, Richard S.E.; Sano, Mary; Sultzer, David L.; Stroup, T. Scott; Dagerman, Karen S.; Hsiao, John K.; Lebowitz, Barry D.; Lyketsos, Constantine G.; Tariot, Pierre N.; Zheng, Ling; Schneider, Lon S. (2011). "Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD". American Journal of Psychiatry. 168 (8): 831–839. doi:10.1176/appi.ajp.2011.08121844. ISSN 0002-953X. 
  249. 249.0 249.1 Lebedev, Alexander V.; Lövdén, Martin; Rosenthal, Gidon; Feilding, Amanda; Nutt, David J.; Carhart-Harris, Robin L. (2015). "Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin". Human Brain Mapping. 36 (8): 3137–3153. doi:10.1002/hbm.22833. ISSN 1065-9471. 
  250. 250.0 250.1 Vollenweider, Franz X; Geyer, Mark A (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. ISSN 0361-9230. 
  251. 251.0 251.1 Horváth, Lajos; Szummer, Csaba; Szabo, Attila (2017). "Weak phantasy and visionary phantasy: the phenomenological significance of altered states of consciousness". Phenomenology and the Cognitive Sciences. 17 (1): 117–129. doi:10.1007/s11097-016-9497-4. ISSN 1568-7759. 
  252. 252.0 252.1 "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 829. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  253. Guilleminault, C. (2001). "Excessive daytime sleepiness: A challenge for the practising neurologist". Brain. 124 (8): 1482–1491. doi:10.1093/brain/124.8.1482. ISSN 1460-2156. 
  254. Bereshpolova, Y.; Stoelzel, C. R.; Zhuang, J.; Amitai, Y.; Alonso, J.-M.; Swadlow, H. A. (2011). "Getting Drowsy? Alert/Nonalert Transitions and Visual Thalamocortical Network Dynamics". Journal of Neuroscience. 31 (48): 17480–17487. doi:10.1523/JNEUROSCI.2262-11.2011. ISSN 0270-6474. 
  255. Ware, M. A.; Wang, T.; Shapiro, S.; Robinson, A.; Ducruet, T.; Huynh, T.; Gamsa, A.; Bennett, G. J.; Collet, J.-P. (2010). "Smoked cannabis for chronic neuropathic pain: a randomized controlled trial". Canadian Medical Association Journal. 182 (14): E694–E701. doi:10.1503/cmaj.091414. ISSN 0820-3946. 
  256. Landauer, Ali A.; Howat, Peter (2007). "Low and moderate alcohol doses, psychomotor performance and perceived drowsiness". Ergonomics. 26 (7): 647–657. doi:10.1080/00140138308963386. ISSN 0014-0139. 
  257. Koch-Weser, Jan; Greenblatt, David J.; Shader, Richard I.; Abernethy, Darrell R. (1983). "Current Status of Benzodiazepines". New England Journal of Medicine. 309 (7): 410–416. doi:10.1056/NEJM198308183090705. ISSN 0028-4793. 
  258. Corey, PJ; Heck, Amy M; Weathermon, Ronnie A (2016). "Amphetamines to Counteract Opioid-Induced Sedation". Annals of Pharmacotherapy. 33 (12): 1362–1366. doi:10.1345/aph.19024. ISSN 1060-0280. 
  259. Van Putten, Theodore (1981). "Subjective Response to Antipsychotic Drugs". Archives of General Psychiatry. 38 (2): 187. doi:10.1001/archpsyc.1981.01780270073010. ISSN 0003-990X. 
  260. Weiler, John M.; Bloomfield, John R.; Woodworth, George G.; Grant, Angela R.; Layton, Teresa A.; Brown, Timothy L.; McKenzie, David R.; Baker, Thomas W.; Watson, Ginger S. (2000). "Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance". Annals of Internal Medicine. 132 (5): 354. doi:10.7326/0003-4819-132-5-200003070-00004. ISSN 0003-4819. 
  261. 261.0 261.1 261.2 261.3 Santtila, Pekka; Ekholm, Magnus; Niemi, Pekka (1998). "Factors moderating the effects of alcohol on interrogative suggestibility". Psychology, Crime & Law. 4 (2): 139–152. doi:10.1080/10683169808401754. ISSN 1068-316X. 
  262. 262.0 262.1 262.2 Santtila, Pekka; Ekholm, Magnus; Niemi, Pekka (1999). "The effects of alcohol on interrogative suggestibility: The role of State-Anxiety and mood states as mediating factors". Legal and Criminological Psychology. 4 (1): 1–13. doi:10.1348/135532599167707. ISSN 1355-3259. 
  263. 263.0 263.1 263.2 Gudjonsson, Gisli; Hannesdottir, Kristin; Petursson, Hannes; Bjornsson, Gudbjorn (2002). "The effects of alcohol withdrawal on mental state, interrogative suggestibility and compliance: an experimental study". The Journal of Forensic Psychiatry. 13 (1): 53–67. doi:10.1080/09585180210122682. ISSN 0958-5184. 
  264. Levin, E (1996). "Nicotine-Haloperidol Interactions and Cognitive Performance in Schizophrenics". Neuropsychopharmacology. 15 (5): 429–436. doi:10.1016/S0893-133X(96)00018-8. ISSN 0893-133X. 
  265. Vermeeren, A.; Muntjewerff, N. D.; Quint, P. J.; O'Hanlon, J. F.; Jackson, J. L.; Harrison, E. M. (1995). "Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests". Psychopharmacology. 118 (1): 1–9. doi:10.1007/BF02245243. ISSN 0033-3158. 
  266. Johannes, Sönke; Wieringa, Bernardina M.; Nager, Wido; Dengler, Reinhard; Münte, Thomas F. (2001). "Oxazepam alters action monitoring". Psychopharmacology. 155 (1): 100–106. doi:10.1007/s002130100680. ISSN 0033-3158. 
  267. 267.0 267.1 Semlitsch, H.V.; Anderer, P.; Saletu, B. (1995). "Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects". European Journal of Clinical Pharmacology. 49 (3). doi:10.1007/BF00192378. ISSN 0031-6970. 
  268. Naber, Dieter (2011). "Subjective effects of antipsychotic drugs and their relevance for compliance and remission". Epidemiologia e Psichiatria Sociale. 17 (03): 174–176. doi:10.1017/S1121189X00001238. ISSN 1121-189X. 
  269. Kurita, Geana Paula; Lundorff, Lena; Pimenta, Cibele Andrucioli de Mattos; Sjøgren, Per (2008). "The cognitive effects of opioids in cancer: a systematic review". Supportive Care in Cancer. 17 (1): 11–21. doi:10.1007/s00520-008-0497-y. ISSN 0941-4355. 
  270. Twillman, Robert K; Long, Teresa D; Cathers, Teresa A; Mueller, David W (1999). "Treatment of Painful Skin Ulcers with Topical Opioids". Journal of Pain and Symptom Management. 17 (4): 288–292. doi:10.1016/S0885-3924(98)00140-7. ISSN 0885-3924. 
  271. Ersek, Mary; Cherrier, Monique M; Overman, Steven S; Irving, Gordon A (2004). "The cognitive effects of opioids". Pain Management Nursing. 5 (2): 75–93. doi:10.1016/j.pmn.2003.11.002. ISSN 1524-9042. 
  272. Freyd, Jennifer J.; Martorello, Susan R.; Alvarado, Jessica S.; Hayes, Amy E.; Christman, Jill C. (1998). "Cognitive environments and dissociative tendencies: performance on the standard Stroop task for high versus low dissociators". Applied Cognitive Psychology. 12 (7): S91–S103. doi:10.1002/(SICI)1099-0720(199812)12:7<S91::AID-ACP599>3.0.CO;2-Z. ISSN 0888-4080. 
  273. Nebes, Robert D.; Pollock, Bruce G.; Halligan, Edythe M.; Houck, Patricia; Saxton, Judith A. (2011). "Cognitive Slowing Associated With Elevated Serum Anticholinergic Activity in Older Individuals is Decreased by Caffeine Use". The American Journal of Geriatric Psychiatry. 19 (2): 169–175. doi:10.1097/JGP.0b013e3181e4490d. ISSN 1064-7481. 
  274. Crean, Rebecca D.; Crane, Natania A.; Mason, Barbara J. (2011). "An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions". Journal of Addiction Medicine. 5 (1): 1–8. doi:10.1097/ADM.0b013e31820c23fa. ISSN 1932-0620. 
  275. Tapert, S., Schweinsburg, A., Brown, S. (1 January 2008). "The Influence of Marijuana Use on Neurocognitive Functioning in Adolescents". Current Drug Abuse Reviewse. 1 (1): 99–111. doi:10.2174/1874473710801010099. ISSN 1874-4737. Retrieved 4 June 2022. 
  276. Bhattacharyya, Sagnik; Sendt, Kyra-Verena (2012). "Neuroimaging Evidence for Cannabinoid Modulation of Cognition and Affect in Man". Frontiers in Behavioral Neuroscience. 6. doi:10.3389/fnbeh.2012.00022. ISSN 1662-5153. 
  277. Roberto, Aaron J.; Lorenzo, Aileen; Li, Kevin J.; Young, Jonathan; Mohan, Abhishek; Pinnaka, Subhash; Lapidus, Kyle A. B. (2016). "First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone". Case Reports in Psychiatry. 2016: 1–4. doi:10.1155/2016/7257489. ISSN 2090-682X. 
  278. 278.0 278.1 "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 821. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  279. 279.0 279.1 Zoellner, Lori A.; Pruitt, Larry D.; Farach, Frank J.; Jun, Janie J. (2014). "UNDERSTANDING HETEROGENEITY IN PTSD: FEAR, DYSPHORIA, AND DISTRESS". Depression and Anxiety. 31 (2): 97–106. doi:10.1002/da.22133. ISSN 1091-4269. 
  280. Epkins, Catherine C. (1996). "Cognitive specificity and affective confounding in social anxiety and dysphoria in children". Journal of Psychopathology and Behavioral Assessment. 18 (1): 83–101. doi:10.1007/BF02229104. ISSN 0882-2689. 
  281. Bradley, Brendan P.; Mogg, Karin; Lee, Stacey C. (1997). "Attentional biases for negative information in induced and naturally occurring dysphoria". Behaviour Research and Therapy. 35 (10): 911–927. doi:10.1016/S0005-7967(97)00053-3. ISSN 0005-7967. 
  282. Disner, Seth G.; Beevers, Christopher G.; Haigh, Emily A. P.; Beck, Aaron T. (2011). "Neural mechanisms of the cognitive model of depression". Nature Reviews Neuroscience. 12 (8): 467–477. doi:10.1038/nrn3027. ISSN 1471-003X. 
  283. Koster, Ernst H. W.; De Raedt, Rudi; Goeleven, Ellen; Franck, Erik; Crombez, Geert (2005). "Mood-Congruent Attentional Bias in Dysphoria: Maintained Attention to and Impaired Disengagement From Negative Information". Emotion. 5 (4): 446–455. doi:10.1037/1528-3542.5.4.446. ISSN 1931-1516. 
  284. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 821. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  285. Drevets, Wayne C; Gautier, Clara; Price, Julie C; Kupfer, David J; Kinahan, Paul E; Grace, Anthony A; Price, Joseph L; Mathis, Chester A (2001). "Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria". Biological Psychiatry. 49 (2): 81–96. doi:10.1016/S0006-3223(00)01038-6. ISSN 0006-3223. 
  286. Jônsson, Lars-Erik; Änggård, Erik; Gunne, Lars-M (1971). "Blockade of intravenous amphetamine euphoria in man". Clinical Pharmacology & Therapeutics. 12 (6): 889–896. doi:10.1002/cpt1971126889. ISSN 0009-9236. 
  287. Synofzik, Matthis; Schlaepfer, Thomas E.; Fins, Joseph J. (2012). "How Happy Is Too Happy? Euphoria, Neuroethics, and Deep Brain Stimulation of the Nucleus Accumbens". AJOB Neuroscience. 3 (1): 30–36. doi:10.1080/21507740.2011.635633. ISSN 2150-7740. 
  288. Lucas, Richard E.; Diener, Ed; Suh, Eunkook (1996). "Discriminant validity of well-being measures". Journal of Personality and Social Psychology. 71 (3): 616–628. doi:10.1037/0022-3514.71.3.616. ISSN 1939-1315. 
  289. Everitt, Barry J; Robbins, Trevor W (2005). "Neural systems of reinforcement for drug addiction: from actions to habits to compulsion". Nature Neuroscience. 8 (11): 1481–1489. doi:10.1038/nn1579. ISSN 1097-6256. 
  290. 290.0 290.1 290.2 Volkow, N. D. (2000). "Addiction, a Disease of Compulsion and Drive: Involvement of the Orbitofrontal Cortex". Cerebral Cortex. 10 (3): 318–325. doi:10.1093/cercor/10.3.318. ISSN 1460-2199. 
  291. 291.0 291.1 291.2 Hyman, Steven E.; Malenka, Robert C. (2001). "Addiction and the brain: The neurobiology of compulsion and its persistence". Nature Reviews Neuroscience. 2 (10): 695–703. doi:10.1038/35094560. ISSN 1471-003X. 
  292. 292.0 292.1 Soussan, Christophe; Kjellgren, Anette (2015). ""Chasing the High" – Experiences of Ethylphenidate as Described on International Internet Forums". Substance Abuse: Research and Treatment. 9: SART.S22495. doi:10.4137/SART.S22495. ISSN 1178-2218. 
  293. Olives, Travis; Orozco, Benjamin; Stellpflug, Samuel (2012). "Bath Salts: The Ivory Wave of Trouble". Western Journal of Emergency Medicine. 13 (1): 58–62. doi:10.5811/westjem.2011.6.6782. ISSN 1936-900X. 
  294. N. Stanciu, C., M. Penders, T. (1 June 2016). "Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case". Current Psychiatry Reviews. 12 (2): 221–223. 
  295. Pink-Hashkes, S., Rooij, I. J. E. I. van, Kwisthout, J. H. P. (2017). "Perception is in the details: A predictive coding account of the psychedelic phenomenon". London, UK : Cognitive Science Society. 
  296. Hill, R. M.; Fischer, R.; Warshay, Diana (1969). "Effects of excitatory and tranquilizing drugs on visual perception. spatial distortion thresholds". Experientia. 25 (2): 171–172. doi:10.1007/BF01899105. ISSN 0014-4754. 
  297. Fischer, R. (1971). "A Cartography of the Ecstatic and Meditative States". Science. 174 (4012): 897–904. doi:10.1126/science.174.4012.897. ISSN 0036-8075. 
  298. Buckley, P. (1981). "Mystical Experience and Schizophrenia". Schizophrenia Bulletin. 7 (3): 516–521. doi:10.1093/schbul/7.3.516. ISSN 0586-7614. 
  299. Schroll, M. A. (2013). "From ecopsychology to transpersonal ecosophy: Shamanism, psychedelics and transpersonal psychology" (PDF). European Journal of Ecopsychology. 4: 116–144. 
  300. Riley, Sarah C.E.; Blackman, Graham (2009). "Between Prohibitions: Patterns and Meanings of Magic Mushroom Use in the UK". Substance Use & Misuse. 43 (1): 55–71. doi:10.1080/10826080701772363. ISSN 1082-6084. 
  301. Nikolova, I.; Danchev, N. (2014). "Piperazine Based Substances of Abuse: A new Party Pills on Bulgarian Drug Market". Biotechnology & Biotechnological Equipment. 22 (2): 652–655. doi:10.1080/13102818.2008.10817529. ISSN 1310-2818. 
  302. Yeap, C. W., Bian, C. K., Abdullah, A. F. L. (2010). "A Review on Benzylpiperazine and Trifluoromethylphenypiperazine: Origins, Effects, Prevalence and Legal Status". Health and the Environment Journal. 1 (2): 38–50. 
  303. Griffith, John D.; Nutt, John G.; Jasinski, Donald R. (1975). "A comparison of fenfluramine and amphetamine in man". Clinical Pharmacology & Therapeutics. 18 (5part1): 563–570. doi:10.1002/cpt1975185part1563. ISSN 0009-9236. 
  304. Corazza, Ornella; Assi, Sulaf; Schifano, Fabrizio (2013). "From "Special K" to "Special M": The Evolution of the Recreational Use of Ketamine and Methoxetamine". CNS Neuroscience & Therapeutics. 19 (6): 454–460. doi:10.1111/cns.12063. ISSN 1755-5930. 
  305. 305.0 305.1 305.2 305.3 305.4 Solbakk, J. H. (July 2006). "'Catharsis and moral therapy II: An Aristotelian account'". Medicine, Health Care and Philosophy. 9 (2): 141–153. doi:10.1007/s11019-005-8319-1.  Cite error: Invalid <ref> tag; name ":1" defined multiple times with different content
  306. Roseman, L., Nutt, D. J., Carhart-Harris, R. L. (2018). "Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression". Frontiers in Pharmacology. 8. ISSN 1663-9812. 
  307. Tesser, A., Leone, C., Clary, E. G. (September 1978). "Affect control: Process Constraints versus Catharsis". Cognitive Therapy and Research. 2 (3): 265–274. doi:10.1007/BF01185788. ISSN 0147-5916. 
  308. 308.0 308.1 308.2 308.3 308.4 308.5 Winkelman, M. (July 2001). "Psychointegrators: Multidisciplinary Perspectives on the Therapeutic Effects of Hallucinogens". Complementary health practice review. 6 (3): 219–237. doi:10.1177/153321010100600304. ISSN 1533-2101.  Cite error: Invalid <ref> tag; name ":3" defined multiple times with different content
  309. Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., Carhart-Harris, R. L. (October 2015). "LSD enhances the emotional response to music". Psychopharmacology. 232 (19): 3607–3614. doi:10.1007/s00213-015-4014-y. ISSN 0033-3158. 
  310. 310.0 310.1 310.2 310.3 310.4 Gasser, P., Kirchner, K., Passie, T. (January 2015). "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects". Journal of Psychopharmacology. 29 (1): 57–68. doi:10.1177/0269881114555249. ISSN 0269-8811.  Cite error: Invalid <ref> tag; name ":4" defined multiple times with different content
  311. Bogenschutz, M. P., Johnson, M. W. (January 2016). "Classic hallucinogens in the treatment of addictions". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 64: 250–258. doi:10.1016/j.pnpbp.2015.03.002. ISSN 0278-5846. 
  312. 312.0 312.1 312.2 312.3 312.4 Garcia-Romeu, A., Kersgaard, B., Addy, P. H. (August 2016). "Clinical applications of hallucinogens: A review". Experimental and Clinical Psychopharmacology. 24 (4): 229–268. doi:10.1037/pha0000084. ISSN 1936-2293.  Cite error: Invalid <ref> tag; name ":5" defined multiple times with different content
  313. Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., Griffiths, R. R. (December 2016). "Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences". Journal of Psychopharmacology. 30 (12): 1268–1278. doi:10.1177/0269881116662634. ISSN 0269-8811. 
  314. Winkelman, M. (September 1991). "Therapeutic Effects of Hallucinogens". Anthropology of Consciousness. 2 (3–4): 15–19. doi:10.1525/ac.1991.2.3-4.15. ISSN 1053-4202. 
  315. Hartogsohn, I. (2018). "The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity". Frontiers in Neuroscience. 12. ISSN 1662-453X. 
  316. 316.0 316.1 316.2 316.3 Wolfson, P. E. (1 July 2014). "Psychedelic Experiential Pharmacology: Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too): An Interview with Richard Yensen". International Journal of Transpersonal Studies. 33 (2): 160–174. doi:10.24972/ijts.2014.33.2.160. ISSN 1321-0122.  Cite error: Invalid <ref> tag; name ":6" defined multiple times with different content
  317. 317.0 317.1 317.2 317.3 Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., Kolp, A. (1 July 2014). "Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications". International Journal of Transpersonal Studies. 33 (2): 84–140. doi:10.24972/ijts.2014.33.2.84. ISSN 1321-0122.  Cite error: Invalid <ref> tag; name ":7" defined multiple times with different content
  318. Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., Brenneisen, R. (July 2014). "Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases". Journal of Nervous & Mental Disease. 202 (7): 513–520. doi:10.1097/NMD.0000000000000113. ISSN 0022-3018. 
  319. 319.0 319.1 319.2 319.3 319.4 "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 819–20. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms.  Cite error: Invalid <ref> tag; name "DSM5Glossary" defined multiple times with different content Cite error: Invalid <ref> tag; name "DSM5Glossary" defined multiple times with different content Cite error: Invalid <ref> tag; name "DSM5Glossary" defined multiple times with different content
  320. Kiran, C., Chaudhury, S. (1 January 2009). "Understanding delusions". Industrial Psychiatry Journal. 18 (1): 3. doi:10.4103/0972-6748.57851. ISSN 0972-6748. 
  321. Garety, P. A., Freeman, D. (June 1999). "Cognitive approaches to delusions: A critical review of theories and evidence". British Journal of Clinical Psychology. 38 (2): 113–154. doi:10.1348/014466599162700. ISSN 0144-6657. 
  322. Arnone, D., Patel, A., Tan, G. M.-Y. (8 August 2006). "The nosological significance of Folie à Deux: a review of the literature". Annals of General Psychiatry. 5 (1): 11. doi:10.1186/1744-859X-5-11. ISSN 1744-859X. 
  323. 323.0 323.1 323.2 "Depersonalization-derealization disorder". International statistical classification of diseases and related health problems (11th ed.). 2022. Retrieved 20 May 2022. 
  324. 324.0 324.1 Radovic, F., Radovic, S. (2002). "Feelings of Unreality: A Conceptual and Phenomenological Analysis of the Language of Depersonalization". Philosophy, Psychiatry, & Psychology. 9 (3): 271–279. doi:10.1353/ppp.2003.0048. ISSN 1086-3303. 
  325. 325.0 325.1 325.2 325.3 325.4 325.5 325.6 Dissociative Disorders. Diagnostic and statistical manual of mental disorders (5th ed.) (Fifth Edition ed.). American Psychiatric Association. 22 May 2013. doi:10.1176/appi.books.9780890425596.dsm08. ISBN 9780890425558. 
  326. 326.0 326.1 326.2 326.3 326.4 Stein, D. J., Simeon, D. (September 2009). "Cognitive-Affective Neuroscience of Depersonalization". CNS Spectrums. 14 (9): 467–471. doi:10.1017/S109285290002352X. ISSN 1092-8529. 
  327. Erard, R., Luisada, P. V., Peele, R. (July 1980). "The PCP Psychosis: Prolonged Intoxication or Drug-Precipitated Functional Illness?". Journal of Psychedelic Drugs. 12 (3–4): 235–251. doi:10.1080/02791072.1980.10471432. ISSN 0022-393X. 
  328. Pradhan, S. N. (December 1984). "Phencyclidine (PCP): Some human studies". Neuroscience & Biobehavioral Reviews. 8 (4): 493–501. doi:10.1016/0149-7634(84)90006-X. ISSN 0149-7634. 
  329. Mathew, R. J., Wilson, W. H., Chiu, N. Y., Turkington, T. G., Degrado, T. R., Coleman, R. E. (July 1999). "Regional cerebral blood flow and depersonalization after tetrahydrocannabinol adrninistration". Acta Psychiatrica Scandinavica. 100 (1): 67–75. doi:10.1111/j.1600-0447.1999.tb10916.x. ISSN 0001-690X. 
  330. Roy-Byrne, P. P., Hommer, D. (June 1988). "Benzodiazepine withdrawal: Overview and implications for the treatment of anxiety". The American Journal of Medicine. 84 (6): 1041–1052. doi:10.1016/0002-9343(88)90309-9. ISSN 0002-9343. 
  331. Duncan, J. (September 1988). "Neuropsychiatric aspects of sedative drug withdrawal". Human Psychopharmacology: Clinical and Experimental. 3 (3): 171–180. doi:10.1002/hup.470030304. ISSN 0885-6222. 
  332. 332.0 332.1 332.2 332.3 Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., Dollfus, S. (August 2005). "Hallucinogen persisting perception disorder after psilocybin consumption: a case study". European Psychiatry. 20 (5–6): 458–460. doi:10.1016/j.eurpsy.2005.04.008. ISSN 0924-9338. 
  333. 333.0 333.1 "Depressive Disorders". Diagnostic and statistical manual of mental disorders (5th ed.). 2013. doi:10.1176/appi.books.9780890425596.dsm04. 
  334. "Depressive Disorders". International statistical classification of diseases and related health problems (11th ed.). 2022. Retrieved 20 May 2022. 
  335. Conner, Kenneth R.; Pinquart, Martin; Gamble, Stephanie A. (2009). "Meta-analysis of depression and substance use among individuals with alcohol use disorders". Journal of Substance Abuse Treatment. 37 (2): 127–137. doi:10.1016/j.jsat.2008.11.007. ISSN 0740-5472. 
  336. Bender, Ansley; Hagan, Kelsey E.; Kingston, Neal (2017). "The association of folate and depression: A meta-analysis". Journal of Psychiatric Research. 95: 9–18. doi:10.1016/j.jpsychires.2017.07.019. ISSN 0022-3956. 
  337. Spedding, Simon (2014). "Vitamin D and Depression: A Systematic Review and Meta-Analysis Comparing Studies with and without Biological Flaws". Nutrients. 6 (4): 1501–1518. doi:10.3390/nu6041501. ISSN 2072-6643. 
  338. Sublette, M. Elizabeth; Ellis, Steven P.; Geant, Amy L.; Mann, J. John (2011). "Meta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression". The Journal of Clinical Psychiatry. 72 (12): 1577–1584. doi:10.4088/JCP.10m06634. ISSN 0160-6689. 
  339. Huang, Ruixue; Wang, Ke; Hu, Jianan (2016). "Effect of Probiotics on Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Nutrients. 8 (8): 483. doi:10.3390/nu8080483. ISSN 2072-6643. 
  340. Ng, Qin Xiang; Koh, Shawn Shao Hong; Chan, Hwei Wuen; Ho, Collin Yih Xian (2017). "Clinical Use of Curcumin in Depression: A Meta-Analysis". Journal of the American Medical Directors Association. 18 (6): 503–508. doi:10.1016/j.jamda.2016.12.071. ISSN 1525-8610. 
  341. Fournier, Jay C.; DeRubeis, Robert J.; Hollon, Steven D.; Dimidjian, Sona; Amsterdam, Jay D.; Shelton, Richard C.; Fawcett, Jan (2010). "Antidepressant Drug Effects and Depression Severity". JAMA. 303 (1): 47. doi:10.1001/jama.2009.1943. ISSN 0098-7484. 
  342. Zarrouf, Fahd Aziz; Artz, Steven; Griffith, James; Sirbu, Cristian; Kommor, Martin (2009). "Testosterone and Depression". Journal of Psychiatric Practice. 15 (4): 289–305. doi:10.1097/01.pra.0000358315.88931.fc. ISSN 1538-1145. 
  343. Walther, A., Breidenstein, J., Miller, R. (1 January 2019). "Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis". JAMA Psychiatry. 76 (1): 31. doi:10.1001/jamapsychiatry.2018.2734. ISSN 2168-622X. Retrieved 29 May 2022. 
  344. Rock, P. L.; Roiser, J. P.; Riedel, W. J.; Blackwell, A. D. (2013). "Cognitive impairment in depression: a systematic review and meta-analysis". Psychological Medicine. 44 (10): 2029–2040. doi:10.1017/S0033291713002535. ISSN 0033-2917. 
  345. Fava, Giovanni A.; Bech, Per (2015). "The Concept of Euthymia". Psychotherapy and Psychosomatics. 85 (1): 1–5. doi:10.1159/000441244. ISSN 0033-3190. 
  346. Galvão-Coelho, Nicole L.; Marx, Wolfgang; Gonzalez, Maria; Sinclair, Justin; de Manincor, Michael; Perkins, Daniel; Sarris, Jerome (2021). "Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants". Psychopharmacology. 238 (2): 341–354. doi:10.1007/s00213-020-05719-1. ISSN 0033-3158. 
  347. Luoma, Jason B.; Chwyl, Christina; Bathje, Geoff J.; Davis, Alan K.; Lancelotta, Rafael (2020). "A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy". Journal of Psychoactive Drugs. 52 (4): 289–299. doi:10.1080/02791072.2020.1769878. ISSN 0279-1072. 
  348. Ryan, Wesley C.; Marta, Cole J.; Koek, Ralph J. (2014). "Ketamine and Depression: A Review". International Journal of Transpersonal Studies. 33 (2): 40–74. doi:10.24972/ijts.2014.33.2.40. ISSN 1321-0122. 
  349. 349.0 349.1 Gilchrist, P. T., Ditto, B. (January 2015). "Sense of impending doom: Inhibitory activity in waiting blood donors who subsequently experience vasovagal symptoms". Biological Psychology. 104: 28–34. doi:10.1016/j.biopsycho.2014.11.006. ISSN 0301-0511. Retrieved 3 October 2022. 
  350. Poxon, L. H. (2013). ""Doing the same puzzle over and over again": a qualitative analysis of feeling stuck in grief". doi:10.15123/PUB.3490. Retrieved 11 October 2022. 
  351. Kanner, A. M. (June 2004). "Recognition of the Various Expressions of Anxiety, Psychosis, and Aggression in Epilepsy". Epilepsia. 45 (s2): 22–27. doi:10.1111/j.0013-9580.2004.452004.x. ISSN 0013-9580. Retrieved 11 October 2022. 
  352. Hibbert, G. A. (28 January 1984). "Hyperventilation as a cause of panic attacks". BMJ. 288 (6413): 263–264. doi:10.1136/bmj.288.6413.263. ISSN 0959-8138. Retrieved 11 October 2022. 
  353. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 826–7. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  354. Abernethy, M. K., Becker, L. B. (September 1992). "Acute nutmeg intoxication". The American Journal of Emergency Medicine. 10 (5): 429–430. doi:10.1016/0735-6757(92)90069-A. ISSN 0735-6757. Retrieved 11 October 2022. 
  355. Demetriades, A. K., Wallman, P. D., McGuiness, A., Gavalas, M. C. (1 March 2005). "Low cost, high risk: accidental nutmeg intoxication". Emergency Medicine Journal. 22 (3): 223–225. doi:10.1136/emj.2002.004168. ISSN 1472-0205. Retrieved 11 October 2022. 
  356. Milhorn, H. T. (2018). "Substance Use Disorders". Hallucinogen Dependence. Springer International Publishing. pp. 167–177. doi:10.1007/978-3-319-63040-3_12. ISBN 9783319630397. 
  357. Alao, D., Guly, H. R. (1 March 2005). "Missed clavicular fracture; inadequate radiograph or occult fracture?". Emergency Medicine Journal. 22 (3): 232–233. doi:10.1136/emj.2003.013425. ISSN 1472-0205. Retrieved 11 October 2022. 
  358. Di Cyan, E. (1971). "Poetry and Creativeness: With Notes on the Role of Psychedelic Agents". Perspectives in Biology and Medicine. 14 (4): 639–650. doi:10.1353/pbm.1971.0044. ISSN 1529-8795. Retrieved 11 October 2022. 
  359. Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., Fotev, P. S. (January 2017). "PHARMACO - TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS (REVIEW)" (PDF). PHARMACIA. 64 (1). 
  360. Geiger, H. A., Wurst, M. G., Daniels, R. N. (17 October 2018). "DARK Classics in Chemical Neuroscience: Psilocybin". ACS Chemical Neuroscience. 9 (10): 2438–2447. doi:10.1021/acschemneuro.8b00186. ISSN 1948-7193. Retrieved 11 October 2022. 
  361. Kamińska, K., Świt, P., Malek, K. (21 January 2021). "2-(4-Iodo-2,5-dimethoxyphenyl)- N -[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review". Journal of Analytical Toxicology. 44 (9): 947–956. doi:10.1093/jat/bkaa022. ISSN 0146-4760. Retrieved 11 October 2022. 
  362. Cohen, S. (1 May 1963). "Prolonged Adverse Reactions to Lysergic Acid Diethylamide". Archives of General Psychiatry. 8 (5): 475. doi:10.1001/archpsyc.1963.01720110051006. ISSN 0003-990X. Retrieved 11 October 2022. 
  363. APA Dictionary of Psychology, retrieved 15 October 2022 
  364. Schwitzgebel, E. (2019). "The Stanford Encyclopedia of Philosophy". In Zalta, E. N. Introspection (Winter 2019 ed.). Metaphysics Research Lab, Stanford University. 
  365. 365.0 365.1 Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., Araujo, D. B. de (18 February 2015). Hu, D., ed. "The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network". PLOS ONE. 10 (2): e0118143. doi:10.1371/journal.pone.0118143. ISSN 1932-6203. Retrieved 19 October 2022. 
  366. 366.0 366.1 366.2 Frank, P., Sundermann, A., Fischer, D. (4 October 2019). "How mindfulness training cultivates introspection and competence development for sustainable consumption". International Journal of Sustainability in Higher Education. 20 (6): 1002–1021. doi:10.1108/IJSHE-12-2018-0239. ISSN 1467-6370. Retrieved 19 October 2022. 
  367. 367.0 367.1 367.2 Fox, K. C. R., Zakarauskas, P., Dixon, M., Ellamil, M., Thompson, E., Christoff, K. (25 September 2012). Martinez, L. M., ed. "Meditation Experience Predicts Introspective Accuracy". PLoS ONE. 7 (9): e45370. doi:10.1371/journal.pone.0045370. ISSN 1932-6203. Retrieved 20 October 2022. 
  368. Overgaard, M., Mogensen, J. (March 2017). "An integrative view on consciousness and introspection". Review of Philosophy and Psychology. 8 (1): 129–141. doi:10.1007/s13164-016-0303-6. ISSN 1878-5158. Retrieved 20 October 2022. 
  369. Xue, H., Desmet, P. M. A. (July 2019). "Researcher introspection for experience-driven design research". Design Studies. 63: 37–64. doi:10.1016/j.destud.2019.03.001. ISSN 0142-694X. Retrieved 20 October 2022. 
  370. Ericsson, K. A., Fox, M. C. (2011). "Thinking aloud is not a form of introspection but a qualitatively different methodology: Reply to Schooler (2011)". Psychological Bulletin. 137 (2): 351–354. doi:10.1037/a0022388. ISSN 1939-1455. Retrieved 20 October 2022. 
  371. Riga, M. S., Soria, G., Tudela, R., Artigas, F., Celada, P. (August 2014). "The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs". The International Journal of Neuropsychopharmacology. 17 (08): 1269–1282. doi:10.1017/S1461145714000261. ISSN 1461-1457. Retrieved 19 October 2022. 
  372. Barker, S. A. (6 August 2018). "N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function". Frontiers in Neuroscience. 12: 536. doi:10.3389/fnins.2018.00536. ISSN 1662-453X. Retrieved 19 October 2022. 
  373. Santos, R. G. dos, Osório, F. L., Crippa, J. A. S., Hallak, J. E. C. (December 2016). "Classical hallucinogens and neuroimaging: A systematic review of human studies". Neuroscience & Biobehavioral Reviews. 71: 715–728. doi:10.1016/j.neubiorev.2016.10.026. ISSN 0149-7634. Retrieved 19 October 2022. 
  374. Canuso, C. M., Bossie, C. A., Zhu, Y., Youssef, E., Dunner, D. L. (December 2008). "Psychotic symptoms in patients with bipolar mania". Journal of Affective Disorders. 111 (2–3): 164–169. doi:10.1016/j.jad.2008.02.014. ISSN 0165-0327. 
  375. Altman, E., Hedeker, D., Peterson, J. L., Davis, J. M. (15 September 2001). "A comparative evaluation of three self-rating scales for acute mania". Biological Psychiatry. 50 (6): 468–471. doi:10.1016/s0006-3223(01)01065-4. ISSN 0006-3223. 
  376. Young, R. C., Biggs, J. T., Ziegler, V. E., Meyer, D. A. (November 1978). "A rating scale for mania: reliability, validity and sensitivity". The British Journal of Psychiatry: The Journal of Mental Science. 133: 429–435. doi:10.1192/bjp.133.5.429. ISSN 0007-1250. 
  377. Slagter, H. A., Davidson, R. J., Lutz, A. (2011). "Mental Training as a Tool in the Neuroscientific Study of Brain and Cognitive Plasticity". Frontiers in Human Neuroscience. 5. doi:10.3389/fnhum.2011.00017. ISSN 1662-5161. 
  378. Pagnini, F., Philips, D. (April 2015). "Being mindful about mindfulness". The Lancet Psychiatry. 2 (4): 288–289. doi:10.1016/S2215-0366(15)00041-3. ISSN 2215-0366. 
  379. Baer, R. A. (2003). "Mindfulness training as a clinical intervention: A conceptual and empirical review". Clinical Psychology: Science and Practice. 10 (2): 125–143. doi:10.1093/clipsy.bpg015. ISSN 1468-2850. 
  380. Creswell, J. D. (3 January 2017). "Mindfulness Interventions". Annual Review of Psychology. 68 (1): 491–516. doi:10.1146/annurev-psych-042716-051139. ISSN 0066-4308. 
  381. Bishop, S. R., Lau, M., Shapiro, S., Carlson, L., Anderson, N. D., Carmody, J., Segal, Z. V., Abbey, S., Speca, M., Velting, D., Devins, G. (2004). "Mindfulness: A proposed operational definition". Clinical Psychology: Science and Practice. 11 (3): 230–241. doi:10.1093/clipsy.bph077. ISSN 1468-2850. 
  382. "Panic disorder". International statistical classification of diseases and related health problems (11th ed.). 2022. Retrieved 20 May 2022. 
  383. "Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 826. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  384. Freeman, D., Dunn, G., Murray, R. M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B., Cornish, R., Williams, J., Di Simplicio, M., Igoumenou, A., Brenneisen, R., Tunbridge, E. M., Harrison, P. J., Harmer, C. J., Cowen, P., Morrison, P. D. (March 2015). "How Cannabis Causes Paranoia: Using the Intravenous Administration of ∆ 9 -Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia". Schizophrenia Bulletin. 41 (2): 391–399. doi:10.1093/schbul/sbu098. ISSN 1745-1701. 
  385. 385.0 385.1 Lokko, H. N., Stern, T. A. (14 May 2015). "Regression: Diagnosis, Evaluation, and Management". The Primary Care Companion for CNS Disorders. 17 (3): 27221. doi:10.4088/PCC.14f01761. ISSN 2155-7780. 
  386. Fromm, E. (April 1970). "Age regression with unexpected reappearance of a repressed c3ildhood language". International Journal of Clinical and Experimental Hypnosis. 18 (2): 79–88. doi:10.1080/00207147008415906. ISSN 0020-7144. 
  387. Viner, J. (January 1983). "An understanding and approach to regression in the borderline patient". Comprehensive Psychiatry. 24 (1): 49–56. doi:10.1016/0010-440X(83)90049-4. ISSN 0010-440X. 
  388. Kapur, S. (January 2003). "Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia". American Journal of Psychiatry. 160 (1): 13–23. doi:10.1176/appi.ajp.160.1.13. ISSN 0002-953X. 
  389. A"Glossary of Technical Terms". Diagnostic and statistical manual of mental disorders (5th ed.): 827–8. 2013. doi:10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms. 
  390. Jones, J., Dougherty, J., Cannon, L. (July 1986). "Diphenhydramine-induced toxic psychosis". The American Journal of Emergency Medicine. 4 (4): 369–371. doi:10.1016/0735-6757(86)90312-8. ISSN 0735-6757. 
  391. "Angel's Trumpet psychosis: a central nervous system anticholinergic syndrome". American Journal of Psychiatry. 134 (3): 312–314. March 1977. doi:10.1176/ajp.134.3.312. ISSN 0002-953X. 
  392. Strassman, R. J. (October 1984). "Adverse reactions to psychedelic drugs. A review of the literature". The Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001. ISSN 0022-3018. 
  393. Lahti, A. C., Holcomb, H. H., Medoff, D. R., Tamminga, C. A. (1 April 1995). "Ketamine activates psychosis and alters limbic blood flow in schizophrenia". Neuroreport. 6 (6): 869–872. doi:10.1097/00001756-199504190-00011. ISSN 1473-558X. 
  394. Hall, W., Degenhardt, L. (February 2000). "Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence". Australian & New Zealand Journal of Psychiatry. 34 (1): 26–34. doi:10.1046/j.1440-1614.2000.00685.x. ISSN 0004-8674. 
  395. Hurst, D., Loeffler, G., McLay, R. (October 2011). "Psychosis Associated With Synthetic Cannabinoid Agonists: A Case Series". American Journal of Psychiatry. 168 (10): 1119–1119. doi:10.1176/appi.ajp.2011.11010176. ISSN 0002-953X. 
  396. Glasner-Edwards, S., Mooney, L. J. (1 December 2014). "Methamphetamine Psychosis: Epidemiology and Management". CNS Drugs. 28 (12): 1115–1126. doi:10.1007/s40263-014-0209-8. ISSN 1179-1934. 
  397. Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., Medhus, S., Tanum, L., Franck, J. (5 December 2012). "Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?". BMC Psychiatry. 12 (1): 221. doi:10.1186/1471-244X-12-221. ISSN 1471-244X. 
  398. Preskorn, S. H., Denner, L. J. (3 January 1977). "Benzodiazepines and Withdrawal Psychosis: Report of Three Cases". JAMA. 237 (1): 36–38. doi:10.1001/jama.1977.03270280038018. ISSN 0098-7484. 
  399. Gross, M. M., Lewis, E., Hastey, J. (1974). "The Biology of Alcoholism". In Kissin, B., Begleiter, H. Acute Alcohol Withdrawal Syndrome. Springer US. pp. 191–263. doi:10.1007/978-1-4684-2937-4_6. ISBN 9781468429398. 
  400. Silverstein, A., Sṭrumzah, G. G., Blidstein, M., eds. (2018). The Oxford handbook of the Abrahamic religions (First published in paperback ed.). Oxford University Press. ISBN 9780198783015. 
  401. Walsh, S., Strain, E., Abreu, M., Bigelow, G. (1 September 2001). "Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans". Psychopharmacology. 157 (2): 151–162. doi:10.1007/s002130100788. ISSN 0033-3158. 
  402. Hunter, E. C. M., Sierra, M., David, A. S. (January 2004). "The epidemiology of depersonalisation and derealisation. A systematic review". Social Psychiatry and Psychiatric Epidemiology. 39 (1): 9–18. doi:10.1007/s00127-004-0701-4. ISSN 0933-7954. 
  403. Sierra, M., Lopera, F., Lambert, M. V., Phillips, M. L., David, A. S. (1 April 2002). "Separating depersonalisation and derealisation: the relevance of the "lesion method"". Journal of Neurology, Neurosurgery & Psychiatry. 72 (4): 530–532. doi:10.1136/jnnp.72.4.530. ISSN 0022-3050. 
  404. Stankevicius, S. (June 2017). "The self is an illusion: a conceptual framework for psychotherapy". Australasian Psychiatry. 25 (3): 243–245. doi:10.1177/1039856216689531. ISSN 1039-8562. 
  405. 405.0 405.1 405.2 Gasser, P., Kirchner, K., Passie, T. (January 2015). "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects". Journal of Psychopharmacology. 29 (1): 57–68. doi:10.1177/0269881114555249. ISSN 0269-8811. 
  406. Peterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., Cella, D. (February 2002). "Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp)". Annals of Behavioral Medicine. 24 (1): 49–58. doi:10.1207/S15324796ABM2401_06. ISSN 0883-6612. 
  407. 407.0 407.1 407.2 407.3 Trichter, S., Klimo, J., Krippner, S. (June 2009). "Changes in Spirituality Among Ayahuasca Ceremony Novice Participants". Journal of Psychoactive Drugs. 41 (2): 121–134. doi:10.1080/02791072.2009.10399905. ISSN 0279-1072. 
  408. 408.0 408.1 Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., Jesse, R. (December 2011). "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects". Psychopharmacology. 218 (4): 649–665. doi:10.1007/s00213-011-2358-5. ISSN 0033-3158. 
  409. 409.0 409.1 409.2 409.3 Lerner, M., Lyvers, M. (June 2006). "Values and Beliefs of Psychedelic Drug Users: A Cross-Cultural Study". Journal of Psychoactive Drugs. 38 (2): 143–147. doi:10.1080/02791072.2006.10399838. ISSN 0279-1072. 
  410. Griffiths, R. R., Richards, W. A., McCann, U., Jesse, R. (August 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. ISSN 0033-3158. 
  411. 411.0 411.1 MacLean, K. A., Johnson, M. W., Griffiths, R. R. (November 2011). "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness". Journal of Psychopharmacology. 25 (11): 1453–1461. doi:10.1177/0269881111420188. ISSN 0269-8811. 
  412. Kometer, M., Pokorny, T., Seifritz, E., Volleinweider, F. X. (October 2015). "Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations". Psychopharmacology. 232 (19): 3663–3676. doi:10.1007/s00213-015-4026-7. ISSN 0033-3158. 
  413. Lyvers, M., Meester, M. (1 November 2012). "Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner". Journal of Psychoactive Drugs. 44 (5): 410–417. doi:10.1080/02791072.2012.736842. ISSN 0279-1072. 
  414. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., Schmidt, B. L. (December 2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology. 30 (12): 1165–1180. doi:10.1177/0269881116675512. ISSN 0269-8811. 
  415. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R. (3 January 2011). "Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer". Archives of General Psychiatry. 68 (1): 71. doi:10.1001/archgenpsychiatry.2010.116. ISSN 0003-990X. 
  416. Studerus, E., Kometer, M., Hasler, F., Vollenweider, F. X. (November 2011). "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies". Journal of Psychopharmacology. 25 (11): 1434–1452. doi:10.1177/0269881110382466. ISSN 0269-8811.